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Abstract 
In Uganda, infants delivered at a health care facility receive the tuberculosis 
vaccine Bacillus Calmette-Guerin (BCG) on the first day of life. Infants delivered 
at home receive BCG at their first health care facility visit at 6 weeks of age. Our 
aim was to determine the effect of this delay in BCG administration on the 
induced immune response. Our hypothesis was that infants who received BCG at 
6 weeks of age would show an enhanced BCG-induced T cell immunity 
compared to infants vaccinated at birth. 
We optimised several polychromatic flow cytometry reagent panels to compare 
BCG-specific immunity in 9 months-old infants who had received the vaccine 
either at birth or at 6 weeks of age. We used a 12-hour whole blood intracellular 
cytokine/cytotoxic marker assay to measure T cell-associated cytokine 
expression and memory phenotypes. We also compared the capacity of BCG-
specific T cells to proliferate and produce cytokines upon antigenic stimulation 
with a 6-day proliferation assay. Finally, we measured plasma soluble cytokines 
levels in the two groups of infant using multiplex assay. 
We enrolled 92 infants: 50 had received BCG at birth and 42 at 6 weeks of age. 
BCG induced predominantly CD4+ T cell responses, and lesser CD8+ T cell 
responses, in both groups. Birth vaccination was associated with greater 
induction of CD4+ and CD8+ T cells expressing either IFN-γ alone, or IFN-γ 
together with perforin, compared with delayed vaccination. Further, birth 
vaccination induced proliferating cells that had greater capacity to produce IFN-γ, 
TNF-α and IL-2 together, compared with delayed vaccination.  
In conclusion, distinct patterns of T cell induction occurred when BCG was given 
at birth and at 6 weeks of age. We propose that this diversity might impact 
protection against tuberculosis. Our results differ from those of delayed BCG 
vaccination studies in South Africa and the Gambia, suggesting geographical and 
population heterogeneity may affect BCG-induced T cell response. 
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Chapter One: Introduction and literature review 
The overall objective of this project was to determine whether delay of Bacillus 
Calmette-Guerin (BCG) vaccination from birth to 6 weeks of age, due to home 
birth of Ugandan infants, affects the specific immune response induced. Our 
hypothesis was that infants who received BCG at 6 weeks of age would show an 
enhanced BCG-induced T cell immunity compared to infants vaccinated at birth. 
 
1.1. Tuberculosis 
Approximately one third of the world’s population is infected with Mycobacterium 
tuberculosis (M.tb), the causative agent for tuberculosis (TB). Among persons 
latently infected with M.tb, 10% develop active TB during their lifetime. Therefore, 
M.tb infected persons represent a reservoir that drives the TB epidemic. 
Annually, an estimated 9 million new cases of active TB occur, whereas 1.3 
million people die of the disease. Uganda is among top 22 TB endemic countries 
listed by the World Health Organisation (WHO) contributing a cumulative 0.52% 
of the TB cases of the world (WHO, 2013b). Persons within Uganda therefore 
have a high risk of exposure to M.tb infection. 
 
M.tb is an intracellular pathogen transmitted when a person with active 
pulmonary TB coughs and releases microdroplets containing the M.tb bacilli. 
When persons in the vicinity inhale the microdroplets containing the M.tb bacilli, 
several outcomes may occur depending on bacterial, host or environmental 
factors: (i) The host immune system may succeed in eliminating the bacilli, (ii) 
The infection may persist without causing active disease, a situation referred to 
as latent TB infection (LTBI), or (iii) The infection may progress into active TB. 
Factors that determine the progression from LTBI to active disease include the 
age of the individual, host immune status and socio-economic factors.  
Regarding age, infants are more susceptible to developing TB disease following 
infection, compared to adults. This may be explained, in part, by the reduced 
responsiveness of the infant’s immune system to toll-like receptor (TLR) ligand 
stimulation compared adults (Corbett et al., 2010). As regards immune status, 
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persons with human immunodeficiency virus (HIV) infection have increased 
susceptibility to developing TB disease, compared with uninfected individuals 
(Lawn et al., 2009). HIV causes depletion of CD4+ T cells, which are important in 
the adaptive immune response to M.tb infection. Various socio-economic factors 
are associated with increased risk of developing TB disease including 
compromised nutrition and poor quality of housing (Romaszko et al., 2008). 
 
1.2. Approaches to control of TB 
In 2006, the Stop TB Partnership set a goal to reduce the incidence of new TB 
cases globally to less than one case per million population by the year 2050 
(Raviglione, 2007). Modeling studies suggest that it will be difficult to achieve this 
goal using a partially effective vaccine, like BCG, despite wide vaccination 
coverage (Abu-Raddad et al., 2009). Rather, a multipronged approach may be 
needed to effectively reduce the TB epidemic. Young et al. used an age 
structured mathematical model to show that an approach that combines mass 
vaccination campaigns and effective drug therapy can reduce the incidence of 
TB to less than 10 cases per million population by the year 2050 (Young and 
Dye, 2006). The current approaches for control of M.tb infection and TB are 
discussed in greater detail below. 
 
1.2.1. Drugs  
Drugs may be used for the treatment of M.tb infection or active TB. Persons with 
LTBI can be treated with isoniazid (INH) for 6 to 9 months (WHO, 1982). The 
treatment of LTBI is aimed at reducing the reservoir of latent infection, thereby 
preventing M.tb reactivation and development of new cases of active TB. INH 
prophylaxis can reduce the incidence of TB by up to 90% (Ferebee, 1970). 
However, the use of single anti-tuberculosis drug may result in drug resistance, 
especially in persons with undiagnosed active disease (Balcells et al., 2006). 
Therefore, the diagnosis of active TB should be excluded prior to initiation of 
chemoprophylaxis. 
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Successful treatment of active TB disease involves the use of a combination of 
different anti-TB drugs, plus strategies to secure adherence to the treatment. The 
Directly Observed Treatment Short course (DOTS) strategy has been used 
successfully to achieve adherence. First line regimen for treatment of TB consists 
of isoniazid, pyrazinamide, rifampicin and ethambutol. Persons with resistance to 
isoniazid and rifampicin, also known as multi drug resistant (MDR) TB patients, 
are treated with a second line treatment regimen that may include drugs like 
capreomycin and neomycin (Lalloo, 2010). A third line regimen is used for 
patients with extensively drug resistant TB (XDR), defined as resistance to 
isoniazid and rifampin, plus any fluoroquinolone and at least one of three 
injectable second-line drugs (amikacin, kanamycin, or capreomycin). Drugs for 
treatment of patients with XDR TB may include linezolid and rifabutin (Lalloo, 
2010). 
   
1.2.2. Diagnostics 
Early diagnosis of TB is important for timely initiation of treatment. There are 
various laboratory methods that can be used for diagnosis of LTBI and active TB. 
The tuberculin skin test (TST) is used to diagnose persons with LTBI. TST 
measures immunological response to purified protein derivative (PPD) antigens 
from M.tb. However, the TST is limited in its ability to differentiate between LTBI 
and previous BCG vaccination (Harada, 2006), given that many proteins in PPD 
shares homology between M.tb and BCG. This challenge can be overcome by 
use of the interferon gamma release assays (IGRA) that measure the levels of 
IFN-γ released in response to the proteins early secretory antigenic target 6 
(ESAT-6) and culture filtrate protein 10 (CFP-10)(Ewer et al., 2003). Genes 
encoding for these two antigens were deleted during the attenuation of BCG 
(Behr et al., 1999). The sensitivity of IGRAs is however reduced in HIV infection 
(Raby et al., 2008). 
 
Active pulmonary TB may be diagnosed by use of direct sputum microscopy; 
however, this method has a low sensitivity in detection of M.tb bacilli 
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(Cattamanchi et al., 2009). Alternatively TB can be detected in a sputum sample 
by use of Lowenstein Jensen culture (Levidiotou et al., 1999). Also, TB can be 
diagnosed in a sputum sample, using a mycobacterial growth indicator tube 
(MGIT). The disadvantage of MGIT cultures is the long time to generate results 
(Brittle et al., 2009) and the required specialist training. Pulmonary TB may also 
be diagnosed using chest X-ray radiography. A specialist radiologist is needed 
for an accurate interpretation of X-rays. The GenXpert MTB/RIF is PCR based 
technique that uses sputum samples to detect M.tb DNA, and the most common 
genomic determinant of rifampicin resistance. This method produces results 
within two hours. However, the cost of purchasing the equipment and the skill 
needed to operate the machine limit the use of this technique in resource limited 
settings.   
 
1.2.3. Public health measures 
Governmental commitment is important for the efficient control of TB epidemic. 
For example, governments may design policies that ensure efficient delivery of 
vaccines at a grassroots level. The government may as well play a role in 
ensuring availability of basic diagnostic tools for TB at the district health centers 
coupled with additional reference laboratories to support the district facilities in 
identifying drug resistant cases. There is also need of policies to ensure 
equitable distribution of anti-tuberculosis drugs, their prescription and adherence 
monitoring (Abubakar et al., 2013). 
  
1.3. The BCG vaccine 
BCG is currently the only vaccine licensed for the prevention of TB (Fine PEM, 
1999). The vaccine was developed from a virulent strain of Mycobacterium bovis 
(M.bovis), isolated from the milk of a heifer with TB mastitis. Calmette and Guérin 
subjected this pathogenic strain to 230 passages over glycerinated bile potato 
medium at the Institut Pasteur in Lille, France, to generate BCG. In 1921, the first 
reports of the successful use of BCG for prevention of TB emerged when oral 
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administration of the vaccine to a baby born to a mother with TB resulted in 
protection of this infant from development of active disease (Bonah, 2005).  
 
In the United Kingdom, BCG vaccination was included into the routine 
vaccination programme in 1953 after studies demonstrated efficacy of BCG in 
prevention of TB disease (WHO, 1972). In 1974, this was followed by a World 
Health Organisation (WHO) recommendation for universal BCG vaccination 
resulting in incorporation into the expanded program for infant immunization 
(EPI). Currently, the WHO recommends administration of BCG soon after birth in 
TB endemic settings, where the risk of exposure to M.tb infection is high (WHO, 
2004). To date, over 80 percent coverage of BCG vaccination has been achieved 
in countries where the vaccine is used (WHO, 2013a). Approximately 100 million 
doses of BCG vaccine are administered worldwide each year.  
 
1.3.1. BCG use in Uganda 
The Uganda national expanded program on immunization (UNEPI) guidelines 
recommend that BCG be routinely administered soon after birth (UNEPI, 2003). It 
is practical to administer BCG to newborn babies while still in the health care 
center where birth takes place. However, about 40% of Ugandan infants are born 
at home (Fadnes et al., 2011, Nankabirwa et al., 2011), resulting in a missed 
opportunity to administer BCG. Infants who miss BCG vaccination at birth 
commonly receive the vaccine at their first visit to a health center, usually at 6 
weeks of age, for further expanded program on immunization (EPI) vaccination 
(WHO, 2004). Therefore, a large number of Ugandan infants born at home 
receive BCG at 6 weeks of age. It remains unclear how administration of BCG at 
6 weeks of age may affect vaccine-induced immunity, when compared with 
infants who receive BCG shortly after birth. This is the focus of this project. 
 
1.3.2. Efficacy of BCG in prevention of TB disease 
Multiple clinical trials have assessed efficacy of BCG in prevention of TB disease. 
In 1930, a Norwegian trial involving student nurses showed 80% efficacy of BCG 
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in the prevention of TB disease (Aronson, 1948). Subsequently, in the United 
Kingdom, a clinical trial involving 14-year-old tuberculin skin test (TST)-negative 
individuals showed a 78% efficacy of the Danish strain of BCG in prevention of 
TB disease (Hart and Sutherland, 1977). No evidence of protection was 
observed when the Tice strain of BCG was administered to TST-negative 
individuals in Georgia and Albama, U.S.A. (Comstock and Palmer, 1966). 
Similarly, in the Chingleput trial conducted in South India, no protection was 
observed in individuals who received either the Paris (Pasteur) or the Danish 
strains of BCG (Baily, 1980). Meta-analyses have shown the BCG vaccine is 
between 73 to 77% effective in protecting infants against severe forms of TB, 
such as meningitis and military disease (Bonifachich et al., 2006, Trunz et al., 
2006, Walker et al., 2006). However, the vaccine’s efficacy in preventing 
childhood pulmonary tuberculosis varies in different settings, ranging from 0 to 
80% (Fine, 1995). A meta-analyses of studies indicated that BCG vaccination on 
average is 50% effective in prevention of TB in adults previously vaccinated at 
birth (Brewer, 2000). Also, Mangtani et al., in a recent systematic review of 
randomized controlled trials showed that absence of prior infection with M.tb or 
environmental mycobacteria was associated with higher BCG efficacy against 
pulmonary TB in all ages (Mangtani et al., 2014). There are various other factors 
that have been put forward to explain this variability, which are discussed in 
greater detail below. 
 
1.3.2.1. Vaccine strain 
The original BCG vaccine strain developed by Calmette and Guerin was 
distributed to laboratories all over the world. Since then, several genetically 
different BCG strains have evolved through culturing of the original BCG strain 
under different conditions (Behr et al., 1999). Compared to M. bovis and M. 
tuberculosis, all BCG strains lack the region of deletion one (RD1), which 
appears to be important in mycobacterial pathogenesis. The vaccine strains 
obtained from the Pasteur Institute before 1926 (BCG-Japan and BCG-Moreau) 
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have two copies of the IS6110 insertion, compared with one copy of this 
sequence found in strains obtained from the same institute after 1931 (BCG-
Denmark, BCG-Tice and BCG-Glaxo). In addition, the latter strains lack the 
region of difference two (RD2). Currently, there are more than 20 different BCG 
vaccine strains in use worldwide (Ritz and Curtis, 2009). The most widely used 
BCG strains are BCG-Denmark (Statens Serum Institute, Denmark), BCG-
Russia (Bulbio, Bulgaria) and BCG-Japan (Japan BCG Laboratory) (Stefanova et 
al., 2003). Although not clear, it is possible that efficacy of the BCG vaccine in 
protection against TB may be partly attributed to these strain differences (Milstien 
and Gibson, 1990). Currently, there are insufficient data to suggest that different 
BCG strains could result in differential efficacy in prevention of TB disease 
(Brewer and Colditz, 1995). Aronson et al. demonstrated a lower protective 
efficacy of BCG-Phipps (44%), compared with BCG-Pasteur (59%) in a 
randomized controlled trial involving 3025 children and adults followed up for 50 
years (Aronson et al., 2004). The vaccine strains that were used by Aronson et 
al., study are not currently in use. 
 
1.3.2.2. Environmental mycobacteria 
In animal studies, exposure to environmental mycobacteria was shown to confer 
a degree of protection against subsequent challenge with M.tb (Young et al., 
2007). Furthermore, in clinical studies, individuals with evidence of exposure to 
environmental mycobacteria show some level of protection against TB (Edwards 
et al., 1973). Moreover, several species of environmental mycobacteria share 
antigens with the BCG vaccine (Tortoli, 2003). Therefore, prior exposure to 
environmental mycobacteria may lead to diminished protection conferred by 
subsequent BCG vaccination (Brandt et al., 2002). Furthermore, Flaherty et al. 
demonstrated that, in mice, exposure to environmental mycobacteria post BCG 
vaccination resulted in diminished vaccine-induced immunity to M.tb (Flaherty et 
al., 2006). In areas closer to the equator, prevalence of environmental 
mycobacterial infection is high (Comstock et al., 1974): in these areas BCG 
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appears to have a lower efficacy, compared with temperate regions (Fine, 1995). 
For example, Palmer, et al. demonstrated that guinea pigs previously exposed to 
M. fortuitum, M. avium or M. kansasii had reduced protection imparted by BCG 
(Palmer and Long, 1966). Also, in the Chingleput trial conducted in South India, 
an area with a high prevalence of environmental mycobacteria exposure, no 
protection was observed in individuals who received either the Paris (Pasteur) or 
the Danish strains of BCG (Baily, 1980). 
 
1.3.2.3. Genetic variability of different populations 
Multiple clinical studies have assessed the association of several genes 
controlling cellular immune mechanisms and susceptibility to development of TB 
(Bellamy et al., 1998, Brahmajothi et al., 1991, Goldfeld et al., 1998). A clinical 
study by Stead, et al. conducted in the USA showed infection occurred twice as 
often in black as in white individuals who had equal exposure to active TB in 
nursing homes (Stead 1990). Also, it is postulated that population genetic 
differences might explain the performance of BCG. In the United States Public 
Health Service (USPHS) trials, slightly higher BCG-induced protection against TB 
was observed among black, compared with white participants (Comstock and 
Palmer, 1966). Genetic differences in immune genes may underlie population-
wide differences, as shown by Randhawa et al., who demonstrated an 
association between polymorphisms in TLR6 and altered innate immune 
responses to M.tb and adaptive immune responses to BCG (Randhawa et al., 
2011). 
 
1.3.3.4. Operational factors 
BCG requires storage at 40C prior to administration (Lawn et al., 2009). A break 
in the cold chain may compromise the viability of the vaccine. In resource poor 
countries, it is often challenging to maintain the cold chain during vaccine 
transport (Samant et al., 2007). Although clever innovations such as heat 
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stabilization of vaccines have been introduced, it is likely that this remains a 
significant factor in delivery of a quality vaccine product.  
 
1.3.4. Efficacy of BCG in prevention of M.tb infection 
Mathematical models have demonstrated that prevention of transmission would 
have the greatest impact on the TB epidemic (Dye et al., 2013); therefore, 
vaccination aimed at reducing M.tb infection may have the same effect as 
prevention of disease. Results from various uncontrolled studies suggest that 
BCG may protect against M.tb infection (Eriksen et al., 2010, Young and 
O'Connor, 2005). In study conducted in Turkey among 979 children who were 
household contacts of adults with active TB disease, BCG vaccination was 
associated with a 24% protection against infection with M.tb (Soysal et al., 2005). 
Eisenhunt, et al. demonstrated a 38% effectiveness of prior BCG vaccination in 
prevention of M.tb infection, when 199 pupils exposed to a 9-year-old pupil with 
active pulmonary tuberculosis were evaluated (Eisenhut et al., 2009). However, 
in a study conducted in the Gambia among household contacts of adults with 
active tuberculosis, geographical proximity and the degree of shared activities 
predicted the risk of a positive TST rather than presence of BCG vaccination 
(Lienhardt et al., 2003). This indicates that multiple factors may confound the 
ability of BCG to protect against M.tb infection. 
  
1.4. New vaccination approaches for prevention of TB 
The main focus of new vaccines for prevention of TB is to induce a stronger 
cellular immune response compared with BCG. There are two main strategies 
that are being used to achieve this goal. The first is to replace BCG with 
improved recombinant live BCG constructs or an attenuated strain of M.tb as a 
prime vaccine.  The second strategy aims at enhancing the protective efficacy of 
BCG using a prime-boost subunit vaccine administered after BCG vaccination. 
 
1.4.1. Vaccines aimed at replacing BCG 
Among the approaches aimed at substituting the BCG vaccine is the 
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development of an attenuated strain of M.tb having deletions in two or more 
independent virulence genes (Larsen et al., 2009, Martin et al., 2006). An 
example of such a vaccine is the M. tuberculosis SO2 vaccine. In animal models, 
a high dose aerosol challenge of M. tuberculosis SO2 vaccinated guinea pigs 
resulted in superior levels of protection when compared with BCG vaccination, as 
measured by guinea pig survival and reduction in disease severity in the lung 
(Martin et al., 2006). 
 
A second approach aimed at replacing the BCG vaccine involves use of non-
pathogenic mycobacteria. An example is Mycobacteria w, which has been used 
for immunotherapeutic intervention against TB. The vaccine is designed to 
enhance M.tb specific T cell responses, thus potentiating the efficacy of standard 
chemotherapy. In patients with active TB, improved rates of cure was reported 
when standard chemotherapy was combined with the vaccine (Patel and 
Trapathi, 2003). Another whole cell preparation based vaccine candidate is 
Mycobacterium vaccae (M. vaccae). In a randomised controlled efficacy trial 
conducted in Tanzania, five doses of M. vaccae showed an overall efficacy of 
39% in protection against TB disease (von Reyn et al., 2010). 
 
The third rational approach aimed at replacing BCG is the generation of a 
recombinant BCG vaccine that overexpresses key genes. The rBCGDureC:Hly 
vaccine (VPM1002) expresses the listeriolysin enzyme of Listeria 
monocytogenes. This enzyme enables BCG to escape from the phagosome into 
the cytoplasm. This could result in cross-priming of CD8+ T cells via the MHC 
class I pathway (Winau et al., 2006). In addition, this vaccine is urease C-
deficient, allowing for optimal acidification of the phagosome containing the 
mycobacterium, and therefore presumed enhanced antigen processing. The 
VPM1002 vaccine is currently being evaluated in a Phase IIa clinical trial in 
South African infants. Another recombinant BCG vaccine, rBCG30, is engineered 
to overexpress the immunodominant Ag85B antigen from M.tb (Horwitz et al., 
2000). A phase I clinical trial in adults randomized to receive either rBCG30 or 
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parenteral Tice BCG showed that rBCG30 was safe and significantly increased 
the number of Ag85b-specific T cells capable of inhibiting intracellular 
mycobacteria (Hoft et al., 2008). The third BCG recombinant vaccine, Aeras 422 
was engineered to expresses a pore-forming bacterial molecule perfringolysin. 
The phase I trial of Aeras 422 was discontinued following adverse effects in 
phase I trials (Kaufmann, 2012).  
  
1.4.2. Vaccines aimed at boosting BCG immune responses 
An alternative strategy to replacing the BCG vaccine is to administer a booster 
vaccine aimed at enhancing or modulating BCG-induced immunity. This is 
achieved through use of a protein vaccine co-administered with an adjuvant to 
induce high levels of cellular immunity.  An example of such a vaccine is M72, 
which consists of the fused M.tb proteins Mtb32 and Mtb39 formulated in the 
AS01 adjuvant (Brandt et al., 2004, Leroux-Roels et al., 2013). A second subunit 
vaccine, Hybrid I, is a fusion protein of two secreted antigens: the early secreted 
antigenic target 6 (ESAT-6) and antigen 85B (Ag85B). However, the inclusion of 
ESAT-6 in Hybrid I subunit vaccine confounds the use of interferon gamma 
release assays (IGRAs) for the diagnosis of latent M.tb infection (Pai et al., 
2004). The HyVac4 subunit vaccine exchange ESAT-6 for TB10.4. Therefore 
unlike Hybrid 1, the HyVac4 vaccine maintains the advantage of allowing for the 
use of ESAT-6-specific diagnostic tests in participants vaccinated with the 
vaccine. The fourth subunit vaccine candidate currently in clinical trial is H56. 
Similar to Hybrid 1, this vaccine comprises Ag85B and ESAT-6 antigens in 
addition to a latency-associated protein Rv2660c. The H56 vaccine has a unique 
advantage in its potential ability to target dormant M.tb bacilli. 
 
The second approach in the boost strategy involves the use of a recombinant 
viral vector expressing key M.tb antigens. One such vaccine is the adenovirus 35 
based Aeras 402, which expresses a fusion protein of the mycobacterial antigens 
Ag85A, Ag85B, and TB10.4. The Aeras 402 vaccine is immunogenic and 
protective in mice and non-human primates (Magalhaes et al., 2008, Radosevic 
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et al., 2007). In a phase I clinical trial conducted in South Africa among BCG-
vaccinated adults, this vaccine was shown to be safe and to induce 
polyfunctional CD4+ and CD8+ T cells (Abel et al., 2010). The modified vaccinia 
virus Ankara (MVA) expressing antigen 85A from M.tb is another viral-vectored 
vaccine candidate. This vaccine is composed of a safe replication-deficient strain 
of vaccinia virus, as a delivery system for the mycobacterial antigen Ag85A. In 
phase I and phase IIb clinical trials, this vaccine candidate was shown to be safe 
and highly immunogenic (McShane et al., 2004, Scriba et al., 2012). MVA85A 
induced a sustained antigen-specific multifunctional cytokine producing CD4+ 
and CD8+ T cells. However in a recently completed phase IIb clinical trial of 
healthy South African infants, no efficacy against TB disease or M.tb infection 
was observed with this vaccine (Tameris et al., 2013). 
 
1.5. Immune control of M.tb 
The great majority (90%) of persons infected with M.tb do not develop active TB 
during their lifetime. This indicates that most individuals’ host response is able to 
control the replication of the bacilli. Our understanding of this immunological 
control of M.tb infection remains incomplete. A more comprehensive 
understanding of the role played by different components of the immune system 
is needed for rational design of vaccines and therapeutic interventions. This 
section focuses on the different aspects of the immune system involved in the 
control of M.tb. 
 
1.5.1. Innate immune response to M.tb 
Innate immunity refers to the host responses that occur upon first encounter with 
a pathogen. The cell types that play a role in this frontline of defense against M.tb 
infection include macrophages and dendritic cells. The innate immune arm is 
non-specific for antigens and lacks immunological memory (Kurtz, 2005). 
However in a recent study, Kleinnijenhuis et al., showed that BCG vaccination of 
in healthy volunteers resulted in a twofold-enhanced release of monocyte-derived 
cytokines, such as TNF and IL-1β (Kleinnijenhuis et al., 2012).  This suggests 
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that mycobacterial components including BCG can induce trained immunity 
through epigenetic reprogramming of innate cells. In this section, various 
components and processes that make up the innate host response to M.tb are 
discussed in greater detail. 
 
1.5.1.1. Phagocytosis and recognition of M.tb 
In the lungs, M.tb is primarily taken up by alveolar macrophages. Subsequently, 
monocyte derived macrophages and dendritic cells take part in phagocytosis of 
the inhaled M.tb (Henderson et al., 1997). Scavenger receptors mediate uptake 
of opsonised M.tb, while mannose and complement receptors take up non-
opsonised M.tb (van Crevel et al., 2002). Also, various C-type lectin receptors 
including DC-SIGN can recognise M.tb and initiate phagocytosis of the pathogen 
(Berrington and Hawn, 2007, Kleinnijenhuis et al., 2011). 
 
Different classes of pattern recognition receptors (PRRs) that play a role in the 
detection of M.tb by phagocytes have been identified (Figure 1). These include 
the Toll-like receptors (TLRs) TLR2, TLR6, TLR9 (Bafica et al., 2005, Berrington 
and Hawn, 2007), and TLR4 (Means et al., 1999). TLRs are composed of a 
cytoplasmic domain that is homologous to the signaling domain of IL-1 receptor 
that links to IL-1R-associated kinase (IRAK) through the adapter molecule 
MyD88 (Oddo et al., 1998). This serine kinase activates the transcription factors 
like NF-kb to signal the production of pro-inflammatory cytokine, IL-12 (Brightbill 
et al., 1999, Oddo et al., 1998).  The importance of TLRs in the initial host 
response to M.tb is evidenced by an increased susceptibility to M.tb in myeloid 
differentiation protein 88 (MyD88)-deficient mice (Fremond et al., 2004). 
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Figure 1: Phagocytosis and immune recognition of M.tb. Various receptors for phagocytosis 
of M.tb by macrophages and dendritic cells include the complement receptors Mannose receptors 
and scavenger receptors. TLRs are pattern recognition receptors that play a central role in 
immune recognition of M. tuberculosis. Binding of mycobacterial antigens to TLRs results in 
intracellular signaling pathways lead to cell activation and cytokine production (Adapted from 
Van Cravel, et al 2002).  
 
1.5.1.2. Intracellular control of M.tb 
Macrophages are the major cells of the immune system involved in killing of M.tb. 
The mechanisms by which the macrophages mediate the growth inhibition or 
killing of intracellular M.tb are discussed in greater detail below.  
 
Phagolysosome fusion: Upon phagocytosis of M.tb, the bacilli reside within a 
phagosome. Subsequently, the phagosome fuses with the lysosome, a complex 
vacuolar organelle (Kornfeld, 1987). The lysosome contains hydrolytic enzymes 
that are capable of degrading the phagocytosed microbe (Kornfeld, 1987). 
Fusion of the phagosome and the lysosome is followed by maturational changes 
characterised by acidification of the phagolysosome for optimal function of the 
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hydrolytic enzymes (Desjardins et al., 1994). Upon acidification of the 
phagolysosome, the lysosomal hydrolytic enzymes degrade the microbe. 
 
Reactive oxygen intermediates: The second mechanism by which macrophages 
control intracellular M.tb is by generation of free radicals. For example, hydrogen 
peroxide is a reactive oxygen intermediate (ROI) generated via an oxidative 
burst. ROI are produced by activated macrophages and are mycobactericidal 
(Walker and Lowrie, 1981). Also, macrophages generate nitric oxide and reactive 
nitrogen intermediates (RNI) in a nitric oxide synthesase-2 (NOS2) dependent 
mechanism. In mice, RNI are protective against infection with M.tb as 
demonstrated by increased disease burden in lungs of NOS2 double knockout 
mice, compared with wild type controls (MacMicking et al., 1997). In humans, 
patients with active pulmonary TB have increased levels of exhaled NO 
compared to healthy controls (Wang et al., 1998). 
 
Autophagy: Autophagy is a process in which long-lived cytosolic macromolecules 
and whole organelles are delivered to lysosomes for degradation. Autophagy 
also plays a key role in immune responses to M.tb (Harris et al., 2009). In an 
experimental study in vitro killing of intracellular bacilli was observed when 
autophagy was induced in M.tb-infected macrophages (Gutierrez et al., 2004). 
Autophagy is stimulated by the Th1 cytokines TNF-α and IFN-γ and is inhibited 
by the Th2 cytokines interleukin IL-4, IL-13 (Harris et al., 2007) and the anti-
inflammatory cytokine IL-10 (Van Grol et al., 2010). Also, vitamin D induces 
autophagy via cathelicidin (Roth et al., 2004). Autophagy plays a key role in 
antigen processing and presentation (Jagannath et al., 2009). Therefore, 
autophagy enhances the presentation of antigens to T cells and the control of 
M.tb infection. Our understanding of the cellular mechanisms involved in the 
autophagic processes would be potentially useful in designing vaccines that can 
induce autophagy to improve control of infection. 
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1.5.1.3. Cytokines produced by innate cells 
IL-12: Dendritic cells and macrophages produce IL-12 in response to 
phagocytosis of M.tb (Oppmann et al., 2000). IL-12 drives type 1 T cell (Th1) 
differentiation important in control of M.tb. The importance of IL-12 in immunity 
towards M.tb was demonstrated in animal studies that showed increased 
bacterial burden and reduced survival time in IL-12p40 gene deficient mice, 
compared with controls (Cooper et al., 1997). In humans, functional genetic 
mutations have been identified in the genes encoding IL-12p40 (Remus et al., 
2004), IL-12Rβ1 (de Jong et al., 1998) in patients with recurrent or fatal non-
tuberculous mycobacterial infections. This indicates that this cytokine is likely 
important in control of M.tb.  
 
IL-6: IL-6 is produced at the site of infection in response to infection with M.tb 
(Law et al., 1996). IL-6 has both anti- and pro-inflammatory properties. For 
example, this cytokine may inhibit the production of TNF-α (Schindler et al., 
1990). In mice, the role of IL-6 in immunity towards M.tb is evidenced by an early 
increase of bacterial burden coupled by a delay in the production of IFN-γ 
following aerosol challenge with M.tb, in IL-6 double knockout mice compared to 
controls, indicating the importance of this cytokine in early infection with M.tb 
(Saunders et al., 2000).  
 
IL-1: IL-1 is another pro-inflammatory cytokine produced by macrophages, 
monocytes and dendritic cells during infection with M.tb (Dahl et al., 1996) at the 
site of disease (Law et al., 1996). In mice, IL-1α and IL-1β double knock out mice 
have increased M.tb growth and impaired granuloma formation compared to the 
wild type (Yamada et al., 2000). Further more, mice lacking IL1-receptor type I 
have increased disease burden compared to the wild type indicating the 
importance of this cytokine in protection against TB (Juffermans et al., 2000).  
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IFN-γ: Natural killer (NK) cells, alveolar macrophages (Wang et al., 1999) and 
CD4+ and CD8+ T cells produce IFN-γ. The detailed role of this cytokine in control 
of M.tb is discussed in section 1.5.2.3. 
 
TNF-α: TNF-α is another cytokine that plays a key role in immune response to 
M.tb. The Macrophages, dendritic cells, and T cells cytokine produce TNF-α 
(Henderson et al., 1997, Ladel et al., 1997). The detailed role of this cytokine in 
control of M.tb is discussed in section 1.5.2.3. 
 
IL-10: IL-10 is an anti-inflammatory cytokine important in control of 
immunopathology resulting from excessive inflammatory response to infection 
(O'Garra and Vieira, 2007). Macrophages produce IL-10 in response to infection 
with M.tb. This cytokine inhibits production of IL-12 resulting in downregulation of 
T cell expression of IFN-γ (D'Andrea et al., 1993). Also, IL-10 downregulates 
surface expression of molecules involved in antigen presentation (Moore et al., 
2001). Furthermore, IL-10 produced by macrophages inhibits T cell proliferation 
(Gong et al., 1996). Although, IL-10 is important for prevention of 
immunopathology due to excessive inflammatory response, excessive production 
of IL-10 may result in the inability of the host to control infection. However, in 
animal studies, mice deficient in IL-10 showed no difference in control of M.tb 
infection compared to the wild type (Jung et al., 2003).  In this project, we 
assessed IL-10 production in 9-month old infants vaccinated with BCG at birth or 
at 6 weeks of age. 
 
Transforming growth factor-β: TGF-β is another anti-inflammatory cytokine 
produced by monocytes in response to M.tb infection (Toossi et al., 1995). This 
cytokine inhibits T cell response to M.tb (Rojas et al., 1999). In macrophages, 
TGF-β inhibits IFN-γ induced NOS2 production (Ding et al., 1990).  
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1.5.1.4. Antigen processing and presentation 
Dendritic cells are the most efficient antigen presenting cells (APC), and the 
bridge between innate and the adaptive immune response (Steinman and 
Hemmi, 2006). Dendritic cells directly take up M.tb or phagocytose dead innate 
immune cells containing tuberculosis bacilli. Thereafter, the M.tb antigens are 
recognised by PRRs resulting in intracellular signalling with concomitant 
maturation: upregulation of co-stimulatory molecules (CD80 and CD86), major 
histocompatibility complex (MHC) class I or class II molecules, and the 
chemokine receptor CCR7 (Trombetta and Mellman, 2005). Mature DCs are also 
able to process antigen for ultimate presentation via MHC class I and/or class II 
molecules (Inaba et al., 2000, Turley et al., 2000). DCs migrate to draining lymph 
nodes.  (Humphreys et al., 2006). In the lymph node, the following events occur 
during the priming of the naïve T cells: (i) presentation of the cognate peptide on 
the MHC class I and MHC class II molecules of the dendritic cells to CD8+ and 
CD4+ T cells, respectively; (ii) provision of co-stimulatory signals through 
interaction of CD80 (B7-1) and CD86 (B7-2) on the dendritic cell with CD28 on 
the T cell; (iii) signaling from pro-inflammatory cytokines produced by the 
dendritic cells such as IL-12 (Curtsinger et al., 1999).   
 
1.5.1.5. Immune evasion by M.tb 
Despite the various effector mechanisms aimed at growth inhibition or killing of 
the intracellular M.tb, the pathogen may survive and continue replicating within 
the macrophage. M.tb has developed several strategies to circumvent the host 
immune responses thereby enabling the pathogen to survive within the 
macrophage. For example, M.tb can prevent fusion of the phagolysosome (Hart 
et al., 1972) and the maturation of the phagolysosome (Sturgill-Koszycki et al., 
1994). In addition, M.tb produces two enzymes, urease (Clemens and Horwitz, 
1995) and glutamine synthases (Harth and Horwitz, 1999), which prevent 
acidification of the phagolysosome therefore preventing the optimal function of 
the hydrolytic enzymes. The M.tb component lipoarabinomannan has neutralising 
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properties for oxygen radicles (Chan et al., 1991). Finally, M.tb preferentially 
induces production of IL-10 which inhibits TNF-α mediated apoptosis of the 
macrophage. Apoptosis of the macrophage results in the death of the 
intracellular M.tb thus limiting the spread of the pathogen (Molloy et al., 1994). 
Therefore, by inhibiting apoptosis, M.tb is able to survive and infect other APCs. 
 
1.5.2. Adaptive immune response to M.tb 
The presentation of the mycobacterial antigens to the T cell results in priming of 
CD4+ and CD8+ T cells. Upon successful activation, T cells differentiate, undergo 
clonal expansion and develop effector function (Macatonia et al., 1995). 
Subsequently, the differentiated T cells migrate from the lymph nodes towards 
the site of infection to execute their effector functions (Mempel et al., 2004). The 
adaptive immune response is specific for M.tb and is characterized by 
development of immunological memory. In this section, cells and effector 
molecules involved in specific immune responses to M.tb are discussed in 
greater detail. 
 
1.5.2.1. Classically restricted T cells    
CD4+ T cells: In mice, the importance of CD4+ T cells in a protective immune 
response against M.tb is supported by increased mortality rates observed in M.tb 
infected CD4+ T cell deficient mice, compared with wild type mice (Caruso et al., 
1999). M.tb infected cynomolgus monkeys treated with anti-CD4+ T cell 
antibodies showed increased pathology and bacterial burden in comparison to 
the controls (Chen 2012). Furthermore, an association between reactivation of 
TB in cynomologus monkeys with LTBI and co-infected with SIV correlated with 
depletion of peripheral CD4+ T cell counts (Diedrich et al., 2010). In HIV-infected 
humans, progression to TB disease correlates with CD4+ T cell decline (Aaron et 
al., 2004, Lawn et al., 2009). 
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Specific CD4+ T cells recognise M.tb peptides on the MHC class II molecule of 
APCs, which may result in multiple effector functions, including production of Th1 
cytokines such as IFN-γ, TNF-α and IL-2. CD4+ T cells may also produce 
cytotoxic molecules in response to M.tb antigens (Bastian et al., 2008). Canaday 
et al., reported upregulation of mRNA expression for granzyme A and B, 
granulysin and perforin in CD4+ T cells from healthy tuberculin skin test (TST) 
individuals following incubation of PBMC with M.tb. Moreover, CD4+ T cells from 
these individuals lysed M.tb infected monocytes in vitro (Canaday et al., 2001).  
As CD4+ T cells are important in immune response to M.tb, we planned to 
investigate this subset in assessment of BCG induced immunity in infants 
vaccinated at birth or at 6 weeks of age. 
 
CD8+ T cells: In animal models, the importance of CD8+ T cell in immunity 
against M.tb is demonstrated by the lesser control of M.tb infection in mice 
lacking MHC I molecules, compared with wild type mice (van Pinxteren et al., 
2000). In BCG-vaccinated rhesus macaques, CD8+ T cells depletion results in 
compromised BCG-induced immune control of M.tb replication. Further, in the 
rhesus macaques previously infected with M.tb and cured by chemotherapy, 
depletion of CD8+ T cells resulted in increased risk of development of active TB 
upon re-infection with M.tb (Chen 2009).  In humans, Bruns et al., reported 
decreased antimicrobial activity mediated by effector memory CD8+ T cells in 
patients receiving anti-TNF-α treatment for rheumatoid arthritis, suggesting that 
CD8+ T cells contribute to host defense against tuberculosis. (Bruns et al., 2009). 
The CD8+ T cells recognise cytosolic antigens loaded as peptides onto MHC 
class I molecules of APCs (Bachmann et al., 1996).   
 
The CD8+ T cell effector function is mediated through production of cytolytic 
molecules such as granzymes, granulysin and perforin (Woodworth et al., 2008, 
Canaday et al., 2001). In addition, CD8+ T cells produce the Th1 cytokine IFN-γ 
(Vesosky et al., 2009), among others. Given the putative role of CD8+ T cells in 
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control of M.tb, we therefore planned to investigate this subset in assessment of 
BCG induced immunity in infants vaccinated at birth or at 6 weeks of age. 
 
1.5.2.2. Non-classically restricted T cells  
Gamma delta (γδ) T cells: γδ T-cells are a subset of lymphocyte that express γ 
and δ chains as the T cell receptor on their surface, compared with the 
conventional CD4+ and CD8+ T cells which express a T-cell receptor composed 
of a dimer of α and β protein chains. γδ T-cells are activated by non-peptide 
phosphoantigens, are not restricted by classical MHC molecules and may 
respond rapidly upon activation (Hayday, 2000, Holtmeier and Kabelitz, 2005).  
The Vγ9Vδ2 subset of Adult γδ T-cells are known for their capacity to express 
cytotoxic molecules such as perforin and granzymes, and their high production of 
the Th1 cytokine, IFN-γ upon in vitro stimulation. Spencer, et al. in a clinical study 
demonstrated that granzyme A produced by γ9δ2 T cells was essential for TNF-α 
production by monocytes resulting in control of intracellular mycobacterial growth 
(Spencer et al., 2013). In viral models, functional fetal γδ T cell responses have 
been shown to be present as early as 21 weeks in utero, suggesting an important 
role of these cells against infection in the prenatal period (Vermijlen et al., 2010). 
In a clinical study, specific functional γδ T cell responses have been 
demonstrated in adults following BCG vaccination (Hoft et al., 1998, Spencer et 
al., 2008). Furthermore, Vermijlen et al. showed that γδ T cells (especially the 
Vγ9+ subset) from PBMC derived from South African 10 week-old infants 
vaccinated at birth with BCG, showed greater capacity to proliferate compared 
with cord blood PBMC from infants. In addition, the γδ T cells from these 10-week 
old infants showed high expression of cytotoxic markers (perforin, granzyme A, 
granzyme B, granulysin), were more highly differentiated, and expressed more 
IFN-γ and TNF-α upon stimulation with BCG (David Vermijlen, unpublished data). 
Although γδ T cells contribute to immunity towards M.tb, our focus in this project 
was on BCG specific αβ T cell subsets, for practical reasons. 
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NKT cells (CD1-restricted ab T cells): The natural killer T (NKT) cell subset 
express the α and β receptor dimer, are stimulated by mycobacterial lipids and 
are restricted by the CD1 molecule. CD1 is an MHC-like molecule composed of 
the a chain and non-covalently bound to β2-microglobulin (Zeng et al., 1997). 
Mycobacterial lipids stimulate CD1-restricted cells to produce cytokine and 
cytolytic molecules (Stenger et al., 1997). In experimental studies using guinea 
pigs, an enhanced CD1-restricted ab T cell response was observed in BCG 
vaccinated animals, compared with the placebo group (Hiromatsu et al., 2002). 
Also, a clinical study, PPD-positive individuals had higher mycobacterial lipid 
specific CD-1 restricted proliferative response, compared with PPD-negative 
controls. This indicates the presence of memory M.tb-specific CD1-resticted ab T 
cells (Ulrichs et al., 2003). In this project our focus was on BCG-specific 
conventional ab T cell subsets. Therefore we did not assess for BCG induced 
CD1-resticted ab T cells, again, for practical reasons. 
 
Mucosal associated invariant T cells (MAIT): Mucosal associated invariant T cells 
(MAIT) constitute up to 4% of peripheral blood T cells. These cells are 
characterized by the expression of Vα7.2/Jα33 TCR (Martin 2009). MAIT cells 
are frequent in the lungs and may be important as first line defense during 
primary infection with M.tb. Lewinsohn, et al. in a clinical study showed that a 
proportion of MAIT CD8+ T cells are restricted by MHC-related molecule 1 (MR1); 
M.tb induced increased expression of MR1 on the surface of lung epithelial cell. 
Finally, MAIT cells recognize lung epithelial cells infected with M.tb (Lewinsohn 
2000). However, the M.tb-reactive MAIT cells are non-specific for M.tb and can 
detect cells infected with other pathogenic organisms. In this project we did not 
assess MAIT cells, for practical reasons. 
 
1.5.2.3. Th1 cytokines 
IFN-γ: IFN-γ is a key effector cytokine in immune response to M.tb. In an 
experimental study where mice were vaccinated with BCG and boosted with 
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modified vaccinia Ankara expressing-antigen 85A (MVA85A), followed by an M.tb 
challenge, frequencies of Ag85A-specific IFN-γ-expressing T cells were positively 
correlated with reduced bacterial load in the lungs, supporting the role of IFN-γ in 
immunity towards M.tb (Goonetilleke et al., 2003). In addition, humans with 
mutations in genes associated with IFN-γ production or signaling show an 
increased risk of disease due to mycobacterial disease (Bogunovic et al., 2012, 
Newport et al., 1996, Ottenhoff et al., 2000).  
 
During induction of M.tb immunity, IL-12 is produced by antigen bearing APCs to 
drive Th1 differentiation and IFN-γ production by T cells (Manetti et al., 1994). 
IFN-γ promotes Th1 differentiation, production of IL-12, and activation of APCs 
through a positive feedback mechanism. In addition, IFN-γ inhibits the 
differentiation of naïve CD4+ T cells to Th2 subsets. Furthermore, IFN-γ 
enhances the initiation and amplification of T cell-dependent immune response 
by stimulating expression of MHC molecules and B7 co-stimulatory molecules on 
APCs (Zhou, 2009). In the event of M.tb exposure and infection, it is proposed 
that BCG-specific IFN-γ produced by T cells activates infected macrophages 
(Figure 2), to control intracellular M.tb directly. (Herbst et al., 2011).  
 
TNF-α: The role of TNF-α in control of M.tb has been shown by increased 
bacterial burden and delayed granuloma formation in mice deficient for the 55 
kDa TNF-α receptor or following anti-TNF-α monoclonal antibody (mAb) 
administration (Bean et al., 1999). In humans, the role of mycobacteria-specific 
TNF-α in M.tb immunity has been shown by an increased risk of TB reactivation 
in rheumatoid arthritis patients receiving anti TNF-α treatment (Nacci and 
Matucci-Cerinic, 2011, Wallis, 2007, Keane et al., 2001). In TB immunity, TNF-
α enhances chemotaxis of APCs such as, neutrophils and DCs to the site of 
infection. Furthermore, TNF-α  supports formation and maintenance of 
granulomas (Algood et al., 2005).  
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Figure 2. A simplified model of the M.tb induced immune response: (A) Mycobacterial 
peptides are presented on MHC molecules of a BCG infected APC to the T cell receptor leading 
to activation of the T cell. In addition, IL-12 produced by the infected macrophage provides 
signals to further activate the T cell, which then produces IFN-γ. This cytokine in turn activates 
the infected macrophage. The activated macrophage produces reactive oxygen intermediates 
(ROI) and nitric oxide (NO), which can directly kill the intracellular bacillus.  
 
 
1.5.2.4. Th17 cytokine 
IL-17 is a pro-inflammatory cytokine (Harrington et al., 2006).  The role of IL-17 in 
TB immunity is supported by an experimental M.tb challenge mouse model that 
demonstrated IL-17 associated enhanced protection against TB development via 
recruitment of neutrophils and monocytes to the lungs, with concomitant 
granuloma formation in wild type mice compared to IL-17 KO mice (Umemura et 
al., 2007). Additionally, IL-17 has been shown to enhance recruitment of the Th1 
cells to the lungs in mice (Khader et al., 2007, Wozniak et al., 2006).  
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1.5.2.5. Th2 cytokines 
High levels of Th2 cytokines may attenuate Th1 immune responses and impede 
induction of anti-mycobacterial immunity (Rook, 2007). The Th2 cytokines, IL-4 
and IL-13, cause alternate macrophage activation, which may negatively impact 
the generation of protective immunity against M.tb (Martinez et al., 2009). 
Indeed, Elias et al., reported a decrease in Th2 cytokine levels, as well as 
enhanced PPD-specific IFN-γ expression, in individuals who received anti-
helminth medication compared to the untreated controls (Elias et al., 2001).  
 
1.5.2.6. T regulatory cytokines 
Regulatory T cells (Tregs) are important in regulation of immune responses to 
prevent immunopathology (Sakaguchi, 2005). Tregs produce IL-10 and 
transforming growth factor (TGF)-β, both of which inhibit Th1 and cytotoxic 
responses (Fiorentino et al., 1991, O'Garra and Vieira, 2004). In addition, 
increased levels of IL-10 and TGF-β have been reported in the lungs of TB 
patients, compared with controls (Bonecini-Almeida et al., 2004). 
 
1.5.2.7. Cytotoxic T cell function  
Cytotoxic T lymphocytes (CTLs) mediate their effector functions through the 
death receptor pathways (Kagi et al., 1994). Furthermore, CTL and NK cells 
secrete cytolytic molecules such as perforin, granulysin and granzymes that are 
important in the control of intracellular infections. In vitro studies have 
demonstrated that cytotoxic CD8+ T cells (Turner and Dockrell, 1996) as well as 
CD4+ T cells (Canaday et al., 2001) play a cytolytic role in immunity against M.tb. 
 
Perforin: The proposed role for perforin in mediating immunity against M.tb 
involves perforation of cell membrane of an infected cell to permit entry of the 
cytolytic granzymes that directly kill M.tb or the infected cell (Thiery et al., 2011). 
Supporting the role of perforin in TB immunity is a study by Rahman et al. that 
	   26	  
showed an association between frequencies of perforin-expressing cells and 
protection when non-human primates vaccinated with a novel TB vaccine 
combination (rBCG/rAD35) and subsequently challenged with M.tb (Rahman et 
al., 2012). Furthermore, in a clinical study, Andersson et al, demonstrated 
decreased mRNA expression levels of perforin in lung lesions from patients with 
pulmonary TB, compared with those from uninfected controls (Andersson et al., 
2007), suggesting that perforin-mediated cytotoxicity is an important aspect of T 
cell immunity (Stenger and Modlin, 1998). 
 
Granulysin: Granulysin is a cytotoxic and proinflammatory molecule belonging to 
the saposin-like family of lipid binding proteins. Granulysin is found in association 
with perforin in cytolytic granules of CTLs and NK cells (Pena and Krensky, 1997, 
Clayberger and Krensky, 2003). This molecule has a broad cytolytic activity 
against tumors cells and microbes including M.tb (Stenger and Modlin, 1998). 
The cytotoxic effect of granulysin is dependent on perforin (Stenger and Modlin, 
1998). The mechanism of granulysin cytotoxicity involves disruption of the target 
cell membrane leading to influx of extracellular calcium (Kaspar et al., 2001), the 
release of cytochrome c and the apoptosis-inducing factor (AIF), leading to the 
death of the target cell (Okada et al., 2003). In addition, granulysin has 
chemoattractant properties for T cells and monocytes (Deng et al., 2005). In a 
clinical study, patients with active TB showed decreased serum levels of 
granulysin, compared with healthy controls, suggesting the importance of 
granulysin in protective immunity against M.tb (Di Liberto et al., 2007). 
Furthermore, Klucar et al, demonstrated perforin and granulysin dependent lysis 
and growth inhibition of M.tb by cytolytic CD4+ T cells (Klucar et al., 2008). 
 
Granzymes: Granzymes are serine proteases that are contained in cytoplasmic 
granules of CTLs. In humans, 5 granzymes encoded by 5 genes have been 
described; grzA, grzB, grzK, grzH, and grzM. Among these, grzA and grzB are 
well characterised and associated with induction of apoptosis in the target cell 
(Zhang 2001). Perforin is essential for translocation of granzymes A and B to the 
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nucleus to induce apoptosis of the target cell. Granzyme A induces apoptosis 
through stimulating the generation of ROS resulting in DNA damage and cell 
death (Chowdhury and Lieberman, 2008). Granzyme B directly activates 
executioner caspases 3 and 7, which results in apoptosis of the target cell 
(Thomas et al., 2000). Healthy individuals from households of patients with TB 
disease demonstrate greater levels of granzymes A and B in blood stimulated 
with CFP-10 peptides, compared with the patients themselves (Madhan Kumar 
and Raja, 2010). 
 
1.6. Granuloma formation 
Formation of the granuloma begins with the migration of the M.tb-specific T cells 
from the regional lymph nodes to the infection site, in the lungs. At the infection 
site, M.tb specific T cells interact with infected macrophages. This results in the 
production of proinflammatory cytokines resulting in recruitment of additional 
mononuclear cells and T cells leading to formation of a granuloma (Davis and 
Ramakrishnan, 2009, Kaufmann, 2001). The granuloma, the hallmark of M.tb 
infection, is a well organised structure consisting of a central area with infected 
macrophages, giant foamy cells and Langhans cells, surrounded by T cells and B 
cells (Russell et al., 2009). The granuloma enables containment of the pathogen 
(Walzl et al., 2011). In the granuloma, the bacilli may be killed or prevented from 
replicating thereby persisting in a latent state.  In 5% of cases, the intracellular 
M.tb bacilli continue to replicate within the granuloma causing death of the 
infected macrophages.  This results in formation of caseous necrotic area at the 
center of the granuloma. The destruction due to necrosis may spread to the rest 
of the granuloma resulting in lung tissue damage and cavitation. Dissemination of 
the M.tb bacilli may occur when the cavity erodes into a blood vessel. 
 
 
1.7. Immune correlates of protection  
Correlates of protection could be defined as markers that predict protection 
against TB disease when vaccinated persons are compared with unvaccinated 
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control persons. In the presence of a known partially efficacious vaccine like 
BCG, it is not possible to conduct placebo-controlled trials to identify correlates of 
protection for ethical reasons. We therefore use the term correlates of risk of 
developing TB disease. (Qin et al., 2007). Our knowledge of the immune 
correlates for protection against development of TB remains limited. Therefore, in 
TB vaccine trials, we measure markers of immune responses that are critical for 
protection against M.tb, e.g., Th1 cytokines production. In an experimental study, 
boosting BCG-primed mice with a recombinant adenovirus expressing M.tb 
Ag85A resulted in greater median fluorescence intensities of polyfunctional CD4+ 
T cells, expressing multiple Th1 cytokines together, that correlated with 
protection against development of TB (Forbes et al., 2008). However, in a clinical 
study conducted in South Africa, the frequency of polyfunctional CD4+ T cells 
expressing multiple Th1 cytokines together, did not correlate with the risk of 
development of TB (Kagina et al., 2010). This may be explained by the presence 
of other unknown function of CD4+ T cells that may be important in protection 
against TB other that production of IFN-γ and TNF-α (Gallegos et al., 2011).  
 
1.8. BCG-induced immunity 
1.8.1. BCG induced cytokine response 
Although the correlates of protection against TB are not known, we proposed to 
investigate CD4+ and CD8+ T cell immunity thought to be critical for control of 
M.tb. In infants and adults, previous studies have reported that vaccination with 
BCG at birth mainly induces specific CD4+ and CD8+ T cells expressing IFN-γ 
(Hoft et al., 2012, Murray et al., 2006, Smith et al., 1999, Soares et al., 2008). 
Also, neonatal BCG vaccination induces specific TNF-α  production by both 
CD4+ and CD8+ T cells (Lalor et al., 2011, Soares et al., 2008). We therefore 
evaluated the frequencies of BCG-specific IFN-γ and TNF-α expressing CD4+ 
and CD8+ T cells in infants vaccinated with BCG at birth and 6 weeks of age. 
 
Moreover, neonatal BCG vaccination also induces IL-2, another Th1 associated 
cytokine (Smith et al., 1999, Soares et al., 2008). Antigen experienced T cell 
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memory pools require IL-2 for maintenance and expansion. The mechanism 
involves IL-2 induced production of the anti-apoptotic marker, Bcl-2 (Miyazaki et 
al., 1995). In addition, IL-2 enhances production of the Th1 cytokine, IFN-γ. A 
study done in our laboratory showed measurable frequencies of BCG-specific IL-
2, produced by conventional T cells in 10 week-old infants, vaccinated with BCG 
at birth (Kagina et al., 2009). We therefore investigated whether frequencies of 
BCG-specific IL-2 expressing CD4+ and CD8+ T cells in infants vaccinated with 
BCG at birth would be greater than those of infants vaccinated at 6 weeks of age. 
 
BCG vaccination also induces IL-17 producing CD4+ T cells. In a clinical study 
conducted by our laboratory, BCG-specific IL-17 producing CD4+ T cells were 
detected in healthy adults, previously vaccinated with BCG at birth (Scriba et al., 
2008). Kagina et al. also showed that BCG induces IL-17-producing T cells (Th17 
cells) (Kagina et al., 2010). In this project, we were therefore interested in 
establishing whether frequencies of BCG-specific IL-17 CD4+ and CD8+ T cells 
would be greater when the vaccine is administered at birth than at 6 weeks of 
age. 
 
BCG is an intracellular organism that induces primarily Th1-mediated immune 
responses. However, studies conducted among infants in Malawi reported PPD-
induced IL-4 production in BCG vaccinated infants. (Lalor et al., 2010). 
Furthermore, PPD-induced IL-13 production among BCG vaccinated infants was 
reported in this study, as well as in BCG vaccinated infants from the Gambia 
(Lalor et al., 2010, Burl et al., 2010). 
 
Also, BCG vaccination induces perforin producing CD4+ T cells. Semple et al, 
demonstrated BCG-induced cytotoxic T cells (Tc) producing perforin in 10-weeks 
infants (Semple et al., 2011). We therefore compared BCG-specific perforin-
expressing CD4+ and CD8+ T cells when the vaccine is administered at birth and 
6 weeks of age based on evidence showing that this cytotoxic molecule is 
induced in infants following the administration of the vaccine (Semple et al., 
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2011). We used CD69 antibody staining to identify BCG-activated, perforin 
expressing CD4+ and CD8+ T cells.  
 
In animal studies, BCG vaccination has been shown to induce granulysin-
producing CD4+ T cells (Endsley et al., 2004). Semple et al., showed that BCG 
vaccination of newborns does induce increased production of granulysin-
producing CD4+ and CD8+ T cells (Semple et al., 2011). However, in this project, 
our focus was not on assessing BCG-specific granulysin expressing CD4+ and 
CD8+ T cells in our study participants. 
 
1.8.2. BCG induced antibody responses   
Evidence from animal studies indicates that BCG vaccination results in 
detectable levels of lipoarabinomannan (LAM)-specific immunoglobulin (Ig) G 
(Watanabe et al., 2006, Maglione et al., 2008). Furthermore, Brown et al in a 
clinical study demonstrated elevated LAM-specific antibodies in BCG vaccinated 
individuals (Brown et al., 2003, de Valliere et al., 2005), indicating that BCG 
induces specific antibody (Ab) responses. In addition, BCG vaccination has been 
shown to induce long-lived memory B cells in individuals lacking ESAT-6 and 
CFP-10 responses (Sebina et al., 2012). A clinical study by de Valliere, et al. 
investigating the role of BCG-induced Ab responses in serum samples from BCG 
vaccinated volunteers showed enhanced phagocytosis of BCG in post 
vaccination samples, enhanced growth inhibitory effects of neutrophils and 
monocytes by BCG-induced antibodies, as well as an enhanced proliferative and 
IFN-γ production by specific CD4+ and CD8+ T cells compared to the 
unvaccinated controls (de Valliere et al., 2005). In this project, we did not focus 
on assessing BCG-specific Ab production. 
 
1.8.3. Memory phenotypes of BCG-specific T cells 
Effective vaccines induce long-lived immunity by generating immunological 
memory (Cellerai et al., 2007, Seder et al., 2008, Miller et al., 2008). Therefore, 
quantification of BCG-induced memory T cells is important. Completed studies 
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from our laboratory and others have shown that BCG vaccination induces 
immunological memory (Soares et al., 2013, Weir et al., 2008).  
 
Different subsets of memory T cells can be defined by evaluating expression of 
different surface markers. For example, CD45RA expression may be used to 
differentiate naïve from memory T cells (Michie et al., 1992). In addition, subsets 
of memory T cells can be classified based on expression of chemokine 
receptors, for example CCR7 (Sallusto et al., 1999). CCR7- T cells have 
immediate effector function and home to sites of inflammation. On the contrary, 
CCR7+ T cells home to secondary lymphoid organs (Campbell and Butcher, 
2000). On the basis of CD45RA and CCR7 co-expression, T cells may be 
classified as naïve-like (CD45RA+CCR7+, TNaive) which are non-antigen 
experienced; central memory (CD45RA−CCR7+, TCM) which are long lived and 
have the potential to expand rapidly upon subsequent encounter with specific 
antigen; effector memory (CD45RA−CCR7−, TEM) are associated with preferential 
production of immediate effector molecules, such as IFN-g and terminally 
differentiated effector memory (CD4+5RA+CCR7−, TEMRA) are the most 
differentiated subset based on telomere length (Harari et al., 2005).  
 
In addition to CD45RA and CCR7 markers, memory T cell subsets can also be 
classified based on expression of CD27 (Fritsch et al., 2005). CD27 functions as 
a co-stimulatory molecule (Croft, 2009, Nolte et al., 2009). CD27 is expressed on 
naive and less differentiated memory T cells (Hintzen et al., 1994). Repeated 
antigenic stimulation of T cells leads to irreversible loss of CD27 expression (De 
Jong et al., 1992). BCG-specific memory T cells previously described include 
naive, effector, central and terminally differentiated T cells (Kagina et al., 2009, 
Soares et al., 2013, Tena-Coki et al., 2010). In this project, we assessed the 
memory and maturational phenotypes of BCG-specific cells in infants vaccinated 
with BCG at birth and 6 weeks of age. 
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1.8.4. Kinetics of BCG induced immune responses  
Current novel vaccination strategies against TB under development involve use 
of BCG as the prime vaccine, followed by boosting with a second vaccine. 
Therefore, knowledge of the kinetics of BCG induced immunity is of critical 
importance in determining the optimal time to administer boost vaccines. In a 
study conducted in the UK among adolescents, Weir, et al. showed that BCG-
induced IFN-γ responses waned after 3 months post vaccination among 
adolescents. In addition, in the same study, adolescents vaccinated at birth 
showed detectable BCG induced immune responses up to 14 years of age (Weir 
et al., 2008). In another study conducted in our laboratory among infants, Soares 
et al., reported BCG induced immunity peaked between 6-10 weeks of age; the 
CD4+ T cell responses at the peak were characterised by predominant 
production of IFN-γ; after the contraction phase, BCG specific T cells appeared to 
be a combination of central and effector memory phenotypes, and produced 
combinations of the Th1 cytokines IFN-γ, IL-2 and TNF-α (Soares et al., 2013). 
Therefore it may be ideal to boost BCG immune responses at 14 weeks post 
BCG vaccination, after the peak effector immune response phase. This would 
reduce the risk of activation induced cell death that may occur when boosting is 
done at the peak (6-10 weeks) of the immune response, when cells are prone to 
exhaustion (McKinstry et al., 2007). Furthermore, boosting at 6 weeks or at 10 
weeks would mean co-administering the vaccine with other EPI vaccines, which 
may result in reduced Th1 responses to the novel TB vaccine (Ota et al., 2011).  
 
1.8.5. Co-variates in BCG-induced immunity 
Studies evaluating immune response to BCG indicate that various factors may 
impact the vaccine-induced immunity. These covariates are discussed in greater 
detail below. 
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1.8.5.1. Route of vaccination 
Upon administration of BCG intradermally or percutaneously, BCG is taken up by 
resident APCs, processed and presented to T cells present in regional lymph 
nodes. Different populations of APCs predominate in different tissues (Knight and 
Stagg, 1993). Also, different APCs have distinct antigen presenting properties 
(Vidard et al., 1992). Therefore, administration of a vaccine via different routes 
may result in differential vaccine-induced immunity. For example, studies of 
acute and chronic viral infection show differential immune responses when 
vaccines are administered using different routes (Holland et al., 2008). In a 
clinical study by Davids et al., greater frequencies of BCG-specific IFN-γ 
expressing CD4+ and CD8+ T cells were found in whole blood from infants who 
received percutaneous Japanese BCG, compared to those who received 
intradermal Danish BCG at birth (Davids et al., 2006). This indicates that the 
route of vaccination may have an effect on vaccine-induced immunity. 
 
1.8.5.2. Vaccine strain 
Various clinical studies have investigated the differences in immunogenicity in 
individuals vaccinated with different BCG strains (Hussey et al., 2002, Davids et 
al., 2006, Gorak-Stolinska et al., 2006) (Aguirre-Blanco 2007). For example, 
Gorak-Stolinska et al., reported similar immunogenicity as measured by the PPD-
specific IFN-γ responses, among school children one year post-vaccination with 
either the Danish-SSI 1331 or the Glaxo-Evans 1077 vaccine (Gorak-Stolinska et 
al., 2006). In another clinical study from South Africa, 10 week-old infants 
vaccinated with percutaneous Japanese BCG showed greater frequencies of 
IFN-γ expressing CD4+ and CD8+ T cells, and greater CD4+ and CD8+ T cell 
proliferation compared with infants who had received intradermal Danish BCG 
(Davids et al., 2006).  However when followed up for two years post BCG 
vaccination, there was no difference in efficacy against TB between infants 
randomized to receive Tokyo 172 BCG through the intradermal or percutaneous 
route (Hawkridge et al., 2008). In a recent randomized clinical trial, Ritz et al., 
	   34	  
compared the immune response to BCG-Denmark, BCG-Japan and BCG-
Russia. Infants in the BCG-Denmark and BCG-Japan groups had a higher 
proportion of polyfunctional CD4+ T cells compared to infants in the BCG-Russia 
vaccination group (Ritz et al., 2012). Similarly, greater IFN-γ responses to 
mycobacterial antigens were observed in infants previously vaccinated with BCG 
Danish strain compared to those who received either BCG-Russia or BCG-
Bulgaria strains (Anderson et al., 2012).  
 
1.8.5.3. Co-infection with helminths 
Infection with helminths mainly induces a Th2 immune response characterised by 
production of IL-4 and IL-5 (Bundy et al., 2000). In addition, helminths induce 
production of IL-10, an anti-inflammatory cytokine. Therefore, immune responses 
induced by helminth infection may result in attenuation of BCG-induced Th1 
responses. In support of this hypothesis is a study by Elias et al., showing that 
BCG-specific Th1 responses were greater in adults who received anti-helminth 
medication prior to BCG vaccination, compared with those in the placebo group 
(Elias et al., 2001). The reduced Th1 responses were associated with greater 
frequencies of TGF-β producing CD4+ T cells in the placebo group (Elias et al., 
2008). In another clinical study, the BCG-specific immune responses of children 
born to mothers with helminth infection were reduced compared to those born to 
mothers without the infection (Malhotra et al., 1999). Moreover, Webb et al., in a 
randomised clinical trial, showed that infants born to mothers randomised to 
receive anti-helminth medication showed decreased IL-5 and IL-13 levels 
compared to those in the placebo group (Webb et al., 2011). On the contrary, no 
effect was observed on mycobacterial specific Th1 responses among Ugandan 
infants born to helminth-infected mothers (Elliott et al., 2010). It is important to 
note that in young infants, the likelihood of helminth infection is lower compared 
to that in observed in adults (Belyhun et al., 2010).  
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1.8.5.4. Host immune deficiency 
The immune response to live BCG is mediated through the adaptive arm of the 
immune system. Therefore, in an immune deficiency state, such as during HIV 
infection, characterized by depletion of CD4+ T cells, the immune response to 
BCG is compromised. In a clinical study conducted in our laboratory, Mansoor et 
al., showed that HIV infection in infants severely impairs BCG-induced immune 
responses (Mansoor et al., 2009). Furthermore, there have been case reports of 
BCG disease (BCGosis) following administration of BCG to immune 
compromised babies (Hesseling et al., 2009). Therefore, WHO current 
recommends that BCG not be given to HIV-exposed babies, if public health 
structures allow this (Hesseling et al., 2008). Data from our study on effect of 
delaying BCG vaccination will inform if there may be an immunological beneficial 
effect of administering BCG to HIV-exposed uninfected infants later in life.  
 
1.8.5.5. Age at which BCG is administered 
Neonatal cell-mediated immune responses are quantitatively and qualitatively 
different from those of adults. This is evidenced by the increased susceptibility to 
intracellular infections such cytomegalovirus and TB in infants, compared with 
adults (Siegrist, 2001). Compared with adults, neonates’ innate cells produce 
less of the Th1-promoting cytokine IL-12 (Goriely et al., 2004, Corbett et al., 
2010), and display diminished TLR4 expression (Sadeghi et al., 2007) and 
signaling (Yan et al., 2004). In addition, the adaptation of the neonatal immune 
system to the in utero environment is associated with a bias towards type 2 
immune responses in newborns (Warner, 2004). This may potentially result in a 
suboptimal response to BCG. During the first 6 weeks of life, the infant immune 
system would have started adapting to the new an ex-utero environment 
(Yazdanbakhsh et al., 2002) and might therefore be better primed to respond to 
BCG if given at 6 weeks of age. 
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Data from our laboratory has previously shown that delaying BCG vaccination to 
10 weeks of age resulted in higher frequency of BCG-induced polyfunctional T 
cells at one year of age (Kagina et al., 2009). 
 
1.9. Rationale of the study  
Currently, our knowledge of the factors constituting optimal protection against 
M.tb infection and active disease remain limited (Hanekom, 2005). Therefore, 
BCG vaccination remains critical in understanding the nature of vaccine-induced 
immunity. What we learn from the current BCG is likely to apply also to modified 
BCG vaccines of the future. Also, BCG is likely to form the cornerstone of future 
TB vaccination strategies as the prime vaccine in the prime-boost paradigm of 
new vaccines (Parida and Kaufmann, 2010). Therefore, studies designed to 
enhance the understanding of the optimal schedule to vaccinate infants with 
BCG for optimal priming are research priorities.  
  
Multiple studies have investigated the effect of delaying BCG vaccination (Table 
1). Comparable host responses were shown between birth and delayed 
vaccination when PPD-induced IFN-γ production was used as the outcome (Burl 
et al., 2010, Hussey et al., 2002, Marchant et al., 1999). In contrast, a more 
detailed study from our group in South Africa showed that delaying BCG from 
birth to 10 weeks of age resulted in induction of a greater frequency of BCG-
specific polyfunctional CD4+ T cells, i.e., cells that express IFN-γ, TNF-α and IL-2 
together (Kagina et al., 2009). Importantly, in all previous studies, infants were 
randomized to receive BCG either at birth or later age after birth.   In contrast, we 
wished to address effect on BCG-induced immune response, in the setting where 
delayed vaccination occurred due to home delivery of infants. We hypothesized 
that BCG vaccination at 6 weeks of age would result in an enhanced specific T 
cell response, compared with administration at birth.  
 
Previous studies investigating the effect of delaying BCG vaccination on BCG- 
induced immunity have either used the tuberculin skin test (Ildirim et al., 1992), 
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soluble cytokine levels (Burl et al., 2010, Hussey et al., 2002, Ildirim et al., 1992) 
or T cell cytokine responses (Kagina et al., 2009) as the immunological readouts. 
In our study, we simultaneously assessed different immunological readouts as 
detailed in the aims section below. This multipronged approach allowed for a 
comprehensive comparative picture of BCG-induced immunity in infants 
vaccinated with BCG at birth and at 6 weeks of age. Our report is of the most 
comprehensive immunological assessment of delayed BCG vaccination reported 
to date.  
In this study, we looked at 6 weeks of age, because we propose that earlier BCG 
vaccination in high endemic areas may be advantageous. This may as well be 
the optimal time to vaccinate infants that are exposed to HIV infection. 
We hypothesized that infants who received BCG at 6 weeks of age will show an 
enhanced BCG-induced T cell immunity compared to infants vaccinated at birth. 
 
Study Duration of 
BCG delay 
Method to 
measure 
outcome 
Key findings 
Ildrim et al. 
1992 
12 weeks TST Greater PPD specific induration 
at one year in delayed BCG 
group 
 
Marchant et 
al. 1999 
8 and 16 
weeks 
Elisa No difference in PPD specific 
Th1 responses at one year in 
both groups 
 
Hussey et al. 
2002 
10 weeks Elisa No difference PPD specific Th1 
cytokine response at one year 
in both groups 
 
Kagina et al. 
2009 
10 weeks WB-ICS Greater Th1 cytokine 
responses at one year in 
delayed group 
 
Burl et al. 
2010 
18 weeks Elisa No difference Th1 and Th17 
PPD specific responses at 9 
months 
Abbreviations used: Purified protein derivative, PPD; Tuberculin skin test, TST; 
Enzyme linked immunosorbet assay, Elisa.  
 
Table 1: Delayed BCG vaccination studies. The duration of delay in BCG vaccination from birth, 
assay used as well as the outcomes of the studies are show.  
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1.10. Objectives of this project 
1. To optimise a 9-colour flow cytometry panel to measure BCG-specific CD4+ 
and CD8+ T cell responses in infants vaccinated with BCG at birth or at 6 weeks 
of age (Chapter 3). 
 
2. To compare the frequency of BCG-specific IFN-γ, TNF-α, IL-2, IL-17 and/or 
perforin expressing CD4+ and CD8+ T cells in infants vaccinated with BCG at 
birth or at 6 weeks of age (Chapter 4). 
 
3. To evaluate memory phenotypes of BCG-specific CD4+ and CD8+ T cells in 
infants vaccinated with BCG at birth or at 6 weeks of age (Chapter 5). 
 
4. To compare levels of soluble cytokines in plasma from whole blood stimulated 
with BCG in infants vaccinated with BCG at birth or at 6 weeks of age (Chapter 
6). 
 
5. To compare the ability of CD4+ and CD8+ T cells to proliferate, and the 
capacity of the proliferating cells to produce cytokines, in infants vaccinated with 
BCG at birth or at 6 weeks of age (Chapter 7). 
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Chapter two: Materials and methods 
2.1. Study setting and design 
This was an observational study. Healthy 9-month old infants were enrolled at 
the Child Health and Development Centre (CHDC) in Mulago National Referral 
Hospital, Kampala, Uganda. This hospital is located in Kampala, the country’s 
capital city. The CHDC provides free vaccination as part of the national 
immunization program. Over 95% of the mothers coming in with their babies to 
the CHDC reported having had voluntary counseling and testing during 
pregnancy or had taken part in prevention of mother to child transmission of HIV 
program. 
 
2.2. Participant recruitment  
At the CHDC, a trained health worker conducted the recruitment of healthy 9-
months old infants into this study. Mothers who brought their infants for measles 
vaccination at 9 months of age were approached and informed verbally about the 
study. Informed consent was obtained from infant’s mothers interested in 
participating in the study.  
 
2.3. Enrollment 
Infants who satisfied the inclusion criteria were enrolled in the study.  
 
2.3.1. Inclusion criteria 
1. Infants with evidence of having received BCG vaccination, either through 
documentation in the immunization card, or by presence of a BCG scar. 
2. Infants whose parent or guardian gave informed consent. 
 
2.3.2. Exclusion criteria 
We used the following criteria to exclude infants from enrollment into this study. 
1. Infants whose mothers did not take part in a maternal to infant transmission of 
HIV prevention program during pregnancy. 
2. Infants or infants with mothers with documented evidence of HIV infection. 
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HIV exposure or infection of infants may affect the BCG-induced immune 
response. 
3. Infants who had received any vaccine within a month prior to enrolment. 
4. Infants who had a low birth weight as defined by weight less than 2.5 
kilograms as recorded on growth card or on delivery discharge note. 
5. Infants born before term (less than 38 weeks of gestation). 
6. Infants who had a history of significant perinatal complications, such as an 
emergency cesarean section or severe neonatal jaundice. 
7. Infants exposed to TB disease in the household in the first 9 months of life. 
8. Infants who had any acute condition such as febrile illness, diarrhea or a cold, 
at the time of enrollment.  
9. Infants who had a history of any chronic disease including TB over first 9 
months of life. 
10. Infants taking any immunosuppressive therapy like steroids within four weeks 
of enrollment. 
11. Infants who had clinically apparent anemia. 
12. Infants who had low weight for age or other signs of malnutrition. 
 
2.4. Clinical and demographic assessment 
A child health growth card was used to identify infants who received BCG at birth 
or at 6 weeks of age as well as other EPI vaccines. A questionnaire was 
administered to prospective volunteers to capture basic demographic data. 
Infants’ weight was measured followed by a clinical examination to assess for 
any clinical signs and symptoms. 
 
 
	   41	  
 
Figure 3. Overview of the study procedures. We enrolled 9-months old infants previously 
vaccinated with BCG at birth or at 6 weeks of age. 5 ml whole blood was drawn from each 
participant and transported to the Makerere university immunology laboratory for the 12-hour 
WBA and 6-day proliferation assays. White cells and plasma were harvested, frozen at -800C 
then later shipped to SATVI laboratory for ICS and multiplex assays. 
 
 
2.5. Blood collection and initial processing 
5ml of peripheral whole blood was drawn from the infant into a sodium heparin 
tube by a trained phlebotomist. To ensure the safety of study participants, we 
followed the national guidelines for maximum volumes of blood that may safely 
be collected. This is less than 3 ml per kg body weight, the limit that can be 
drawn from a healthy infant (Howie, 2011). A maximum of 3 attempts were 
allowed for blood collection. The collected blood was transported to the 
immunology laboratory, Makerere University College of Health Sciences, within 
an hour of being drawn for processing. The collected blood was allocated into 
five tubes with or without antigen as indicated in Table 2.  
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Total 
volume of 
blood 
taken 
 
6-Day 
whole 
blood 
assay 
 
12-hour whole blood assay 
Total 
volume 
used 
  WBA-
BCG 
WBA-
UNS 
WBA-
PHA 
WBA-
TB10.4 
 
6 1 1 1 1.0 1 5.0 
5 1 1 1 0.5 1 4.5 
4 1 1 1 0.5 0.5 4 
3 1 1 0.5 0.5 0 3 
2.5 1 0.5 0.5 0.5 0 2.5 
 
Table 2. Prioritization of blood collected for assays used. A maximum of 5 ml whole blood 
collected from 9-month old infants and stimulated in the 12-hour WBA and 6-day proliferation 
assays. Blood was allocated to the different assay conditions depending on the blood volumes 
collected from the infants. The assay conditions included unstimulated, BCG, PHA, and TB10.4. 
The quantities of the antigen (BCG, PHA, and TB10.4) added were adjusted according to blood 
volume incubated. 
 
 
2.6. Whole blood incubation and cryopreservation 
2.6.1. Twelve-hour (short-term) whole blood assay  
One ml heparinised whole blood was incubated with either BCG (Danish strain 
1331, Statens Serum Institut, 1.2X106cfu/ml), phytohaemagglutinin (PHA, Sigma-
Aldrich, 5µg/ml, positive control) or left unstimulated, as previously described 
(Hanekom et al., 2004). The co-stimulatory antibodies anti-CD28 and anti-CD49d 
(at 1µg/ml each, BD Biosciences, San Jose, CA) were added to all assay 
condition to enhance the specific response (Waldrop et al., 1997). Blood was 
incubated at 37oC for 7 hours, after which plasma was removed and stored at -
80oC for later measurement of soluble cytokine levels as described in in chapter 
6. Thereafter, Brefeldin-A (Sigma-Aldrich, 10µg/ml) was added and the blood 
was incubated for a further 5 hours. Cells were harvested, fixed in BD FACS 
	   43	  
Lysing Solution (BD Biosciences) and frozen at -800C. Later, the samples were 
shipped on dry ice to the South African Tuberculosis Vaccine Initiative (SATVI) 
laboratory for further processing to measure T cell-associated cytokine 
expression and memory phenotypes as described in subsequent chapter 4 and 5 
respectively.  
 
2.6.1.1. Immune outcomes evaluated in the short-term assay to assess for BCG-
Specific T cell responses.   
I. The total frequency of CD4+ and CD8+ T-cells expressing Th1 (IFN-γ, IL-2 
and TNF-α), Th17 (IL-17) cytokines and perforin. 
II. The frequency of CD4+ and CD8+ T-cell subsets expressing either one or 
a combination of IFN-γ, IL-2, TNF-α and IL-17, singly of in combination. 
III. The soluble levels of Th1 (IFN-γ and IL-2) cytokines 
IV. The soluble levels of Th2 (IL-4, IL-5 and IL-13) cytokines  
V. The soluble levels of the immunoreguratory cytokine, IL-10.  
2.6.1.2. Immune outcomes evaluated in the twelve-hour whole blood assay to 
characterise BCG-specific T cell phenotypes. 
I. The frequency of BCG specific CD4 T-cell expressing either one or a 
combination of CD45RA, CCR7 and CD27. 
II. The frequency of BCG specific CD8 T-cell expressing either one or a 
combination of CD45RA, CCR7 and CD27.  
 
2.6.2.  Six-day whole blood proliferation assay  
A further 1ml whole blood was diluted in 9 ml of RPMI media and mixed in a 
sterile polypropylene tube. One ml of diluted blood was incubated with either 
BCG (Danish strain 1331, Statens Serum Institut, 1X105 cfu/ml) at day zero or 
PHA (Sigma-Aldrich, 1µg/ml, positive control) at day three, or left unstimulated. 
Incubation continued for 6 days at 37°C in 5% CO2(Soares et al., 2010). Four 
hours prior to the end of the cell culture phorbol 12-myristate 13-acetate (PMA, 
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Sigma-Aldrich, 20ng/mL), ionomycin (Sigma-Aldrich, 10µg/mL) and Brefeldin-A 
(Sigma-Aldrich, 2µg/mL) were added to induce cytokine expression. At the end of 
culture, red cells were lysed with BD FACS Lysing Solution (BD Biosciences) 
white blood cells were fixed and frozen at -800C. Later, the samples were 
shipped on dry ice to the SATVI laboratory for further processing to measure the 
ability of T cell to proliferate and the capacity of proliferating cells to produce 
cytokines.  
 
2.6.2.1.  Immune outcomes evaluated in the six-day assay 
I. Frequency of BCG- specific Ki67 expressing CD4+ and CD8+ T cells. 
II. Proportion of BCG-specific (i.e., Ki-67+) CD4+ and CD8+ T cells producing 
Th1 cytokines (IFN-γ, IL-2, TNF-α) and IL-17, singly or in combination. 
 
2.7. Sample size calculation  
Sample size calculation was based on a study done in Cape Town that 
investigated the effect of delaying BCG vaccination to 10 weeks on the induced 
CD4+ and CD8+ T cell responses (Kagina et al., 2009). In this pilot study, the 
mean log10 difference of the frequency of CD4+ T cells co-expressing IFN-γ, TNF-
α, and IL-2 between children vaccinated at birth and 10 weeks of age was 0.55. 
Assuming a linear change in the frequency of CD4+ T cells co-expressing IFN-γ, 
TNF-α, and IL-2 when the vaccine is delayed from to 10 weeks of age, at 6 
weeks we would expect a lower difference of 0.4. We therefore needed to study 
36 subjects in both arms of our study to be able to reject the null hypothesis that 
the population means of the two study groups are equal with probability (power) 
0.8. The type I error probability associated with this test of this null hypothesis is 
0.05 and a Z of 1.96. 
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2.8. Ethical considerations 
2.8.1. Informed consent 
A trained member of the clinical study team conducted the written informed 
consent process. Informed consent was administered in English or in the home 
language (Luganda) using appropriately translated consent forms. The person 
taking the consent explained the protocol to the infants’ parents or guardian and 
ensured that they fully understood the research protocol before obtaining their 
signature. One copy of the consent forms was kept under appropriate lock with 
the questionnaire. A copy of the consent form was given to the parent or 
guardian. 
 
2.8.2. Ethical approvals 
The study was approved by the institutional review board of the School of Public 
Health, Makerere University College of Health Sciences (IRB00005876FWA-
HDREC066), the Uganda National Council for Science and Technology, as well 
as the University of Cape Town Research Ethics Committee (HREC Ref Number 
: 176/2012). 
 
2.9. Contributions 
Dr. F. Lutwama wrote the study proposal, designed and conducted the 
experiments and wrote this chapter under supervision of Dr. B.M.N. Kagina, Prof. 
H. Mayanja-Kizza and Prof. W.A. Hanekom. 
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Chapter 3: Optimisation of a 9-colour flow cytometric assay to measure 
BCG-induced cytokine and cytotoxic marker expression in T cells 
 
3.1. Introduction    
Our aim was to optimise a 9-colour flow cytometry assay to measure BCG-
specific CD4+ and CD8+ T cell responses in thawed, fixed white blood cells, 
generated by incubation of whole blood with BCG, as described in Chapter 2.  
  
We chose polychromatic flow cytometry (PFC) to assess BCG-specific T cell 
responses for our studies for the following reasons. First, PFC allows for 
assessment of multiple immune characteristics using small blood volumes. This 
was of particular advantage in our study where it was only possible to safely 
collect small blood volumes. Second, PFC allows for simultaneous evaluation of 
multiple parameters on a single cell basis (Mahnke and Roederer, 2007, 
Roederer et al., 2004). Third, our laboratory has vast experience with the use of 
PFC in assessment of BCG-specific T cell responses (Kagina et al., 2010, 
Mansoor et al., 2009, Soares et al., 2008). Finally, similar assays, although more 
limited, had been used in a previous project of our laboratory, when the specific T 
cell outcomes of delaying BCG from birth to 10 weeks of age in South African 
infants were compared (Kagina et al., 2009).   
 
Several challenges arise in designing large PFC panels, where more than 4 
variables are detected per cell. These include limited availability of antibody 
conjugates, limitations in specific flow cytometer configurations, and spectral 
overlap of emission from sub-optimal antibody-fluorochrome combinations that 
may lead to measurement errors (Perfetto et al., 2004, Roederer, 2001). It is 
therefore paramount to perform careful optimisation of PFC panels prior to their 
application in clinical studies. This includes choice of the most optimal antibody-
fluorochrome combinations for the particular application, and introduction of 
excellent quality control procedures for both staining and analysis (Baumgarth 
and Roederer, 2000).   
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Here, we describe optimization of a PFC panel to measure BCG-specific 
immunity in CD4+ and CD8+ T cells.  
 
3.2. Rationale for selection of phenotypic and functional T cell markers 
We considered several T cell markers that are induced by BCG vaccination of 
infants, and which may play a role in protection against TB. These included CD3, 
CD4, CD8, CD69, IFN-γ, TNF-α, IL-2, IL-4, IL-13, IL-17 and perforin (Table 3).  
 
We included CD3 to allow us identify T lymphocytes. From T lymphocytes, we 
were interested in selecting CD4+ and CD8+ T cells. Both CD4+ and CD8+ T cells 
are induced by BCG vaccination, and both subsets may play a role in protection 
against TB (see Chapter one, section 1.7.1).  
 
We also considered inclusion of CD69, an early activation marker expressed on 
the surface of antigen stimulated cells (Testi et al., 1994), and may play a co-
stimulatory role in T cell activation and proliferation (Ziegler et al., 1994). 
Previous studies have used CD69 to successfully identify M.tb-specific T cells 
(Avgustin et al., 2005, Hughes et al., 2005). In our experiments, we used CD69 
to identify BCG-activated, perforin expressing CD4+ and CD8+ T cells. Perforin is 
contained in cytolytic granules, which degranulate upon T cell stimulation 
releasing this cytolytic molecule (Makedonas et al., 2009). Therefore, inclusion of 
CD69 in our ICS panel enabled us to measure newly formed perforin upon T cell 
stimulation. We therefore incorporated CD69 in our ICS antibody panel to identify 
BCG-activated and perforin expressing T cells in infants vaccinated with BCG at 
birth of at six weeks of age. 
 
Previous studies conducted in our laboratory show that BCG vaccination induces 
specific CD4+ and CD8+ T cells expressing IFN-γ, TNF-α  and IL-2. We therefore 
considered inclusion of these cytokines (IFN-γ, TNF-α and IL-2) in our PFC 
panel. A detailed discussion of the role of these cytokines in immunity against 
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M.tb and BCG vaccination is discussed in detail in chapter one (section 1.5.2.3 
and 1.8).   
 
BCG vaccination also induces IL-17 producing CD4+ T cells. (Scriba et al., 2008). 
(Kagina et al., 2010). A detailed role of IL-17 in immunity against M.tb is 
discussed in chapter 1 (section 1.8). Investigators in our laboratory have reported 
detectable IL-17 expression in specific CD4+ T cells. We therefore included this 
marker in our PFC panel. 
 
A previous study from our laboratory showed that, BCG-specific expression of IL-
4 and IL-13 by CD4+ and CD8+ T cells was very low, in 10-weeks old infants 
(Soares et al., 2008). However, there is no reported data on the expression 
levels of these cytokines in 9-months old infants. We therefore chose to assess 
the expression levels of IL-4 and IL-13 cytokines in this age group. 
 
Moreover, BCG vaccination also induces IL-10 (Marchant et al., 1999, Ota et al., 
2002), an immunoregulatory cytokine that may inhibit M.tb induced immune 
responses (O'Garra and Vieira, 2004). However, a previous study in our 
laboratory showed that this cytokine is expressed at very low levels in our 
preferred assay system. We therefore did not consider IL-10 for inclusion in our 
PFC panel. 
 
Finally, we considered inclusion of perforin, a cytotoxic molecule induced by BCG 
vaccination (Semple et al., 2011). We used the newly introduced anti perforin-PE 
(B-D48 antibody clone) capable of detecting both the preformed perforin in the 
cytotoxic granules as well as newly formed perforin residing in the endoplasmic 
reticulum (Hersperger et al., 2008). Table 3 below shows a summary of the 11 T 
cell markers considered for evaluation in our PFC panel for the study. 
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Surface marker Description 
CD3 T cell marker 
CD4 T cell marker	  
CD8 T cell marker	  
CD69 Early activation T cell marker 
IFN-γ Th1 cytokine  
IL-2 Th1 cytokine 
TNF-α Th1 cytokine 
IL-17 Th17 cytokine 
IL-4 Th2 cytokine 
IL-13 Th2 cytokine 
Perforin Cytolytic molecule 
 
Table 3: Candidate T cell markers for PFC panel. The table shows the phenotypic and 
functional T cell markers considered for inclusion in the PFC panel, and the rationale for 
consideration of each marker.  
 
3.3. Capacity and configuration of our flow cytometer  
Our laboratory is equipped with a LSRII flow cytometer (BD Biosciences), a multi 
colour instrument configured with red, blue and violet lasers. The red laser has 
three detectors, the blue laser has 8 detectors while the violet laser has 3 
detectors. Based on this configuration, the cytometer would allow a 12 colour 
PFC panel, at least, excluding side scatter (SSC) and forward scatter (FCS) 
detection. Table 4 shows a summary of this configuration and capacity. We 
therefore proposed that one panel would suffice for all anticipated 
measurements. 
 
3.4. Rationale for selection of optimal antibody-fluorochrome combinations 
Next, we proceeded to select antibody-fluorochrome combinations. We 
considered the flow cytometer configuration, anticipated expression levels of the 
proposed T cell, cytokine and cytotoxic markers, as well as the brightness of the 
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fluorochromes (BIS). This strategy is critical to minimize spectral overlap inherent 
in large PFC panels (Baumgarth and Roederer, 2000).  
 
First, we considered antibody-fluorochrome constructs available in our 
laboratory. Next, we consulted existing data of the expression levels of BCG-
induced T cell markers (Kagina et al., 2010, Mansoor et al., 2009, Soares et al., 
2013). We then selected the antibody-fluorochrome combination proposed to be 
most optimal for each marker (Maecker et al., 2004). The ideal match would be a 
highly expressed marker with a fluorochrome with low BIS, and vise versa. Using 
this criterion, the 11 T cell markers considered could be classified in to three 
different categories, (a) antigens that are well characterized and are either 
expressed or not a cell surface (CD3, CD4 and, CD8). (b) Antigens that are 
expressed in a relatively high molecular density per cell but exhibit a continuous 
expression (CD69, IFN- γ, TNF−α and perforin). (c) Antigens that are expressed 
at a low density or by a low frequency of cells (IL-17, IL-2, IL-4 and IL-13). We 
considered matching bright flourochomes to dim T cell markers and vice versa 
(Table 4).  
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Laser Detector LP (nm) BP (nm)  Fluorochrome BIS 
Blue 
(488nm) 
FSC 
SSC 
A 
B 
C 
D 
E 
F 
 
 
735 
685 
635 
600 
550 
505 
488/10 
 
780/60 
695/40 
670/14 
610/20 
576/26 
530/30 
 
 
PE-CY7 
PerCP-CY5.5 
PE-Cy5, PerCP 
PE-Texas Red 
PE 
FITC 
 
 
4 
3 
3, 2 
NR 
5 
3 
Violet 
(405nm) 
A 
B 
C 
580 
505 
605/10 
560/40 
440/40 
QDot 605 
QDot 565 
PacBlue 
NR 
NR 
1 
Red 
(633nm) 
A 
B 
C 
735 
690 
780/60 
720/40 
660/20 
APC-Cy7 
Alexa Fluor 700 
APC, Alexa Fluor 647 
2 
2 
5, 5 
 
Table 4: Flow cytometer configuration and fluorochrome brightness index score. The 
SATVI LSR II has 3 lasers and 14 detectors. Each detector has long pass (LP) and band pass 
(BP) filters. The possible fluorochromes that can be used for the different detectors are shown. 
The fluorochromes brightness index score (BIS) are indicated from lowest (1=dimmest) to highest 
(5=brightest). The BIS for PE-Texas Red, Qdot-565 and -605 are not reported (NR). 
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3.5. Materials and methods 
3.5.1. Study participants and blood collection  
Whole blood was collected from four healthy adult participants. We recruited and 
consented these adults at the University of Cape Town, South Africa. All 
participants provided written informed consent. The protocol was approved by 
the Research Ethics Committee of the University. Participants were excluded 
from the study for the following reasons: presence of any acute or chronic 
disease, use of any immunosuppresive treatment, pregnancy and no history of 
BCG vaccination. From each healthy participant, 3 ml whole blood was collected 
into heparinized tubes and transferred to the laboratory for stimulation with viable 
BCG in a short-term whole blood assay.  
 
3.5.2. Antigens 
Bacillus Calmette-Guérin (BCG, Danish 1331) was obtained from Statens Serum 
Institut, Copenhagen. Each lyophilised vial contained 2-8x106 colony forming 
units (CFUs), and was reconstituted with RPMI and used at a final concentration 
of 1.2x106 CFU/ml. Phytohemagglutinin (PHA, Sigma-Aldrich), a positive control, 
was used at a final concentration of 5 µg/ml. 
 
3.5.3. Short-term whole blood stimulation and cryopreservation  
From each study participant, 1 mL whole blood was left unstimulated or 
stimulated with either BCG (Danish strain 1331, Statens Serum Institut, 1.2 x 
106cfu/ml) or PHA and incubated at 37oC for 7 hours. Brefeldin-A (Sigma-Aldrich, 
10µg/ml) was then added and the blood was incubated for a further 5 hours. Red 
cells were lysed and white cells fixed in FACS lysing solution (BD Biosciences). 
Multiple vials of the stimulated and fixed white cells were cryopreserved for later 
intracellular staining and flow cytometry analysis. Figure 4 shows a summary of 
the whole blood assay procedures that we used. 
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Figure 4. Procedures for the 12-hour whole blood assay. BCG and co-stimulatory antibodies 
(anti-CD28 and anti-CD49d) were prepared and placed in tubes and kept at 2° to 8°C in the 
laboratory. Blood, collected in a sodium-heparinized syringe, was added drop wise to an opened 
tube, up to a level marked on the side of the tube. The tube was closed, vortexed then incubated 
at 37°C in a water bath. Brefeldin-A was added at 7 h. After 12 h, water bath was preprogrammed 
to switches off. The temperature gradually dropped to room temperature. After 20 h, cells were 
harvested following incubation with EDTA. Red cells were lysed and white cells fixed with FACS 
lysing solution. The cells were cryopreserved in FBS/DMSO solution. (modified from Hanekom 
et al, 2005) 
 
 
3.5.4. Intracellular cytokine staining assay and flow analysis 
We used a “one step” staining method, previously optmised in our laboratory, to 
assess the functional profiles of T cells. In this assay, fixed, cryopreserved white 
cells from the stimulated whole blood were thawed, washed in phosphate 
buffered saline (PBS, BioWhittaker), permeabilised in Perm/Wash Buffer (BD 
Biosciences) and stained with combinations of monoclonal antibodies (mAbs) for 
1 hour at 4°C, as previously described (Hanekom et al., 2004). Cells were then 
washed and acquired on the flow cytometer (BD Biosciences). For quality 
assurance, compensation was done with positive and negative anti-mouse Ig 
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kappa-beads (BD Biosciences) labeled with the respective fluorochrome-
conjugated antibodies. Cytometer Setting and Tracking (CST) beads (BD 
Biosciences) were used for daily settings.	   After acquisition, data were 
compensated and analysed using FlowJo software (v9.4.11; Treestar). Flow data 
were exported to Pestle v1.7 (Mario Roederer, Vaccine Research Center, 
National Institute of Allergy and Infectious Diseases, National Institutes of Health) 
and Spice (v5.1) for further analysis (Roederer et al., 2011).	  
 
3.5.5. Antibody titration 
We titrated each of the commercially obtained antibody-fluorochrome conjugates 
by serial dilution to determine the optimal antibody titer. We used between 6 and 
8 two-fold serial dilutions for each antibody-fluorochrome combination. Our 
starting titer volume was twice the volume recommended by the manufacturer. 
Outcomes included visual separation between the negative and positive 
populations using dotplots, frequency of positive events and signal-to-noise ratio 
using MFIs.  We used either or both the following parameters to determine the 
optimal antibody titer for each antibody: (i) a titer at which optimal resolution 
between unstained (noise) and stained (signal) cells was observed, (ii) the 
antibody volume at the plateau or peak area of plots.  
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3.6. Results 
3.6.1. IL-4 and IL-13 expression 
Our laboratory has successfully used different 7 and 8 PFC panels to 
characterize the BCG-specific T cell responses (Kagina et al., 2010, Mansoor et 
al., 2009, Soares et al., 2008). In these studies, the following antibody-
fluorochrome conjugates were used: CD3-Pac Blue, CD4-Qdot 605, IFN-γ-Alexa 
Fluor 700, IL-2-FITC, TNF-α-PECy7, IL-17-Alexa Fluor 647 and CD8-PerCP 
Cy5.5 (Kagina et al., 2010, Soares et al., 2008, Scriba et al., 2008). We therefore 
considered the use of these optimized antibody-fluorochrome combinations 
before proceeding to explore additional antibody-fluorochrome conjugates for 
inclusion in our study PFC panel.  
 
We aimed to additionally evaluate the expression levels of IL-4, IL-13, Perforin 
and CD69 in our assay system. This was critical in choosing the optimal 
antibody-fluorochrome combinations for our 9-colour PFC panel because 
markers expressed at low levels should be assigned to fluorochromes with the 
greatest BIS.  
 
To address this aim, we used the fixed white cells from BCG-stimulated whole 
blood, as described in the methods section. We used human intracellular 
cytokine-2 (HICK-2) cells (BD Biosciences), which are fixed lymphoid cells that 
express detectable levels of IL-4 and IL-13 as positive control because PHA-
induced IL-4 and IL-13 producing T cells were barely detectable (data not 
shown). We thawed, washed and stained the cells using a basic 4-colour PFC 
panel: CD3-PacBlue, CD4-Qdot 605, CD8-PerCP Cy5.5, and either IL-4-PE or 
IL-13-PE. Clinical results from earlier experiments in our laboratory indicated low 
frequencies of BCG-specific IL-13 and IL-4 T cells. We therefore used antibodies 
with the highest BIS for both cytokines. 
 
We found that the median frequency for BCG-specific IL-14-expressing CD3+ T 
cells was below 0.01% (IQR, 0.00-0.09) (n=3, Figure 5D), while the median 
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frequency for BCG-specific IL-13-expressing CD3+ T cells was 0.008% (IQR,0.00-
0.01) (n=3, Figure 5D). Previous studies of BCG-induced CD4+ T cell cytokine 
response in our laboratory have shown a general trend of greater response to 
BCG, in adults than infants. Therefore, we concluded the BCG-induced IL-4 and 
IL-13 CD4+ T cell response was very low, and likely lower in infants for reliable 
measurement and excluded these candidate markers from our PFC study panel.  
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Figure 5: BCG-specific CD3+ T cells producing IL-4 and IL-13 cytokines. We measured the 
specific responses using the short-term whole blood assay. We used blood samples from healthy 
adults for these experiments. Representative flow cytometry plots of IL-4 (top row) and IL-13 
(bottom row) expression are shown. Frequency of IL-4 (B) and IL-13 (C) expressing CD3+ T cells 
in unstimulated (UNS) and BCG-stimulated blood samples is shown. Scatter plot to depict 
frequencies of total BCG-specific (after background subtraction) IL-4 and IL-13 expressing in 
CD3+ T cells is shown in (D). On the scatter plots, the horizontal lines represent the median 
frequencies of the specific cells. 
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3.6.2. CD69 expression 
Having excluded IL-4 and IL-13 from our candidate T cell markers list, we were 
therefore left with 9 candidate T cell markers for optimizing the antibody-
fluorochrome combination. Of the 9 candidate T cell markers left in our antibody-
fluorochrome combination optimization list, only CD69 and perforin had not been 
previously measured in our laboratory, using our preferred assay system. We 
first titrated the CD69-PerCP-Cy5.5 antibody, chosen because we had identified 
a newly available CD8-Qdot 565 antibody that would replace the already 
optimized CD8-PerCP-Cy5.5 antibody in our laboratory, freeing the PerCP-Cy5.5 
detector. For the titration experiments, we used the fixed white cells from 
stimulated whole blood as described in the methods section. Regardless of the 
antibody concentrations, CD69 showed a continuous expression by CD3+ T cells 
(Figure 6A). When we plotted a graph of antibody titer volume against the 
frequency of the BCG-induced CD69+CD3+ T cells, we showed a typical titration 
curve with a plateau at 0.31µl of antibody, which was then chosen for use 
(Figure 6B).  We also plotted a signal to noise ratio graph of the titration results. 
Signal to noise ratio assessment (Figure 6C) did not show definitive results 
(Figure 6C). 
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Figure 6: CD69-PerCP-Cy5.5 antibody titration. We used 8 different CD69-PerCP-Cy5.5 
antibody concentrations for the titration using BCG stimulated whole blood from an adult 
volunteer. For flow analysis, singlets were first selected, then lymphocytes. Finally CD69 
expression on CD3+ T cells was assessed at different antibody concentration (A). The optimal 
titration volume was assessed by plots of the frequency of CD3+ T cells expressing CD69 (B) and 
the MFI of the signal (CD69+) to noise (CD69-) ratio (C).  
 
 
Having established the optimal CD69-PerCP-Cy5.5 antibody concentration, our 
next step was to evaluate if the early activation marker, CD69 was measurable in 
our assay system to identify antigen-specific CD4+ and CD8+ T cells. We used 
the frozen cells generated for these experiments. We stained the stimulated and 
fixed white cells from whole blood with the following antibodies: CD3-PacBlue, 
CD69-PerCPCy 5.5, CD4-Qdot 605 and CD8-PE-Cy7. Representative dot plots 
for CD69 expressing CD4+ and CD8+ T cells are shown in Figure 7A. CD69 was 
unregulated upon BCG stimulation for both CD4+ (Figure 7B) and CD8+ (Figure 
7C) T cells.  
The median frequency for BCG-specific CD69-expressing CD4+ T cells was 3.6% 
(n=3, Figure 7C), while the median frequency for BCG-specific CD69-expressing 
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CD8+ T cells was 2.8% (n=3, Figure 7D). Therefore, we concluded the BCG-
induced CD69 expressing CD4+ and CD8+T cell responses was measureable in 
our assay system and therefore included the T cell marker in our final study PFC 
panel. 
 
 
 
Figure 7: Expression of CD69 by BCG-specific CD4+ and CD8+ T cells. We measured the 
expression of CD69 by T cells using the short-term whole blood assay. Representative flow 
cytometry data of CD69 expression by CD4+ (top row) and CD8+ (bottom row) is shown (A). 
Frequency of CD69 expression by CD4+ (B) and CD8+ (C) T cells in unstimulated (UNS) and 
BCG-stimulated samples are shown. Figure D shows the summary data of BCG-induced (after 
background subtraction) CD69 expressing CD4+ and CD8+ T cells from 4 participants. On the 
scatter plots, the horizontal lines represent the median frequencies of the specific cells. 
 
	   61	  
3.6.3. Perforin expression 
Our next aim was to evaluate whether BCG-induced perforin was measureable in 
our assay system. Before addressing this aim, we titrated the newly introduced 
PE conjugate of the D-B48 antibody clone chosen because we wanted to detect 
both preformed and newly formed perforin (Hersperger et al., 2008). Also, the PE 
channel was open on our list of antibody-fluorochrome combination, taking into 
account previously optimized antibodies in our laboratory. 
 
Fixed white cells from BCG stimulated whole blood were divided into 8 aliquots 
and each was stained with different concentrations of Perforin-PE antibody. 
Figure 8A shows the flow cytometry plots of the different antibody titre volumes 
against perforin expression by CD3+ T cells. When we plotted the frequency of 
perforin expressing cells (Figure 8B) as well as the signal to noise ratio of 
perforin expressing cells (Figure 8C) we observed a typical antibody titration 
curve. Both plots showed the curve plateaued at a concentration of 2.50µl, which 
was chosen for subsequent experiments.  
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Figure 8: Perforin-PE antibody titration. Eight different perforin-PE antibody concentrations 
were tested using fixed white cells from BCG stimulated whole blood. For flow analysis, singlets 
were selected, then lymphocytes from which we selected CD3+ T cells. Flow cytometry data of 
CD69 expression, measured by MFI at different concentrations are shown (A). We then 
measured frequencies (B) and signal to noise ratio (C) of perforin expression by CD3+ T cells at 
different antibody titer volumes. The optimal titration volume was assessed by plots of the 
frequency of CD3 T cells expressing perforin (B) and the signal (perforin+) to noise (perforin-) 
ratio against the titration volume  
 
 
After establishing the optimal concentration of the Perforin-PE antibody, we 
proceeded to measure BCG-induced perforin expression. We used fixed white 
cells from BCG stimulated whole blood samples collected from 8 healthy adult 
volunteers. We gated on CD69+ cells to assess specific perforin expression 
(Murray et al., 2006). Our results showed that perforin was expressed at high 
frequencies following BCG than in the unstimulated sample. Although detectable 
in both CD4+ and CD8+ T cells, frequencies were higher in the latter subset 
(Figure 9). We concluded that BCG-induced perforin T cell response is 
measurable in our assay system. We therefore included perforin-PE in our study 
PFC antibody panel. 
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Figure 9. BCG-specific perforin expression by CD4+ and CD8+ T cells. We measured the 
specific responses using the short-term whole blood assay. Representative flow cytometry data of 
perforin expression by CD8+ T cells in a negative control (unstimulated) sample (top row) or BCG 
stimulated sample (bottom row) (A). Perforin expression in CD4+ (B) and CD8+ (C) T cells 
following no stimulation or stimulation with BCG. Scatter plot to depict frequency of BCG-specific 
perforin expression in CD4+ and CD8+ T cells is shown in D and E respectively. On the scatter 
plots, the horizontal lines represent the median frequencies of the specific cells. 
 
 
3.3.4. CD8-QDot 565 antibody titration 
Our next step was to titrate the newly introduced CD8-QDot 565 antibody using 
the samples we had previously used to titrate other antibodies. We used a similar 
titration method as for other antibodies. We showed the CD8-Qdot 565 antibody 
staining could give distinct populations of CD8+ and CD8- T cells at a titre volume 
of 0.5µl and above (Figure 10A). When we plotted the frequency of CD8-
expressing CD3+ T cells (Figure 10B) as well as the signal to noise ratio of CD8-
expressing CD3+ T cells (Figure 10C) against the antibody concentration, we 
chose the antibody titer volume of 0.5µl. With this antibody concentration, we 
could easily discriminate CD8-expressing CD3+ T cells from non CD8-expressing 
CD3+ T cells.  
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Figure 10. CD8-Qdot 565 antibody titration. Eight different CD8-Qdot 565 antibody 
concentrations were tested using fixed white cells from BCG stimulated whole blood. For flow 
analysis, singlets were selected, then lymphocytes from which we selected CD3+ T cells. Flow 
cytometry plots of CD8+ expression was then measured by MFI at different concentrations (A). 
We then measured frequencies (B) and signal to noise ratio (C) of CD8+ expression by CD3+ T 
cells at different antibody concentrations.  
 
Following the successful titrations and tests of the CD69-PerCPCy5.5, Perforin-
PE and CD8-Qdot 565 antibodies, we were now ready to combine these into the 
existing and optimized panel  (CD3-Pac Blue, CD4-Qdot 605, CD8-Qdot 565, 
CD69-Cy5.5PerCP, TNF-α-Cy7PE, IFN-γ-Alexa 700, IL-2-FITC, IL-17-Alexa 647 
and Perforin-PE) to assemble a final 9 colour PFC panel.  
 
Before this final PFC antibody assembly step, we wanted to test if adding EDTA 
to our staining buffer could improve the quality of staining by antibodies 
conjugated to Qdot (CD4 and CD8 antibodies).  
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3.6.5. Effect of staining buffer on CD4-Qdot 604 and CD8-Qdot 565 brightness 
Quantum dots (Qdot) are fluorescent nanocrystals that are widely used in flow 
cytometry analysis (Chattopadhyay et al., 2006). Antibodies conjugated to Qdot 
are sensitive to heavy metals such as iron, copper and zinc. These heavy metals 
are contained in staining buffers (Meallet-Renault et al., 2006). Previous studies 
have shown that adding EDTA, at a concentration of 1mM, can improve the BSI 
of antibodies conjugated with Qdot (Zarkowsky et al., 2011). We therefore 
compared the brightness of CD4-Qdot 605 and CD8-Qdot 565 if staining is done 
using BD Perm/wash with or without addition of 1mM EDTA. We used fixed white 
cells from BCG stimulated whole blood. Representative flow cytomety plots for 
this staining are shown (Figure 11A). No differences were observed in the 
quality of CD4+ and CD8+ staining with or without 1mM EDTA, when we analysed 
the expression levels by frequencies (Figure 11B, C) or by signal to noise ratios 
(Figure 11D, E).  
 
We concluded that not adding 1mM EDTA to the BD Perm/wash staining buffer 
in our ICS experiments would not affect the quality of CD4-Qdot 605 and CD8-
Qdot 565 antibody staining in our PFC panel. Therefore, in our subsequent ICS 
experiments, we did not add EDTA to BD perm/wash staining buffer. 
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Figure 11: Effects of adding 1mM EDTA to staining buffer on Qdot-conjugated antibodies. 
Whole blood from three adult volunteers was stimulated with BCG for 12 hours, red blood cells 
lysed, white cells fixed, followed by cryopreservation. An ICS assay was performed using BD 
Perm/wash with or without 1mM EDTA added. Representative flow cytometry data showing 
expression of CD4+ and CD8+ T cells with EDTA (top row) or without EDTA (bottom row) are 
shown (A). Frequency of CD4+ (B) and CD8+ (C) T cells with or without EDTA. Median 
fluorescence intensity of CD4+ and CD8+ T cells with or without EDTA are shown in (D) and (E) 
respectively. 
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3.6.6. Final antibody-fluorochrome combination PFC panel 
Our final PFC antibody panel comprised of the following: CD3-PacBlue, CD4-
QDot 605, CD8-QDot 565, CD69-Cy5.5PerCP, TNF-α-Cy7PE, IFN-γ-Alexa 700, 
IL-2-FITC, IL-17-Alexa 647 and Perforin-PE (Table 5).  
 
Marker Laser Detector Fluorochrome  Manufacturer Cat.No 
CD4 Violet A Qdot 605 Invitrogen Q10008 
CD8 Violet B Qdot 565 Invitrogen Q10152 
CD3 Violet C Pac Blue BD 558117 
IFN-γ Red B Alexa 700 BD 544699 
IL-17 Red C Alexa 647 eBiosciences 51-7178 
TNF-α Blue A Cy7PE eBiosciences 25-7349 
CD69 Blue C Cy5.5PerCP Biolegend 310926 
Perforin Blue E PE Diaclone 854.951.010 
IL-2 Blue F FITC BD 340448 
 
Table 5: Description of the final antibody-fluorochrome combinations. For our final PFC 
antibody panel, all the 9 selected T cell markers and the fluorochrome combination chosen are 
shown. The lasers, channels (detectors) on the LSR II cytometer for assessing these markers, 
supplying company of the antibodies as well as the catalogue numbers are shown as well.  
 
 
3.6.7. Optimisation of photomultiplier tube (PMT) voltage 
Our next aim was to establish the optimal PMT voltages for all the selected 
channels in our 9-colour PFC panel. Optimal PMT voltages ensure that for each 
fluorescence parameter, the best signal to noise ratio is achieved (Maecker and 
Trotter, 2006). Suboptimal PMT voltage results in the stained antibodies not 
being on the detectable scale, or may yield unclear differentiation between 
negative and positive events.  
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To achieve the optimal PMT voltages for our PFC antibody panel, we used the 
FACSDIVATM 6.0 software’s Cytometer Setup & Tracking (CS&T) to first define 
the baseline cytometer voltages for our selected channels. The BD FACSDIVATM 
6.0 software’s CS&T automatically determines the optimal range for the following 
parameters: laser delays, linear range (±2%), fluorescence detector efficiency 
(Qr), optical background (Br), electronic noise (SDEN) and the baseline PMT 
voltage settings based on performance of the dim beads (Table 6).  
 
The baseline PMT voltages defined for blue laser channels were as follows in: 
667 for Cy5.5PerCP, 701 for both Cy7PE and 620 for PE, and 690 for FITC 
(Table 6) Baseline voltages for the red laser channels were 647 for Alexa Fluor 
647 and 781 for Alexa Fluor 700  (Table 6). The baseline voltages for the violet 
laser channels were 823 for Qdot 605, 589 for Qdot 565 and 646 for Pac Blue 
(Table 6). For further PMT voltage optimization, we tested and adjusted the 
CS&T baseline voltages using unstained cells, followed by single stained mouse 
kappa compensation beads.  
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Laser Detector Parameter PMTV  Bright 
Bead 
Robust 
CV 
DIM 
Bead 
Robust 
CV 
SDEN Qr Br 
Blue FCS FCS 614 5.31 23.78 N/A N/A N/A 
Blue G SSC 394 4.21 2.47 N/A N/A N/A 
Blue F FITC 690 3.48 58.87 29.4 0.0096 405 
Blue E PE 620 3.13 71.06 20.5 0.0544 684 
Blue B PerCP-Cy5.5 667 6.50 94.82 20.3 0.0022 136 
Blue A PE-Cy7 701 11.46 889.56 22.7 0.0022 36 
Red C Alexa 647 646 3.61 60.16 18.1 0.0077 90 
Red B Alexa 700 781 4.47 46.66 79.1 0.0055 0 
Violet C Pac Blue 646 4.94 84.46 21.2 0.0193 5935 
Violet B Qdot 565 589 5.06 76.30 15.9 0.0328 285 
Violet A Qdot 605 823 8.53 294.91 18.5 0.0028 491 
 
Table 6: Baseline PMT settings. CS&T beads were placed in a falcon tube and run on a LSR II 
cytometer. The baseline parameters automatically generated by the CS&T system including: 
Baseline PMT voltages, bright bead robust CV, standard deviation of median fluorescence 
intensity of the bright bead, fluorescence detector efficiency (Qr), optical background (Br), and 
electronic Noise (SDEN). 
 
 
3.6.8. Choice of the final PMT voltages 
Next, we adjusted the baseline PMT voltages while using unstained cells to 
achieve adequate positioning (within the first log decade on the x-axis scale) of 
the negative cell population. Thereafter, a similar approach was used to adjust 
the PMT voltages further while using the single stained mouse kappa 
compensation beads to achieve adequate positioning of the positive stained cell 
population (past the first decade of the x-axis but below the fifth decade) for each 
channel.  
 
Using the unstained cells, we adjusted the baseline PMT voltages from 667 to 
550 for Cy5.5PerCP, from 701 to 560 for Cy7PE, from 530 to 620 for PE, and 
from 690 to 560 for FITC to give an on scale negative cell population for the blue 
laser (Figure 12A). The voltage adjustments for the red laser channels were as 
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follows: from 646 to 560 for Alexa Fluor 647 and from 781 to 550 for Alexa Fluor 
700  (Figure 12B). The voltage adjustments for the violet laser channels were as 
follows: From 823 to 550 for Qdot 605, from 589 to 500 for Qdot 565 and from 
624 to 500 for Pac Blue (Figure 12C).    
 
Finally, when we used single stained anti-mouse kappa-compensation beads 
(BD Biosciences), labelled with the specific fluorochrome-conjugated antibodies 
selected for the 9-colour panel, no adjustments were made to the voltages as the 
positive stained beads were in optimal fluorescence intensity for all the channels 
(Figure 13A, B and C)  
 
From these experiments, we established the optimal PMT voltages for each and 
every channel selected in our final PFC antibody panel to provide maximum 
resolution of the positive and negative antibody staining. 
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Figure 12: PMT voltage settings using unstained cells. Unstained cells were acquired on LSR 
II.  Lymphocytes were selected by forward scatter-area (FSC-A) against side scatter-area (SSC-
A). For each channel of the final 9-colour PFC panel, PMT voltages were adjusted to the 
established CS&T baseline settings. Then, the PMT voltages were adjusted until the unstained 
lymphocytes were detected within the first and second decade of the scale for the channels in the 
blue laser (A), red laser (B) and violet laser (C). 
 
 
	   72	  
 
 
Figure 13: PMT voltage settings using single stained anti-mouse kappa compensation 
beads. In 9 separate 5mL falcon tubes, single drops of negative and positive anti-mouse kappa 
compensation beads were added. To each of the tubes, the optimal antibody staining 
concentrations for CD3-PacBlue, CD4-Qdot 605, CD8-QDot 565, CD69-Cy5.5PerCP, Perforin-PE, 
TNF-Cy7PE, IFN-γ-Alexa 700, IL-2-FITC and IL-17-Alexa 647 were added to each of the 9 tubes 
and acquired on LSR II.  On the forward scatter-area (FSC-A) against side scatter-area (SSC-A) 
plot, we selected the bead population.. The final PMT voltage settings showed distint negative and 
positive beads population for the blue laser (A), red laser (B) and violet laser (C). 
 
 
After we established the optimal PMT voltages for each of the 9 channels. Our 
next task was to test if the size of the PFC panel was optimal in measuring the 
BCG-induced T cell response.  
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3.6.9. Measurement of BCG-induced T cell responses using 5, 7 and 9 PFC 
antibody panels 
Our next aim was to assess if the 9-colour PFC antibody panel assembled for our 
study, was as sensitive as smaller (5 and 7) PFC antibody panels in detecting the 
BCG-induced T cell response. Larger panels are more vulnerable to spectral 
overlap than smaller panels and this may compromise the sensitivity to measure 
some markers (Perfetto et al., 2004).  
 
Fixed white cells from BCG stimulated or unstimulated whole blood derived from 
four healthy adult volunteers were stained with a 5, 7 or 9-colour PFC antibody 
panels. The 5-colour PFC antibody panel was selected based on the T cell 
markers that are highly induced following stimulation of whole blood (IFN-γ and 
TNF-α) (Maecker et al., 2004) and markers that are most highly expressed in our 
list of 9 candidate markers (CD3, CD4 and CD8). Two additional markers (IL-2 
and IL-17) were added to the 5-colour PFC antibody panel. Finally, CD69 and 
perforin antibodies were added to assemble the final target 9-colur PFC antibody 
panel. Table 7 shows the markers included in the 5, 7 and 9-colour panels.  
Our results showed the 9-colour PFC panel was as sensitive as the 5- and 7-
colour PFC panels in quantifying the frequencies of BCG-induced IFN-γ- and 
TNF-α-expressing CD4+ T cells (Figure 14B and C). The Frequencies of CD4+ T 
cells were also similar across the 3 panels (Figure 14A). 
 
We were successful in assembling a sensitive 9-colour PFC antibody panel to 
compare BCG-induced T cell immunity in our study. 
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Laser Detector 5 colour panel 7 colour panel 9 colour panel  
Violet  A CD4 CD4 CD4 
Violet  B CD8 CD8 CD8 
Violet  C CD3 CD3 CD3 
Red  B IFN-γ IFN-γ IFN-γ 
Red C  IL-17 IL-17 
Blue  A TNF-α TNF-α TNF-α 
Blue B   CD69 
Blue E   Perforin 
Blue F  IL-2 IL-2 
 
Table 7: Summary of 5-, 7- and 9-colour antibody-fluorochrome combinations. Three 
different panels were used to assess if the panel size compromised the sensitivity and reliability 
to measure the BCG-induced T cell immunity. 
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Figure 14: Frequencies of, CD4+ T cells, specific CD4+IFN-γ+ and CD4+TNF-α+ detected 
using a 5-, 7- and 9-colour PFC panels.  We performed whole blood Intracellular cytokine 
staining on fixed white cells from BCG stimulated whole blood from 3 healthy adult volunteers. 
We used 5-, 7- or 9-colour PFC antibody panels to stain the cells. The graphs depict frequencies 
of CD4+ expressing CD3+ T cells (A), IFN-γ-expressing CD4+ T cells (B), and TNF-α-expressing 
CD4+ T detected with the 5-colour (open dots), 7-colour (grey dots) or a 9-colour PFC antibody 
panel (black dots).  
 
We showed that our optimized 9-colour PFC antibody panel was sensitive in 
quantifying the BCG-induced T cell immunity. Our final step was to assess for the 
performance and reliability of the 9-colour panel by fluorescence minus one 
experiments (FMO. 	  
3.6.10. Fluorescence minus one (FMO) analysis  
Our final experiments aimed to assess unintended signals due to spectral 
overlap (Maecker et al., 2004), detected in each of the 9 channels selected for 
our final PFC antibody panel. FMO is used to address our aim; this involves 
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assessing signal in a specific channel when no antibody for that channel is 
present, while all the other antibodies are present (Perfetto et al., 2004). The 
signal detected in the FMO detector can be quantified and is an indication of the 
spectral overlap from other fluorochromes in the panel.  
 
We used fixed white cells from BCG stimulated whole blood derived from a 
healthy adult. We split the cells into 10 aliquots. One aliquot was stained with a 
full 9-colour panel or 9 combinations of the panel minus a single antibody-
fluorochrome. The FMO controls showed an acceptable range of spectral overlap 
of between 0.00% (IFN-γ-Alexa 700) to 0.52% (CD8-Qdot 565) for all the 
channels (Table 8). The frequencies of the different T cell markers in the PFC 
panel were similar when measured by different FMO controls as well as the full 
9-colour PFC antibody panel. Our data indicates that the spectral overlap 
detected in all the nine channels was minimal and would not compromise the 
reliability of the panel to measure the BCG-induced T cell immunity. 
 
We also showed low coefficients of variation (CVs) of the frequencies of the 
different T cell markers measured for each of the FMO controls, and for the full 9-
colour PFC antibody panel (Table 8). The CV was calculated by dividing the 
standard deviation of a frequency by the mean frequency. For immunological 
assays a CV of up to 30% may be considered acceptable (Nomura et al., 2000). 
The intra-assay CV ranged from 1% for BCG-specific CD3+ frequencies to 20% 
for BCG-specific CD4+IL-17+ and CD4+TNF-α+ frequencies (Table 7).  
 
In summary, we succeeded in optimising a 9-colour PFC antibody panel that was 
sensitive and reliable in quantifying BCG-specific T cell responses. 
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               Frequency of positive events detected (%) 
FMO CD3 CD4 CD8 CD69 IFN-γ  IL-2 TNF-α  IL-17 Perforin 
PacBlue 0.050 43.10 25.00 19.90 3.01 0.30 1.54 0.36 36.7 
Qdot 605 76.70 0.01 22.90 13.30 2.69 0.30 1.35 0.24 35.3 
Qdot 565 77.30 43.70 0.52 15.80 2.92 0.30 1.53 0.29 35.8 
PerCp Cy5.5 76.80 40.70 28.70 0.13 2.78 0.31 1.41 0.24 35.9 
Alexa 700 77.20 40.90 25.80 16.40 0.00 0.32 0.87 0.31 35.3 
FITC 76.10 40.50 25.80 16.00 3.68 0.03 1.03 0.37 34.7 
PE-Cy7 76.60 40.50 25.60 16.40 2.83 0.33 0.07 0.36 35.1 
Alexa 647 76.80 41.00 25.10 16.40 3.23 0.30 1.07 0.08 33.4 
PE 77.40 41.10 24.90 16.10 3.26 0.30 1.00 0.44 0.06 
Full Panel 74.80 39.70 24.70 16.40 2.59 0.37 1.14 0.38 33.1 
 
CV 0.01 0.03 0.06 0.10 0.11 0.07 0.20 0.20 0.03 
 
Table 8: Fluorescence minus one (FMO). Whole blood from an adult volunteer was stimulated 
with BCG then white cells fixed and harvested. Fixed white cells were stained with the optimized 9-
colour panel or with FMOs (shaded boxes). The spectral overlap was assessed by comparing the 
expression frequencies of cells for different markers with or without single antibody-fluorochrome.  
 
 
3.6.11. Gating strategy to identify BCG-Specific T cells 
The aim of our next experiment was to develop a gating strategy to facilitate a 
focused analysis of the T cell markers we had included in our optimized 9-colour 
PFC antibody panel. The development of the gating strategy was guided by our 
main study question: is there a difference in the BCG-induced T cell immunity 
when BCG is administered at birth or at 6 weeks of age in Ugandan infants? We 
used the cells stained with the 9-colour PFC antibody panel in our FMO controls 
experiment to develop the gating plan.   
 
Our gating strategy started with a time gate to select cells acquired only at the 
same fluorescence intensity over time. Next, we used keeper gate to exclude 
antibody aggregates commonly formed by Qdots. These aggregates can non-
specifically label some cells leading to false positive signal. Then we proceeded 
to create a lymphocytes gate on a forward scatter-area (FSC-A) against side 
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scatter-area (SSC-A) plot. Then, doublet cells were excluded by gating on 
forward scatter-area (FSC-A) against forward scatter-height (FSC-H). Then, we 
selected conventional T cells by gating on CD3-expressing cells from which 
CD4+ and CD8+ T cells were gated. Finally, CD4+ and CD8+ T cells expressing 
IFN-γ, IL-2, TNF-α, IL-17, CD69 and perforin were selected (Figure 15). The 
developed gating strategy was used to create an analysis template. All 
subsequent ICS experiments perfomed using the optimized 9-colour PFC 
antibody panel were loaded on the analysis template to perform batch analysis.  
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Figure 15. Gating strategy. Flow cytometry analysis of BCG-specific CD4+ and CD8+ T cell 
cytokine and perforin responses evaluated in the short-term whole blood ICS assay. We first used 
a time gate to select cells acquired at similar fluorescence intensity over time. Then, we 
proceeded to a keeper gate to exclude antibody aggregates. Next, lymphocytes were selected 
using a forward scatter-area (FSC-A) against side scatter-area (SSC-A) gate. Then, doublet cells 
were excluded by gating on forward scatter-area (FSC-A) against forward scatter-height (FSC-H). 
Conventional T cells were selected by gating on CD3 expressing cells, which were further divided 
to CD4+ and CD8+ T cells. Total Intracellular cytokine (IFN-γ, IL-2, TNF-α, IL-17) and perforin 
expression was then assessed on CD4+ and CD8+ T cells. Finally, Boolean gating was used to 
assess for cytokine and perforin co-expression 
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3.6.12. BCG-specific CD4+ and CD8+ T responses in healthy adults  
Having optimized our PFC antibody panel and finalized the gating strategy, we 
aimed to assess whether profiles of BCG-specific T cells, measured using our 
PFC antibody panel, yielded patterns similar to those previously reported from 
our laboratory. Whole blood from 5 adult healthy volunteers was left unstimulated 
or stimulated with BCG or PHA, followed by ICS analysis.  
 
We applied the gating strategy described above to analyse the frequencies of 
BCG-specific cytokine and perforin expression by CD4+ T cells. Flow data was 
then exported to Microsoft Excel where we subtracted unstimulated from the 
stimulated responses. Thereafter, we used GraphPad Prism version 5.0a for 
analysis. Representative Flow cytometry data showing unstimulated, BCG and 
PHA-specific IFN-γ, TNF-α, IL-2 and IL-17 frequencies by CD4+ T cells are 
shown in Figure 16.  
 
The BCG-specific CD4+ and CD8+ T cell co-expression showed that the most 
dominant subset was single IFN-γ-producing cells (Figure 17A). Other subsets 
expressed at high frequencies included polyfunctional (IFN-γ+TNF-α+IL-2+), 
double positives (IL-2+IFN-γ+, IL-2+TNF-α+ and IFN-γ+TNF-α+) as well as single 
positives (IL-2+, IL-17+, TNF-α+ and perforin+), mainly by CD4+ T cells (Figure 
17A). We concluded that the patterns of BCG-induced CD4+ and CD8+ T cell 
cytokines detected by using our optimized PFC antibody panel were similar to 
those previously reported in our laboratory (Scriba et al., 2008).  
 
We also observed that perforin was only co-expressed with IFN-γ and not with 
any other cytokine (Figure 17B). The cytokine and perforin expression pattern 
we observed is similar to what has been reported in a study that assessed 
cytokine and cytolytic molecule expression in T cells in response to stimulation 
with viral peptides (Makedonas et al., 2010). 
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Figure 16: Frequencies of BCG specific CD69, IFN-γ , TNF-α , IL-2, IL-17 and perforin CD4+ 
T cells. Whole blood was either left unstimulated (left panels), or was stimulated with BCG 
(middle panels) or PHA (right panels) for 12 hours. Brefeldin-A was added in the last 5 hours to 
capture intracellular cytokines for detection by flow cytometry. CD4+ T cells were stained for 
TNF-α and IL-17 (upper panel), IL-2 and IFN-γ (middle panel), and perforin and CD69 (lower 
panel). 
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Figure 17. BCG-specific CD4+ T cell cytokine subsets. Whole blood samples from 5 adult 
volunteers were left unstimulated or stimulated with BCG for 12 hours. White cells were 
harvested and subsequently stained with the 9-colour PFC antibody panel the acquired on the 
flow cytometer. Box and whisker plots show the frequencies of distinct subsets of specific CD4+ T 
cells based on combinations of IFN-γ, TNF-α, IL-2, and IL-17 cytokine expression (A), and 
CD69+CD4+ based on IFN-γ and perforin co-expression (B). The horizontal line represents the 
median, the boxes represent the interquartile range, and the whiskers represent the minimum and 
maximum values. 
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We also analysed the profiles of specific CD8+ T cells using a similar approach to 
that of CD4+ T cells. The representative flow cytometry data in Figure 18 show 
unstimulated, BCG- and PHA-stimulated samples. Frequencies of IFN-γ, TNF-α, 
IL-2 and IL-17 in CD8+ T cells are also shown in (Figure 19). The BCG-specific 
CD8+ T cell co-expression showed that the most dominant subset was single 
IFN-γ-producing cells as well as double positives (IFN-γ+TNF-α+)  (Figure 19A). 
Perforin was only co-expressed with IFN-γ and not with any other cytokine 
(Figure 19B). We concluded that the patterns of BCG-induced CD8+ T cell 
cytokines were similar to those previously reported (Scriba et al., 2008, Soares et 
al., 2013).  
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Figure 18: Frequencies of antigen specific CD69, IFN-γ , TNF-α , IL-2, IL-17 and perforin 
CD8+ T cells. Whole blood was either left unstimulated (left panels), or was stimulated with BCG 
(middle panels) or PHA (right panels) for 12 hours. Brefeldin-A was added in the last 5 hours to 
capture intracellular cytokines for detection by flow cytometry. CD8+ T cells were stained for 
TNF-α and IL-17 (upper panel), IL-2 and IFN-γ (middle panel), and perforin and CD69 (lower 
panel). 
 
 
 
	   85	  
 
Figure 19. BCG-specific CD8+ T cell perforin subsets. Whole blood samples from 5 adult 
volunteers were left unstimulated or stimulated with BCG for 12 hours. White cells were 
harvested and subsequently stained with the 9-colour panel before acquisition on the flow 
cytometer. Box and whisker plots show the frequencies of distinct subsets of specific CD8+ T cells 
based on combinations of IFN-γ, TNF-α, IL-2, and IL-17 cytokine expression (A), and CD69+CD8+ 
based on IFN-γ and perforin co-expression (B). The horizontal line represents the median, the 
boxes represent the interquartile range, and the whiskers represent the 10th and 90th percentiles. 
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3.6.13. BCG-specific CD4+ T cell responses in healthy 10-weeks old infants  
We were satisfied with the performance of the optimized 9-colour PFC antibody 
panel in quantifying antigen specific T cells using adult samples. Next, we wished 
to evaluate the performance of the PFC antibody panel in measuring the BCG-
specific T cell response in infant-derived whole blood samples.  
 
We used cryopreserved fixed white cells derived from whole blood from 5 healthy 
infants that was left unstimulated or stimulated with BCG or SEB, followed by ICS 
analysis. Representative flow cytometry plots showing unstimulated, BCG- and 
SEB-stimulated samples are shown in Figure 20. The BCG-induced CD4+ T cell 
co-expression showed that the most dominant subsets included polyfunctional 
(IFN-γ+TNF-α+IL-2+), double positives (IFN-γ+TNF-α+ and IFN-γ+IL-2+) as well as 
single positives (IFN-γ+, IL-2+, IL-17+, TNF-α+ and perforin+) CD4+ T cell (Figure 
21A). We observed similar cytokine expression patterns for CD4+ infants to those 
observed to those observed in adults. Infants showed lower BCG-induced CD4+ 
T cell cytokine frequencies than adults. We concluded that the patterns of BCG-
induced CD4+ and CD8+ T cell cytokines were comparable to what has been 
previously reported (Kagina et al., 2010, Soares et al., 2010). 
 
We then assessed perforin expression in the infant samples. Similar to what we 
observed with adult samples, perforin was only co-expressed with IFN-γ and not 
with any other cytokine (Figure 21B).  
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Figure 20: Intracellular cytokine expression in CD4+ T cells derived from whole blood of a 
representative 10-week old infant, BCG vaccinated at birth. Whole blood was either left 
unstimulated (left panels), or was stimulated with BCG (middle panels) or SEB (right panels) for 
12 hours. Brefeldin-A was added in the last 5 hours to capture intracellular cytokines for 
detection by flow cytometry. CD8+ T cells were stained intracellularly for TNF-α and IL-17 (upper 
panel), IL-2 and IFN-γ (middle panel), and Perforin and CD69 (lower panel). 
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Figure 21. BCG-specific CD4+ T cell cytokine subsets. Whole blood samples from five 10-
weeks old infants were left unstimulated or stimulated with BCG for 12 hours. White cells were 
harvested and subsequently stained with the 9-colour panel before acquisition on the flow 
cytometer. Box and whisker plots show the frequencies of distinct subsets of specific CD4+ T cells 
based on combinations of IFN-γ, TNF-α, IL-2, and IL-17 cytokine expression (A), and CD69+CD4+ 
based on IFN-γ and perforin co-expression (B). The horizontal line represents the median, the 
boxes represent the interquartile range, and the whiskers represent the 10th and 90th percentiles. 
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Our next step was to assess BCG-specific CD8+ T cell cytokine patterns in 
cryopreserved infant-derived whole blood samples. We used a similar analysis 
strategy to that used for CD4+ T cells. Figure 22 shows representative flow 
cytometry plots showing unstimulated, BCG and SEB-specific IFN-γ, TNF-α, IL-2 
and IL-17 frequencies. The BCG-specific single IFN-γ producing CD8+ T cells 
were the dominant subset (Figure 23A). Infants showed BCG-induced CD8+ T 
cell cytokine frequencies that were similar to those seen in adults. Similar to what 
we observed for CD4+ T cells, perforin was only co-expressed with IFN-γ and not 
with any other cytokine (Figure 23B). We concluded that the patterns of BCG-
induced CD8+ T cell cytokines were comparable to what has been previously 
reported (Kagina et al., 2010, Soares et al., 2010).  
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Figure 22: Intracellular cytokine expression in CD8+ T cells derived from whole blood of a 
representative 10-week old infant, BCG vaccinated at birth. Whole blood was either left 
unstimulated (left panels), or was stimulated with BCG (middle panels) or SEB (right panels) for 
12 hours. Brefeldin-A was added in the last 5 hours to capture intracellular cytokines for 
detection by flow cytometry. CD8+ T cells were stained intracellularly for TNF-α and IL-17 (upper 
panel), IL-2 and IFN-γ (middle panel), and Perforin and CD69 (lower panel). 
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Figure 23. BCG-specific CD8+ T cell cytokine subsets. Whole blood samples from five 10-
weeks old infants were left unstimulated or stimulated with BCG for 12 hours. White cells were 
harvested and subsequently stained with the 9-colour panel before acquisition on the flow 
cytometer. Box and whisker plots show the frequencies of distinct subsets of specific CD8+ T cells 
based on combinations of IFN-γ, TNF-α, IL-2, and IL-17 cytokine expression (A), and CD69+CD8+ 
based on IFN-γ and perforin co-expression (B). The horizontal line represents the median, the 
boxes represent the interquartile range, and the whiskers represent the 10th and 90th percentiles. 
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3.7. Discussion  
In this chapter, we successfully optimised a 9-colour PFC antibody panel to 
measure BCG-specific Th1 (IFN-γ, TNF-α and IL-2), Th17 (IL-17) and Tc 
(perforin) in stimulated whole blood cells from both adult and infants. We showed 
that the 9-colour panel was sensitive and reliable in quantifying BCG-specific T 
cell responses in our WB-ICS assay system.  
 
Careful and meticulous development of large PFC antibody panels is important to 
ensure that flow cytometry data generated is reliable (Mahnke and Roederer, 
2007). We used a stepwise approach to ensure optimal selection of antibody-
fluorochrome combinations. We also utilized existing experience in our laboratory 
during the optimization process.  We began by listing candidate T cell markers 
based on our study questions and the known functions of the selected markers in 
immunity against M.tb. In summary, we selected the final candidate markers 
based on the following criteria: (i) the reported immune relevance of the T cell 
markers to address our research questions, (ii) the capacity of the LSR II flow 
cytometer to measure the different parameters, (iii) the availability and 
performance of antibody-fluorochrome combinations, (iv) the available of PFC 
panels already optimized in our laboratory and, (v) the expression levels of the 
markers considered for inclusion in our PFC panel using the 12-hour WBA-ICS.  
 
Individual T cells may be associated with the release of more than one cytokine 
and cytotoxic molecules. It is therefore important to focus on the production 
pattern of each active T-cell individually. Furthermore, particular T-cell subsets 
have been shown to associate with protection in viral and intracellular bacteria 
infection (Darrah et al., 2007, Forbes et al., 2008). The BCG-specific cytokine 
production assay described here enabled for delineation of different T cell 
subsets defined by production of the cytokines (IFN-γ, TNF-α, IL-2 and IL-17) 
and perforin by using whole blood stimulated with BCG.  
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Evaluation for BCG-specific perforin expression is challenging because this 
molecule is constitutively expressed and released upon antigenic stimulation. 
However perforin can also be rapidly upregulated upon antigenic stimulation 
(Makedonas et al., 2009). In order for us to be reliably measure BCG-specific 
perforin production, we used two strategies; first, we used the newly introduced 
anti perforin-PE B-D48 antibody clone is capable of detecting both the preformed 
perforin in the cytotoxic granules as well as newly formed perforin residing in the 
endoplasmic reticulum (Hersperger et al., 2008); second, we restricted our 
analysis to perforin+CD69+ cells based on studies that have used this marker to 
identify activated subsets of T cells expressing specific cytolytic molecules 
(Murray et al., 2006). 
 
Among the variables known to affect the results of ICS assays is the choice of 
the staining buffer. In our study, we observed no differences in frequencies as 
well as MFIs of markers conjugated on Qdot. We speculate that the BD/perm 
wash staining buffer we used does not contain substantial levels of heavy metals 
that could compromise on fluorescence of Qdot antibody conjugates. 
 
Following successful development of a large PFC antibody panel, it is useful to 
test the performance of the developed PFC panel. We tested this by FMO 
experiments. The FMO in our optimized 9-colour PFC panel revealed minimal 
spectral “spill over” into any of the channels utilized. We therefore concluded that 
the results generated by our 9-colour panel were reliable in measuring BCG-
specific T cell responses in infant samples. 
 
Finally, we developed a gating strategy to optimize identification of true positive 
results and eradication of false positives. We included steps aimed at minimizing 
false positivity: we gated on the lymphocyte population (thus excluding 
monocytes that may autoflourescence) and we excluded cell doublets. As 
expected, the majority of samples had very low (less than 0.05%) background 
staining. This is may be explained by the very low constitutive cytokine producing 
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cells in peripheral blood given that cytokine production is dependent on 
continuous APC and T-cell contact (Slifka et al., 1999). 
 
In summary, our results highlight the importance of careful and stepwise 
development of PFC panels to measure BCG-specific T cells by intracellular 
cytokine staining. We utilized this panel in Chapter 4 and modified versions of 
this panel in Chapter 5 and 7 to evaluate different aspects of BCG-specific 
immune responses in infants vaccinated at birth or at 6-weeks of age. 
 
 
3.5. Contributions 
Dr. F. Lutwama designed the experiments, conducted the laboratory assays and 
data analysis, and wrote this chapter under supervision of Prof. W.A. Hanekom, 
Dr. B.M.N. Kagina, and other members of the SATVI laboratory. 
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Chapter 4: Comparison of frequency of specific CD4+ and CD8+ T cells 
producing cytokines and perforin following BCG vaccination at birth or at 6 
weeks of age  
 
4.1. Introduction  
In this chapter, we describe the comparative frequency of BCG-specific IFN-γ, 
TNF-α, IL-2, IL-17 and perforin expressing CD4+ and CD8+ T cells in infants 
vaccinated with BCG at birth or 6 weeks of age. We hypothesised that infants 
vaccinated at birth would have lower frequencies of BCG-specific CD4+ and 
CD8+ T cells than infants vaccinated at 6 weeks of age. 
 
We proposed to investigate CD4+ and CD8+ T cell immunity thought to be critical 
for control of M.tb.  Furthermore, in infants, previous studies have reported that 
vaccination with BCG at birth mainly induces specific CD4+ and CD8+ T cells 
expressing IFN-γ (Kagina et al., 2010, Murray et al., 2006, Soares et al., 2008). 
Neonatal BCG vaccination also induces specific TNF-α  production by both CD4+ 
and CD8+ T cells (Lalor et al., 2011, Soares et al., 2008). We therefore evaluated 
the frequencies of BCG-specific TNF-α expressing CD4+ and CD8+ T cells in 
infants vaccinated with BCG at birth and 6 weeks of age.  
 
IL-2 is another Th1 cytokine induced following neonatal BCG vaccination (Smith 
et al., 1999, Soares et al., 2008) Antigen experienced T cell memory cells require 
IL-2 for maintenance and expansion. Our laboratory has shown measurable 
frequencies of BCG-specific IL-2, produced by conventional T cells in 10 week-
old infants, vaccinated with BCG at birth (Kagina et al., 2009).  We therefore 
investigated whether frequencies of BCG-specific IL-2 expressing CD4+ and 
CD8+ T cells in infants vaccinated with BCG at birth would be greater than those 
of infants vaccinated at 6 weeks of age.  
 
In a clinical study conducted previously by our laboratory, BCG-specific IL-17 
producing CD4+ T cells were detected in healthy adults, previously vaccinated 
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with BCG at birth (Scriba et al., 2008). In our study, we were therefore interested 
in establishing whether frequencies of BCG-specific IL-17 CD4+ and CD8+ T cells 
would be different when the vaccine is administered at birth than at 6 weeks of 
age.  
 
We also compared BCG-specific perforin-expressing CD4+ and CD8+ T cells 
when the vaccine is administered at birth and 6 weeks of age based on evidence 
showing that this cytotoxic molecule is induced in infants following the 
administration of the vaccine (Semple et al., 2011). We used CD69 antibody 
staining to identify BCG-activated, perforin expressing CD4+ and CD8+ T cells.  
 
Our aim was to compare the frequencies of: (i) the BCG-specific total cytokine 
and perforin expressing CD4+ and CD8+ T cells in fixed whole blood from infants 
vaccinated at birth or at 6 weeks of age; (ii) the BCG-specific CD4+ and CD8+ T 
cells subsets expressing the different cytokine and/or perforin between the two 
groups of infants. 
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4.2. Material and methods 
4.2.1. Study participants 
The infants studied in this chapter were selected from the cross sectional cohort 
described in chapter 2.  
 
4.2.2. Twelve-hour whole blood assay 
Whole blood was stimulated with specific antigens for a total of 12 hours as 
described previously in chapter 2 (section 2.7.1). 
 
4.2.3. Antibodies for intracellular cytokine staining assay  
The following fluorescently conjugated monoclonal antibodies (mAbs) were used: 
anti-CD3 Pacific Blue (UCHT1), anti-IFN-γ Alexa Fluor 700 (B27), anti-IL-2 FITC 
(5344.111), all from BD Biosciences, San Jose, CA; anti-CD4 QDots605 (S3.5) 
and anti-CD8 QDots565 (3B5), all from Invitrogen, Eugene, OR; anti-TNF-α PE-
Cy7 (Mab11), and anti-IL-17 Alexa Fluor 647 (eBio64CAP17), from 
eBiosciences, San Diego, CA; anti-CD69 PerCP-Cy5.5 (FN50), from Biolegend, 
San Diego, CA; and anti-Perforin PE (B-D48), from Diaclone, Besancon, France. 
All antibodies were titrated to find optimal concentrations for use as described in 
chapter 2 (section 3.5.5). Table 9 shows a summary of antibody-fluorochrome 
combinations we used in this assay. 
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Marker Fluorochrome Description 
CD3 Pac Blue T cell marker 
CD4 Qdots 605 T cell marker 
CD8 Qdots 565 T cell marker 
CD69  PerCpCy5.5 Early activation marker 
IFN-γ Alexa Fluor 700 Th1 cytokine 
IL-2 APC Th1 cytokine	  
TNF-α PE-Cy7 Th1 cytokine	  
IL-17 APC Th17 cytokine 
Perforin PE Cytotoxic molecule 
 
Table 9: Flow cytometry antibody-fluorochrome panel to evaluate cytokine and perforin-
expressing CD4+ and CD8+ T cells on cryopreserved fixed cells from stimulated whole 
blood collected from the study participants. 
 
4.2.4. Intracellular cytokine staining assay and flow cytometry analysis 
We used a “one step” staining method as described in chapter 3 (section 3.5.4) 
to measure the BCG-specific T-cells cytokines and cytolytic molecule expression 
in infants following BCG vaccination at birth and at 6 weeks of age.	  
 
4.2.5. Data analysis 
In this section, “specific” refers to either cytokine or cytotoxic expression. For 
each participant’s sample, the frequencies of specific CD4+ and CD8+ T cells 
detected in the negative control (unstimulated) were subtracted from frequencies 
of the specific CD4+ and CD8+ T cells detected in the corresponding BCG-
stimulated samples. Samples were excluded from the final analysis if the 
frequency of specific CD4+ T cells in the positive control condition was lower than 
the median plus 3 times the median absolute deviations (3xMAD) of the 
frequencies of specific CD4+ T cells of all the negative control samples. We 
chose to use CD4+ T cells to define this criterion because the BCG-specific 
immune responses were predominantly observed in this T cell subset. 
The Mann-Whitney U test was used to assess differences in immunological 
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outcomes between the two groups. Characteristics of the two groups of infants 
were compared using Pearson’s chi-squared test for categorical variables. Prism 
5.0 (GraphPad Software Inc.) was used for statistical analysis. A p-value below 
0.05 was considered significant. The impact of vaccination group, sex, household 
income, and weight (independent variables) on the frequency of cytokine 
expressing T cells (outcome variable) was determined by multivariate linear 
regression analysis using STATA 12.1, (Stata Corporation, College Station, 
Texas, USA).  
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4.3. Results 
4.3.1. Participants’ characteristics 
We enrolled 92 infants at 9 months of age in Kampala, Uganda. Fifty of these 
infants had received BCG at birth and 42 infants received the vaccine at 6 weeks 
of age. Participants’ recruitment and clinical exclusions are summarized in 
Figure 24. The weights at 9 months of age and gender distribution in both 
groups of infants were comparable (Table 10). The birth weight for infants 
vaccinated at 6 weeks of age were not available as they were mostly born at 
home. We have therefore not included this variable.	  Infants vaccinated with BCG 
at birth were more likely to be from a higher social economic background than 
infants vaccinated at 6 weeks of age (Table 10). 
Screened: 105 
infants 
Recruitment: 92 
Vaccinated with 
BCG at birth: 50 
Blood collected 
and incubated: 44 
Unsuccessful or 
insufficient blood 
collected: 6  
Vaccinated with 
BCG at 6 weeks 
of age: 42 
Blood collected 
and incubated: 40 
Unsuccessful or 
insufficient blood 
collected: 2 
Did not meet 
inclusion criteria: 
13 
 
 
Figure 24. Recruitment, enrollment and exclusion of infants in the study. Initially infants 
interested in taking part in the study were screened and eligible infants were enrolled into the 
study. Blood was then drawn from the infants on the day of enrollment. 
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Variable Vaccinated at 
birth: (n=44) 
Vaccinated at 6  
weeks of age: (n=40) 
P-value 
Sex n (%) 
     Female  
     Male  
 
18 (41) 
26 (59) 
 
20 (53) 
18 (47) 
 
0.29a 
Income n (%) 
     Below 125 USD 
     Above 125 USD 
 
12 (27) 
32 (73) 
 
25 (64) 
14 (36) 
 
0.001a 
Season of BCG 
administration n(%) 
     Dry 
     Rainy 
 
 
               28 (64) 
       16 (36) 
 
     
            24 (60) 
            16 (40) 
 
    
     0.73a 
Weight at 9 months 
(Kg) (Median, IQR) 
 
9.0 (8, 9.55) 
 
    8.5 (8, 9.45) 
 
   0.26b 
 
Table 10. Demographic characteristics of the study participants at 9 months of age. Gender, 
income, season of BCG administration and weight of the infants vaccinated with BCG at birth or at 
6 weeks of age are shown. Differences in the characteristics were statistically evaluated:  aChi 
Square and bMann–Whitney U tests were used for the analysis. 
 
 
4.3.2. Gating strategy 
We used the gating strategy developed during the optimisation process 
described in chapter 3 (section 3.6.11). We used the strategy to analyse the 
BCG-specific cytokine and perforin expressing CD4+ and CD8+ T cells. Figure 25 
shows representative flow cytometry dotplots to identify the specific CD4+ and 
CD8+ T cells from a 9-month old infant vaccinated with BCG at 6 weeks of age. 
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Figure 25: Frequencies of BCG specific CD69, IFN-γ , TNF-α , IL-2, IL-17 and perforin CD4+ 
T cells. Whole blood was either left unstimulated, or was stimulated with BCG for 12 hours. 
Brefeldin-A was added in the last 5 hours to capture intracellular cytokines for detection by flow 
cytometry. Representative flow cytometry plots of cytokine and perforin expression in an 
unstimulated (top row) and BCG stimulated (bottom row) sample from an infant vaccinated with 
BCG at birth are shown. 
 
 
 
4.3.3. Participants’ exclusion from the analyses  
We used the exclusion criteria described in the data analysis section to ensure 
only successfully processed samples were included in the final analyses. Table 
11 shows the participants excluded form the analysis. 
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Reason for 
exclusion 
44 infants vaccinated 
at birth (all samples 
processed) 
40 infants vaccinated at 6 
weeks (all samples 
processed) 
Number of infants excluded from the WB-ICS final 
analyses 
PHA responses < 
median + 3MAD of 
all negative controls 
combined 
0 6 
 
Table 11: Exclusions from the final WB ICS analysis. Infant samples with a PHA CD4 T cell 
total cytokine response of less than the median plus 3MAD of the frequencies of specific CD4+ T 
cells of all the negative control samples were excluded from the analysis. 
 
4.3.4 Greater frequencies of BCG-specific total IFN-γ expressing CD4+ T cells in 
birth vaccinated infants, compared with infants vaccinated at 6 weeks of age 	  
Our aim was to compare the frequency of BCG-specific cytokine and perforin 
expressing CD4+ T cells in infants vaccinated with BCG at birth or at 6 weeks of 
age. Our hypothesis was that birth vaccinated infants would have lower 
frequencies of BCG-specific CD4+ T cells than infants vaccinated at 6 weeks of 
age. The great majority of infants vaccinated with BCG at either time point had a 
detectable specific IFN-γ, TNF-α, IL-2, IL-17 and perforin CD4+ T cell response 
(Figure 26A, B). Frequency of BCG-specific CD4+ T cells expressing either IL-2, 
IL-17, TNF-α or perforin were comparable in the 2 vaccination groups (Figure 
26A, B). However infants vaccinated with BCG at birth had greater frequencies 
of CD4+ T cells expressing IFN-γ, compared with infants vaccinated at 6 weeks of 
age (Figure 26A). 
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Figure 26. Frequencies of specific CD4+ T cells producing cytokines and perforin. We 
measured the specific responses using the short-term whole blood assay. Scatter plots depict 
frequencies of total IFN-γ, TNF-α, IL-2, and IL-17 cytokine expressing CD4+ T cells (A), and total 
perforin expressing CD69+CD4+ T cells (B). On the scatter plots, the horizontal lines represent 
the median frequencies of the specific cells. The results shown are corrected for unstimulated 
responses. The Mann–Whitney U test was used to compare differences in frequencies of 
cytokine and perforin expressing CD4+ T cells between infants vaccinated at birth (blue circles) or 
6 weeks of age (red circles). P values less than 0.05 were considered significant. 
 
4.3.5. Greater frequencies of BCG-specific CD4+ T cells expressing IFN-γ, with or 
without perforin, in infants vaccinated at birth compared with those vaccinated at 
6 weeks of age 	  
The observed difference in BCG-specific CD4+ T cells expressing IFN-γ between 
the two groups prompted us to further assess the profile of the vaccine-induced 
immune responses. Therefore, we compared the profile of BCG-specific CD4+ T 
cell expressing IFN-γ, TNF-α, IL-2 and IL-17 alone or in different combinations, 
between the two groups of infants. In both groups, we did not observe co-
expression of IL-I7 with any of the cytokines evaluated (Figure 27A and B), 
therefore, we did not compare these outcomes between the two groups: the 
frequencies were too low for reliable comparison. The frequencies of BCG-
specific polyfunctional (IL-2+IFN-γ+TNF-α+), double positive (IL-2+IFN-γ+, IL-
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2+TNF-α+ and IFN-γ+TNF-α+) as well as single positive (IL-2+, TNF-α+ or IL-17+) 
CD4+ T cell subsets were not different between the two groups (Figure 27A). 
However, the birth vaccinated group had greater frequencies of BCG-specific 
IFN-γ single-positive CD4+ T cells, than the 6 weeks of age vaccinated group 
(Figure 27A). We also evaluated the co-expression of the different specific 
cytokines with perforin. Only IFN-γ was co-expressed with perforin in both groups 
of infants. We showed that frequencies of specific IFN-γ+perforin+ double-positive 
CD4+ T cells were greater in the birth than 6 weeks of age vaccinated infants 
(Figure 27C).   
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Figure 27. BCG-specific CD4+ T cell cytokine subsets. We measured specific responses 
using the short-term whole blood assay. Box and whisker plots show frequencies of the distinct 
subsets of specific CD4+ T cells based on combinations of expression for: IFN-γ, TNF-α, IL-2, 
and IL-17 (A and B) as well as IFN-γ and perforin (C) only. Co-expression of all cytokines was 
assessed on CD4 T cells while that of IFN-γ and perforin was on CD69+CD4+. Whiskers 
represent the maximum and minimum value; the box represents the interquartile range, while 
the line in the box represents the median. Values are shown after subtraction of the 
unstimulated responses in the negative controls from the BCG-stimulated samples. The Mann–
Whitney U test was used to compare the difference in frequencies of CD4+ T cell subsets 
between infants vaccinated at birth (blue bars) or 6 weeks of age (red bars). P values less than 
0.05 were considered significant. 
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4.3.6. Greater frequencies of BCG-specific total IFN-γ expressing CD8+ T cells in 
infants vaccinated at birth compared with those vaccinated at 6 weeks 	  	  
Next, we compared the frequency of BCG-specific IFN-γ, TNF-α, IL-2, IL-17 and 
perforin expressing CD8+ T cells in infants vaccinated at birth or 6 weeks of age. 
Our hypothesis was that birth vaccinated infants would show lower frequencies of 
BCG-specific CD8+ T cells than infants vaccinated at 6 weeks of age. We 
performed an identical analysis as that performed for CD4+ T cells. In both 
groups, BCG-specific CD8+ T cell responses were dominated by IFN-γ and 
perforin expression (Figure 28A, B). As for CD4+ T cells, the frequencies of 
BCG-specific TNF-α, IL-2, IL-17 and perforin expressing CD8+ T cells in both 
groups were not different, while infants vaccinated with BCG at birth had a 
greater frequency of specific CD8+ T cells expressing IFN-γ compared with 
infants vaccinated at 6 weeks of age (Figure 28A). 
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Figure 28. BCG-specific CD8+ T cell cytokine and perforin responses. Scatter plots depict 
frequencies of total IFN-γ, TNF-α, IL-2, and IL-17 cytokine expressing CD8+ T cells (A), and 
perforin expressing CD69+CD8+ T cells (B). The horizontal lines shown in the scatter plots 
represent the median frequencies of the specific cells. Values are shown after subtraction of the 
unstimulated responses (negative controls) from the BCG-stimulated samples. The Mann–
Whitney U test was used to compare the difference in frequencies of cytokine and perforin 
expressing CD8+ T cells between the infants vaccinated at birth (blue bars) or 6 weeks (red bars) 
vaccinated infants. P values less than 0.05 were considered significant. 
 
 
4.3.7. Greater frequencies of BCG-specific CD8+ T cells expressing IFN-γ, with or 
without perforin, in infants vaccinated at birth compared with those vaccinated at 
6 weeks of age  	  
Next, we proceeded to compare the profile of BCG-specific CD8+ T cell subsets. 
As for CD4+ T cells, single expressing IFN-γ  CD8+ T cell were the dominant 
subset, while IL-17 expressing cells were the least dorminant subset in both 
infant groups (Figure 29A). In both groups, we did not observe co-expression of 
IL-17 with any of the cytokines evaluated (Figure 29A and B), therefore, we did 
not compare these outcomes between the two groups: the frequencies were too 
low for reliable comparison. The frequencies of BCG-specific CD8+ T cells 
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expressing only TNF-α or IL-2 were also not different between the two groups. 
Consistent with what we observed for CD4+ T cells, the birth vaccinated group 
had greater frequencies of specific CD8+ T cells expressing only IFN-γ compared 
with infants vaccinated at 6 weeks of age (Figure 29A). 
Further analysis of BCG-specific CD8+ T cell subsets showed that perforin was 
either expressed alone or co-expressed with IFN-γ, and not any other cytokine 
(Figure 29C). Also similar to CD4+ T cells, the birth vaccinated group had greater 
frequencies of specific CD8+ T cells that expressed IFN-
γ alone, or in combination with perforin (Figure. 29C). 
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Figure 29. BCG-specific CD8+ T cell cytokine subsets. Box and whisker plots show the 
frequencies of the distinct subsets of specific CD8+ T cells based on combinations of expression 
for: IFN-γ, TNF-α, IL-2, and IL-17 (A and B) as well as IFN-γ and perforin (C) only. Co-expression 
of all cytokines was assessed on CD8+ T cells while that of IFN-γ and perforin was on 
CD69+CD8+cells. Whiskers represent the maximum and minimum value; the box represents the 
interquartile range, while the line in the box represents the median. Values are shown after 
subtraction of the unstimulated responses in the negative controls from the BCG-stimulated 
samples. The Mann–Whitney U test was used to compare the difference in frequencies of CD8+ T 
cell subsets	  between infants vaccinated at birth (blue bars) or 6 weeks of age (red bars). P values 
less than 0.05 were considered significant.	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4.3.8. No difference in the frequency of TB10.4-specific CD4+ T cells expressing 
cytokines or perforin in the two groups of infants 	  
We also measured TB10.4-specific T cell responses in the two groups of infants. 
We chose to evaluate TB10.4 specific responses because the protein is 
expressed by BCG and is an immunodominant antigen (Skjot et al., 2000). Some 
novel TB vaccines designed to boost the BCG-induced immunity have 
incorporated TB10.4 protein (Abel et al., 2010). We compared the frequencies of 
TB10.4-specific cytokine and perforin expressing CD4+ T cell in infants 
vaccinated with BCG at birth or at 6 weeks of age. The great majority of infants 
vaccinated with BCG at either time point had a detectable specific IFN-γ, TNF-α, 
IL-2, IL-17 and perforin CD4+ T cell response (Figure 30A, B). The frequencies 
of BCG-specific IFN-γ, TNF-α, IL-2, IL-17 and perforin expressing CD4+ T cells in 
both groups were not different (Figure 30A, B).  
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Figure 30. TB10.4-specific CD4+ T cell cytokine and perforin response. Scatter plots depict 
frequencies of total IFN-γ, TNF-α, IL-2, and IL-17 cytokine expressing CD4+ T cells (A), and 
perforin expressing CD69+CD4+ T cells (B). The horizontal lines represent the median 
frequencies. The blue and red circles represent infants vaccinated at birth or 6 weeks of age BCG 
vaccinated infants respectively. Values are shown after subtraction of the unstimulated responses 
in the negative controls from the TB10.4-stimulated samples. The Mann–Whitney U test was used 
to compare the difference in frequencies of cytokine and perforin expressing CD4+ T cells 
between infants vaccinated at birth (blue circles) or 6 weeks of age (red circles). P values less 
than 0.05 were considered significant. 
 
 
4.3.9. No difference in the frequencies of TB10.4-specific CD8+ T cell expressing 
cytokines or/and perforin in the two groups of infants 	  
Next, we compared frequencies of TB10.4-specific IFN-γ, TNF-α, IL-2, IL-17 and 
perforin expressing CD8+ T cells in infants vaccinated with BCG in the two 
groups. In both groups, TB10.4-specific CD8+ T cell responses were dominated 
by perforin expression (Figure 31A, B). Similar to CD4+ T cells, frequencies of 
BCG-specific IL-2, IL-17, IFN-γ, TNF-α and perforin expressing CD4+ T cells in 
both groups were not different (Figure 31A, B). 
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Figure 31. TB10.4-specific CD8+ T cell cytokine and perforin response. Scatter plots depict 
frequencies of total IFN-γ, TNF-α, IL-2, and IL-17 cytokine expressing CD8+ T cells (A), and 
perforin expressing CD69+CD8+ T cells (B). The horizontal lines represent the median 
frequencies. The blue and red circles represent infants vaccinated at birth or 6 weeks of age 
BCG. Values are shown after subtraction of the unstimulated responses in the negative controls 
from the TB10.4-stimulated samples. The Mann–Whitney U test was used to compare the 
difference in frequencies of cytokine and perforin expressing CD8+ T cells between infants 
vaccinated at birth (blue circles) or 6 weeks of age (red circles). P values less than 0.05 were 
considered significant. 
 
 
4.3.10. No difference in frequencies of BCG-specific total IFN-γ expressing CD4+ 
and CD8+ T cells in infants from low income category, compared with infants 
from high income category  	  
Next, we evaluated if the observed greater frequencies of IFN-γ expressing CD4+ 
and CD8+ T cell in infants vaccinated at birth compared to 6 weeks could be 
explained by household income. We observed that a higher proportion of infants 
vaccinated at 6 weeks of age were from families of lower social economic status 
than infants vaccinated at birth (Table 10). We compared the frequency of BCG-
specific IFN-γ expressing T cells in infants from low (below 125 USD) and high 
(above 125 USD) household income categories. We observed no differences in 
frequencies of BCG-specific IFN-γ expressing CD4+ and CD8+  (Figure 32A and 
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B) T cells were observed between the high income and the low income groups. 
Nevertheless, frequencies of IFN-γ expressing CD4+ T cell and CD8+ T cell were 
significantly associated with household income (Table 12 and 13). 
 
 
 
 
Figure 32. BCG-specific IFN-γ  expressing CD4+ and CD8+ T cells by income category.. 
Scatter plots depict frequencies of total IFN-γ expressing CD4+ T cells (A) and CD8+ T cells (B). 
On the scatter plots, the horizontal lines represent the median frequencies of the specific cells. 
The results shown are corrected for unstimulated responses. The Mann–Whitney U test was used 
to compare the difference in frequencies of IFN-γ expressing CD4+ T cells and CD8+ T cells 
between infants in above 125 USD income category (open circles) and infants in the below 125 
USD income category (closed circles). P values less than 0.05 were considered significant. 
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LogCD4+ IFNγ+ Coef s.e P-value [95% Conf. Interval] 
Univariate analysis     
Vaccination group 0.3639 0.0969 0.000  0.1710236  0.5567765 
Sex 0.0845 0.1020 0.410 -0.1185748      0.2876241 
Income category 0.2615 0.1017 0.012  0.0591906      0.4637975 
Weight  0.0695 0.0479 0.151 -0.0258983      0.1648879 
Multivariate analysis     
Vaccination group 0.3117 0.1022 0.003  0.1082647  0.5150414 
Income category 0.1554 0.1028 0.135 -0.0493226      0.3600253 
R2 = 0.17; adjusted R2= 0.15 
 
Table 12: Univariate and multivariate linear regression analyses considering LogCD4+ IFNγ+ as 
outcome. The independent variables were vaccination group, sex, household income, and weight. 
In the multivariate analysis, the variables considered were the vaccination group and household 
income.  
 
LogCD8+IFNγ+ Coef s.e P-value [95% Conf. Interval] 
Univariate analysis     
Vaccination group 0.6611 0.1267 0.000  0.4089      0.9133 
Sex 0.0540 0.1502 0.720  -0.2451      0.3532 
Income category 0.3194 0.1429 0.028  0.0348      0.6040 
Weight  0.0477 0.0696 0.496  -0.0912      0.1866 
Multivariate analysis     
Vaccination group 0.6254 0.1351 0.000   0.3564      0.8944 
Income category 0.1053 0.1358 0.440  -0.1648      0.3755 
R2 = 0.26; adjusted R2= 0.24 
 
Table 13: Univariate and multivariate linear regression analyses considering LogCD8+ IFNγ+ as 
outcome. The independent variables were vaccination group, sex, household income, and weight. 
In the multivariate analysis, the variables considered were the vaccination group and household 
income. 
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4.4. Discussion  
In this chapter, we describe a comparison of BCG-induced cytokine and perforin- 
expressing T cell responses between infants vaccinated at birth and at 6 weeks 
of age. We showed that age of vaccination impacted the induced immune 
response, measured at 9 months of age: infants vaccinated at birth had greater 
frequencies of BCG-specific total IFN-γ expressing CD4+ and CD8+ T cells than 
infants vaccinated at 6 weeks of age. Furthermore, infants vaccinated at birth 
showed greater frequencies of BCG-specific single (IFN-γ+) and double (IFN-
γ+perforin+) producing CD4+ and CD8+ T cells than infants vaccinated at 6 weeks 
of age. Finally, the frequencies of TB10.4-specific CD4+ and CD8+ T cell 
responses were not different in both groups of infants.  
 
We measured the specific IFN-γ-expressing cells based on the proposed 
important roles for this molecule in control of mycobacterial infection (Bogunovic 
et al., 2012, Newport et al., 1996, Ottenhoff et al., 2000). In our study, greater 
frequencies of BCG-specific CD4+ and CD8+ T cells expressing either IFN-γ and 
co-expressing IFN-γ and perforin in infants vaccinated at birth, compared to 6 
weeks, could be a reflection of more effective vaccine-take in the former group. 
However, we cannot speculate about clinical relevance of this observation in 
human infants, in terms of protection against TB disease (Kagina et al., 2010); 
BCG-induced correlates of protection are not known. 
 
The proposed role for perforin in mediating immunity against M.tb involves 
perforation of cell membranes of infected cells to permit entry of cytolytic 
granzymes that directly kill M.tb or the infected cells (Thiery et al., 2011). 
Supporting the role of perforin in TB immunity is a study by Rahman et al. that 
showed non-human primates vaccinated with a novel TB vaccine (rBCG/rAD35), 
and subsequently challenged with M.tb, had greater frequencies of 
mycobacteria-specific perforin expressing T cells that associated with better 
protection (Rahman et al., 2012). In this study, we observed increased 
frequencies of BCG-specific IFN-γ+perforin+-expressing T cells when the vaccine 
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was administered at birth compared to 6 weeks of age. However, to the best of 
our knowledge, the association between vaccine-specific IFN-γ+perforin+-
expressing T cells and the risk of TB disease has not been demonstrated in a 
clinical setting.  
 
We also evaluated immune responses to TB10.4, an immunodominant antigen 
present in both BCG and M.tb (Skjot et al., 2000). We showed that infants in both 
groups had detectable TB10.4-specific CD4+ and CD8+ T cell responses. As 
expected, the frequencies of TB10.4-specific T cells were lower than those 
observed following stimulation of whole blood with the whole viable BCG.  
Nevertheless, no differences in the TB10.4-specific CD4+ and CD8+ T cells 
between birth and 6 weeks of age BCG vaccinated infants. We speculate that 
boosting TB10.4-specific T cell responses induced by BCG vaccination in infants 
at birth or at 6 weeks of age, with novel TB vaccines containing the TB10.4 
antigen may result in similar frequencies of these specific immune responses.  
 
What are the possible explanations for the differences observed in the BCG-
induced T cell immunity between the two groups of infants? First, we observed 
that a higher proportion of infants vaccinated at 6 weeks of age were from 
families of lower social economic status than infants vaccinated at birth. Lower 
social economic status may result in poor health seeking behavior (including anti-
helminthes treatment), or poor nutrition of infants leading to suboptimal immune 
responses (Rodriguez et al., 2005). We did not show a difference in the 
frequencies of BCG-specific IFN-γ expressing CD4+ and CD8+ T cell responses 
in infants from a higher income, compared with those from the lower income 
categories. Nevertheless, we observed a significant association between 
frequencies of IFN-γ expressing CD4+ T cell and household income. We 
speculate that the lower social economic status may have indirectly and 
negatively impacted the specific T cell response observed in the group of infants 
vaccinated at 6 weeks of age. 
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Our results could also be explained by co-administration of BCG with DPT-Alum 
(Sartono et al., 2010). We speculate that alum may potentially result in reduced 
Th1 responses through two mechanisms; first, alum induces predominantly 
induces Th2 immune responses (Bungener et al., 2008), which may attenuate 
the BCG-induced Th1 responses (Abbas et al., 1996, Marrack et al., 2009); 
second alum inhibits production of the Th1 promoting cytokine IL-12 by dendritic 
cells (Mori et al., 2012). Therefore, co-administration of DPT-alum with BCG in 
infants vaccinated at 6 weeks of age may have resulted in attenuated IFN-γ CD4+ 
and CD8+ T cell responses relative to infants vaccinated at birth. 
 
The observed differential specific T cell response, when BCG is given at birth 
versus at 6 weeks of age prompts further follow up studies that may give more 
insight into clinical relevance, primarily focusing on the influence of the results to 
the risk of M.tb infection and/or TB disease.  
 
4.5. Contributions 
Dr. F. Lutwama designed the experiments, conducted the laboratory assays and 
data analysis, and wrote this chapter under supervision of Prof. W.A. Hanekom, 
Dr. B.M.N. Kagina, Dr. C.L. Day and Dr T.J Scriba. 
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Chapter 5: Comparison of proportions of specific T-cell memory and 
maturation phenotypes following BCG vaccination at birth and at 6 weeks 
of age 
 
5.1. Introduction 
In this chapter, we describe the comparative proportions of memory phenotypes 
and maturational characteristics of BCG-specific CD4+ and CD8+ T cells. We 
designed follow up studies based on the findings that administration of BCG at 
birth induces greater frequencies of BCG-specific single IFN-γ+ as well as 
bifunctional IFN-γ+perforin+-expressing T cells than BCG administered at 6 weeks 
of age.  
 
We hypothesised that greater frequencies of BCG-specific CD4+ and CD8+ T 
cells expressing IFN-γ positively associate with greater proportions of effector 
memory T cells (TEM).  Our aim therefore was: (i) to compare the proportions of 
memory T cell subsets between the two groups of infants; (ii) to compare the 
maturational phenotype of BCG-specific memory T cells between the two groups 
of infants. 
 
To address our aim, we used a combination of CD45RA, CCR7 and CD27 to 
characterise the specific IFN-γ-expressing CD4+ and CD8+ T cells in both groups 
of infants.  Different subsets of memory T cells can be defined based on the 
expression of the surface markers, CD45RA and CCR7 (Sallusto et al., 1999). In 
addition, memory T cells can be further dissected into different subsets based on 
expression of CD27 (Adekambi et al., 2012, Fritsch et al., 2005, Tena-Coki et al., 
2010). These markers are discussed in detail in chapter 1 (section 1.9). Studies 
in our laboratory have shown presence of specific memory T cells in the 
peripheral blood of 10-week old infants who had received BCG at birth (Kagina et 
al., 2009).  In these studies, an effector memory phenotype was observed in 
BCG-specific memory T cells expressing IFN-γ (Kagina et al., 2009, Soares et 
al., 2008). 
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We used IFN-γ expressing CD4+ and CD8+ T cells to define antigen specific 
CD4+ and CD8+ T cells. Furthermore, we used CD69 antibody to identify early, 
activated and antigen-specific CD4+ and CD8+ T cells (Testi et al., 1994). In our 
preliminary experiments during optimisation, we found that CD4+CD69+ T cells 
not expressing IFN-γ produced IL-2, IL-17 or TNF-α . We were therefore able to 
also characterise antigen-specific and non-IFN-γ-expressing CD4+ and CD8+ T 
cells in the two groups of infants. 
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5.2. Material and methods 
5.2.1. Study participants 
The participants studied in this chapter were 9 month-old infants selected from 
the cross sectional cohort described in chapter 2.	  	  
 
5.2.2. Twelve-hour whole blood assay 
Whole blood was stimulated with specific antigens for a total of 12 hours as 
described previously in chapter 2 (section 2.7.1). 
 
5.2.3. Antibodies for intracellular cytokine staining assay 
The following fluorescently conjugated monoclonal Abs were used: anti-CD3 
Pacific Blue (UCHT1), anti-CD8 Horizon V500 (RPA-T8), anti-IFN-γ Alexa Fluor 
700 (B27), anti-CD45RA FITC (HI100), anti-CD27 APC (L128) and anti-CCR7 
PE (560765), all from BD Biosciences, San Jose, CA; anti-CD4 QDot605 (S3.5) 
from Invitrogen, Eugene, OR; anti-CD69 PerCP-Cy5.5 (FN50), from Biolegend, 
San Diego, CA. All antibodies were titrated to find optimal concentrations for use. 
Table 14 below summarises the flow cytometry panel used in this study. 
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Marker Fluorochrome Description 
CD3 Pac Blue T cell marker 
CD4 Qdots 605 T cell marker 
CD8 Horizon V500 T cell marker 
CD45RA FITC Naïve T cell marker 
CCR7 PE Homing marker 
CD27 APC Maturation marker 
CD69  PerCpCy5.5 Early activation marker 
IFN-γ Alexa Fluor 700 Th1 cytokine 
 
Table 14: Flow cytometry panel for assessing the memory phenotypes of the specific CD4+ and 
CD8+ T cell. Shown are the markers included in the panel, the fluorochromes to which they are 
conjugated, as well as the description of the markers. 
 
 
5.2.4. Intracellular cytokine staining assay and flow cytometry analysis 
In our optimization experiments, we observed that CCR7 staining was optimal at 
37°C. However, the rest of the antibodies in our panel stained optimally at 4°C. 
We therefore used a “two step” staining method to assess memory phenotypes 
of BCG-specific T cells. In this method, we stained for the surface marker, CCR7 
followed by the rest of the surface markers and intracellular cytokines.  
 
Fixed, cryopreserved white cells from the stimulated whole blood were thawed, 
washed in phosphate buffered saline (PBS, BioWhittaker), permeabilised in 
Perm/Wash Buffer (BD Biosciences) and stained with CCR7 mAbs for 30 
minutes at 37°C. Stained cells were then washed in 1mL BD Perm/Wash buffer 
and stained with mAbs to intracellular cytokines and the rest of the surface 
markers for 1 hour at 4°C.  Cells were then washed and acquired on a LSRII flow 
cytometer (BD Biosciences). For quality assurance, compensation was done with 
positive and negative anti-mouse Ig kappa-beads (BD Biosciences) labeled with 
the respective fluorochrome-conjugated antibodies. Cytometer Setting and 
Tracking (CST) beads (BD Biosciences) were used for daily settings.	   After 
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acquisition, data were compensated and analysed using FlowJo software 
(v9.4.11; Treestar). Flow data were then exported to Pestle v1.7 (Mario 
Roederer, Vaccine Research Center, National Institute of Allergy and Infectious 
Diseases, National Institutes of Health) and Spice (v5.1) for further analysis 
(Roederer et al., 2011).  
 
5.2.5. Data analysis 
For each study participant, frequencies of IFN-γ-expressing CD4+ T cells 
detected in the negative control sample were subtracted from frequencies 
detected in the corresponding BCG-stimulated samples to determine the 
frequency of BCG-specific cells. Similar analysis was performed on CD8+ T cells. 
Background subtraction was not performed for memory phenotype analysis. 
Samples were excluded from the final analysis if the frequency of total PHA-
induced IFN-γ-expressing CD4+ T cells was lower than the median plus 3 time 
median absolute deviations (3xMAD) of the specific CD4+ T cells of all the 
negative control samples. In addition, participants were excluded if: (1) frequency 
of BCG-specific IFN-γ-expressing CD4+ T cells was less than 0.01% after 
subtraction of the response in the unstimulated condition; (2) the fold change in 
the frequency of IFN-γ+ or IFN-γ- CD69+ expressing CD4+ T cells in the BCG 
stimulated to the unstimulated sample was less than two and (3) number of BCG-
specific IFN-γ+ or IFN-γ- CD69+ expressing CD4+ T cells was less than 20 after 
subtracting the non-specific cells in the unstimulated sample. 
The Mann-Whitney U test was used to assess differences in the proportions of 
specific T cell memory and maturation phenotypes between the two groups. A p-
value of less than 0.05 was considered statistically significant. The Prism 5.0 
(GraphPad Software Inc.) was used for statistical analyses.  
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5.3. Results 
5.3.1. Participants excluded from the analysis  
We used the exclusion criteria described in the data analysis section. Table 15, 
16 and 17 below show the reasons and number of participants excluded in the 
analysis. 
 
 
Reason for exclusion 
44	   infants	   vaccinated	  
at	   birth	   (all	   samples	  
processed) 
34	   infants	   vaccinated	  
at	  6	  weeks	  (all	  samples	  
processed) 
Frequency of specific IFN-
γ-expressing CD4+ T cells 
< 0.01% 
0 0 
Fold change in the 
frequency of IFN-γ+ CD4+ 
T cells in BCG compared 
to unstimulated sample < 
2 
7 9 
Number of IFN-
γ-expressing CD4+ T cells 
after correcting for the 
unstimulated number of 
cell < 20 
1 2 
 
Table 15: Participants excluded from the final memory phenotype analysis of BCG-specific IFN-
γ-expressing CD4+ T cells.  
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 44	   infants	   vaccinated	  
at	   birth	   (all	   samples	  
processed) 
34	  infants	  vaccinated	  at	  
6	   weeks	   (all	   samples	  
processed) 
Reason for exclusion   
Frequency of specific IFN-
γ-expressing CD8+ T cells < 
0.01% 
 
0 
 
0 
Fold change in the 
frequency of IFN-γ+ CD8+ T 
cells in BCG compared to 
unstimulated sample < 2 
 
20 
 
9 
Number of IFN-
γ-expressing CD8+ T cells 
after correcting for the 
unstimulated number of cell 
< 20 
 
0 
 
0 
 
Table 16: Participants excluded from the final memory phenotype analysis of BCG-specific IFN-
γ-expressing CD8+ T cells 
 
 
 44	  infants	  
vaccinated	  at	  birth	  
(all	  samples	  
processed) 
34	  infants	  vaccinated	  at	  
6	  weeks	  (all	  samples	  
processed) 
Reasons for exclusion   
Frequency of specific IFN-γ- 
CD69+ CD4 T cells < 0.01% 
0 0 
Fold change in the frequency 
of IFN-γ- CD69+CD4 T cells in 
BCG compared to 
unstimulated sample < 2 
20 25 
Number of IFN-γ- CD69+CD4 
T cells after correcting for the 
unstimulated number of cell < 
20 
0 0 
 
Table 17: Participants excluded from the final memory phenotype analysis of BCG-specific 
CD69+ and non-IFN-γ-expressing CD4+ T cells  
 
5.3.2. Gating strategy 
We modified the gating strategy developed during the optimisation process 
described in Chapter 3 to analyse the profile of CCR7, CD45RA and CD27 
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expression by BCG-specific IFN-γ-expressing and non-IFN-γ-expressing 
CD4+CD69+ and CD8+CD69+ T cells. Figure 33 shows the modified gating 
strategy and representative flow cytometry dotplots from an infant vaccinated 
with BCG at 6 weeks of age. 
 
 
 
 
 
Figure 33. Gating strategy to analyse the memory phenotype of the specific IFN-γ–
expressing CD4+ T cells. To analyse expression of CD45RA, CCR7 and CD27 memory markers 
on the specific T cells, we selected CD3+ T cells and divided this population into CD4+ and CD8+ 
T cells. Then, cells expressing IFN-γ or CD69 were selected from the CD4+ T cells. Finally, 
CD45RA and CCR7 and CD27 expression were assessed within the specific IFN-γ- and non-
expresssing cells. A similar analysis strategy was used for CD8+ T cells. 
 
5.3.3. No difference in BCG-specific CD4+ and CD8+ T cell memory phenotypes 
between the two groups 
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We aimed to characterise the profile of memory phenotypes of BCG-specific 
CD4+ and CD8+ T cells expressing IFN-γ. We hypothesized that birth vaccinated 
infants would show a greater proportion of specific IFN-γ+ CD4+ and CD8+ T cells 
expressing an effector memory phenotype, compared to those vaccinated at 6 
weeks of age.  
In both groups of infants, the majority of the BCG-specific IFN-γ-expressing CD4+ 
T cells showed a dominant central memory (TCM) phenotype (Figure 34A). The 
second most dominant memory phenotype characterising the BCG-specific IFN-
γ-expressing CD4+ T cells was TEM, while the proportions of the other phenotypes 
of TNaive and TEMRA were least represented.  
There were no differences in proportions of any of the memory phenotypes 
characterising the BCG-specific IFN-γ-expressing CD4+ T cells between the two 
groups of infants. (Figure 34A). We used a similar strategy to analyse the 
proportions of T cell memory phenotypes expressed by BCG-specific IFN-γ CD8+ 
T cells. BCG-specific IFN-γ-expressing CD8+ T cells mainly showed a TEM and 
TEMRA phenotypes in both groups of infants, and again the two groups were not 
different (Figure 34B).  
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Figure 34. Memory phenotypes of BCG-specific IFN-γ-expressing CD4+ and CD8+ T cells. 
Box and whisker plots show the proportions of BCG-specific IFN-γ-expressing CD4+ T cells (A), 
and BCG-specific IFN-γ-expressing CD8+ T cells (B). In both graphs, expression of the CD45RA 
and CCR7 memory markers, either singly or in combination are shown. Whiskers represent the 
minimum and maximum value; the box represents the interquartile range, while the line in the 
box represents the median. Values are shown without subtraction of the unstimulated 
responses in the negative controls from the BCG-stimulated samples. The Mann–Whitney U 
test was used to compare the difference in proportions of specific T cell memory phenotypes 
between the birth (blue bars) and 6 weeks of age (red bars) vaccinated infants. P values less 
than 0.05 were considered statistically significant. 
 
 
5.3.4. No difference in BCG-specific IFN-γ-non-expressing CD4+ T cell memory 
phenotype between the two groups. 
 
In our studies reported in Chapter 4, we did not observe a difference in the 
frequencies of TNF-α-, IL-2- and IL-17-expressing BCG-specific CD4+ T cells in 
the two groups of infants. The BCG-activated but non-IFN-γ producing T cells 
represented TNF-α-, IL-2- and IL-17-expressing BCG-specific CD4+ T cells (We 
used CD69 in place of TNF-α-, IL-2- and IL-17 because we were limited by the 
number of parameters that we could include in our flow cytometry panel). We 
therefore hypothesised that similar proportions of memory T cell phenotypes 
	   129	  
would be observed between the two groups of infants by the BCG-activated but 
non-IFN-γ producing cells. To test this hypothesis, we assessed the expression 
of memory markers in the activated non-IFN-γ producing CD4+ T cells (IFN-γ- 
CD69+). We observed no difference in the proportions of TNaive, TCM, TEM and 
TEMRA phenotypes of activated and non-IFN-γ producing CD4+ T cells between 
the two groups of infants (Figure 35A). Non-IFN-γ producing CD8+ T cells were 
infrequent and therefore not analysed for memory phenotype. When we analysed 
memory phenotypes of the activated non-IFN-γ producing CD4+ T cells in the 
unstimulated samples, greater proportions of TCM, and TEMR,A CD4+ T cells were 
observed in infants vaccinated at birth than at 6 weeks of age (Figure 35B). The 
phenotype of non-specific (IFN-γ- CD69+) and apparently activated CD4+ T cells 
showed that the birth vaccinated infants had a greater proportion of TCM and 
TEMRA phenotypes than the 6 weeks vaccinated infants (Figure 35B).  
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Figure 35. Memory phenotype of BCG-specific and non-specific CD4+ T cells. BCG-
specific and activated IFN-γ-CD4+ T cells were selected based on CD69 expression as detailed 
in the gating strategy figure (A). BCG-specific IFN-γ-CD69+ CD4+ T cells (A) and non-specific 
IFN-γ-CD69+ CD4+ T cells (B) expressing different combinations of CD45RA and CCR7 either 
singly, or in combination are shown. Whiskers represent the minimum and maximum value; the 
box represents the interquartile range, while the line in the box represents the median. Values 
are shown without subtraction of the unstimulated responses in the negative controls from the 
BCG-stimulated samples. The Mann–Whitney U test was used to compare the difference in 
proportions of specific T cell memory phenotypes between the birth (blue bars) and 6 weeks of 
age (red bars) vaccinated infants. P values less than 0.05 were considered statistically 
significant. 
 	  
5.3.5. No difference in BCG-specific CD4+ and CD8+ T cells maturation 
phenotype between the two groups  
We also evaluated the expression of the maturation marker, CD27 by the BCG-
specific IFN-γ producing CD4+ and CD8+ T cells. We hypothesised that greater 
frequencies of IFN-γ-expressing T cells in the birth vaccinated infants may be 
explained by presence of more differentiated specific T cells than in infants 
vaccinated at 6 weeks of age. Representative flow cytometry plots of CD27 
expression by CD4+ and CD8+ T cells are shown in Figures 36 A and B 
respectively. We observed no difference in BCG-specific IFN-γ-expressing CD4+ 
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and CD8+ T cells expressing CD27 between the two groups of infants (Figures 
36C, D).  
 
 
 
 
Figure 36. CD27 expression by BCG-specific CD4+ and CD8+ IFN-γ-expressing T cells. 
Box and whiskers plots show the proportions of BCG-specific IFN-γ-expressing CD4+ T cells (A) 
and CD8+ T cells (B) expressing CD27. Whiskers represent the minimum and maximum value; 
the box represents the interquartile range, while the line in the box represents the median. 
Values are shown without subtraction of the unstimulated responses in the negative controls 
from the BCG-stimulated samples. The Mann–Whitney U test was used to compare the 
difference in proportions of specific T cells expressing CD27 between the birth (blue bars) and 6 
weeks of age (red bars) vaccinated infants. P values less than 0.05 were considered significant 
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5.4. Discussion 
In this chapter, we compared memory and maturational phenotypes of BCG-
specific IFN-γ-expressing CD4+ and CD8+ T cells in infants either vaccinated at 
birth or at 6 weeks of age. Our results showed BCG-specific CD4+ and CD8+ T 
cells expressing IFN-γ were not different with regard to expression of memory 
and maturational phenotypes in both groups of infants. We also showed that, in 
both groups of infants, BCG-specific IFN-γ-expressing CD4+ T cells were 
characterised by a dominant central memory (TCM) phenotype, while the non-IFN-
γ-expressing CD4+ T cells were mostly ‘naïve” like (CD45RA+CCR7+) and TCM. 
Finally, BCG-specific IFN-γ expressing CD8+ T cells were characterised by TEM 
and TEMRA phenotypes.  
 
In the presence of a persistent antigen such chronic viral infections, effector 
memory cells, characterised by production of cytokines such as IFN-γ dominate 
the specific immune response (Harari et al., 2004). In line with these reports by 
Harari et al., previous studies in our laboratory have shown that BCG-specific 
responses in infants are dominated by IFN-γ producing CD4+ and CD8+ T cells 
(Kagina et al., 2009, Soares et al., 2008). This is contrary to the dominant TCM 
phenotypes of the specific IFN-γ-expressing CD4+ T cells we observed in both 
groups of infants in our study. The discrepancy in the memory phenotypes from 
the previous studies may be explained by the difference in the antibody clone 
used in these studies from ours. Nevertheless, our findings are in agreement with 
a study by Soares et al. that showed a dominant TCM phenotype by BCG-specific 
CD4+ T cells in 27 week old infants vaccinated with BCG at birth (Soares et al., 
2013). Our results suggest that development of the TCM phenotype specific to 
BCG may not be influenced by timing of BCG. It is rational to propose that in 
prime-boost vaccination strategies, boosting with a novel TB vaccine may not be 
sensitive to whether BCG was given at birth or 6 weeks of age.  
 
Our findings that BCG-specific IFN-γ producing CD4+ T cells predominantly 
expressed a TCM phenotype also differ from the BCG-specific TEM reported in 
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mice (Dudani et al., 2002, Henao-Tamayo et al., 2010, Kaveh et al., 2011). BCG 
causes a chronic infection in mice resulting in persistent immune activation 
(Dudani et al., 2002, Mittrucker et al., 2007). This persistence of antigen results 
in induction of BCG-specific effector memory CD4+ and CD8+ T cells (Dudani et 
al., 2002, Henao-Tamayo et al., 2010). However, the TEM phenotype is short-
lived and may underlie the limited duration of protection conferred by BCG 
against TB (Orme, 2010). The TCM phenotype observed in 9-month old infants in 
our study may indicate that BCG does not persist in the human. In line with this 
argument, a recent study from our laboratory shows that BCG-specific T cell 
expressed high levels of BCL-2 and low levels of the activation marker, CD38 
following the contraction phase of the BCG immune response (Soares et al., 
2013).  
 
We also evaluated memory phenotypes of non-IFN-γ expressing CD4+ T cells. 
We had observed that the activated and non-IFN-γ expressing CD4+ T cells 
comprised BCG-specific T cells expressing IL-2, IL-17 and TNF-α. We observed 
that non-IFN-γ-expressing CD4+ T cells in both groups of infants expressed a 
dominant TNaive phenotype. Such ‘naive’ like BCG-specific memory T cells have 
been previously described in our group (Kagina et al., 2009, Soares et al., 2013, 
Tena-Coki et al., 2010, Dintwe et al., 2013). Functionally, the ‘naive’ like specific 
cells described in this study do not fit the definition of classical antigen 
inexperienced cells which would not produce effector cytokines (Sallusto et al., 
1999). Detailed studies in our laboratory are interrogating this population of 
naive’ like mycobacteria-specific T cells with respect to relevance in 
mycobacteria immunity. Regardless of the immune function of the naïve-like 
BCG-specific T cells, our results show no difference in the naive’ like memory 
phenotype CD4+ T cells, irrespective of administration of BCG at birth or 6 weeks 
of age. 
 
We also characterised the memory phenotypes of the IFN-γ-expressing CD8+ T 
cells. Both groups showed dominant TEM and TEMRA phenotypes. Our results are 
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consistent with those of a previous study that reported TEM and TEMRA as the 
dominant phenotypes of PPD-specific CD8+ T cells in healthy children (5-11 
years) (Caccamo et al., 2006, Tena-Coki et al., 2010). This may be explained by 
the presence of TEM and TEMRA memory subsets in circulation in the absence of 
TB disease, in which case the cells would be sequestered to the site of infection 
(Dieli et al., 1999). We observed similar proportions in all CD8+ T cell memory 
phenotype subsets in the two groups of infants. 
 
The loss of CD27 expression has been associated with repeated antigenic 
stimulation of the T cells with concomitant T cell senescence (De Jong et al., 
1992). We showed that in both groups of infants, a high proportion of BCG-
specific IFN-γ expressing CD4+ and CD8+ T cells expressed CD27, although at 
similar proportions. Our results are in agreement with a previous study reporting 
high proportion of CD27 expression on specific CD4+ and CD8+ T cells from BCG 
vaccinated infants (Tena-Coki et al., 2010).  
 
In summary, our data indicate that BCG vaccination at birth or at 6 weeks of age 
results in similar memory phenotypes expressed by both CD4+ and C84+ T cells. 
Future studies should assess if the predominant CD4+ T cell central memory 
phenotype we report in these 9 month-old infants is associated with long term 
persistence of BCG-specific memory T cells. 
 
5.5. Contributions 
Dr. F. Lutwama designed the experiments, conducted the laboratory assays and 
data analysis, and wrote this chapter under supervision of Prof. W.A. Hanekom, 
Dr. B.M.N. Kagina, Dr. C.L. Day and Dr T.J Scriba. 
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Chapter 6: Comparison of BCG-specific soluble cytokine plasma levels 
following BCG vaccination at birth and at 6 weeks of age  
 
6.1. Introduction  
In this chapter, we describe the comparative plasma cytokine levels in infants 
vaccinated with BCG at birth or 6 weeks of age. In the previous two chapters, we 
showed that vaccination of infants with BCG at birth induces greater frequencies 
of CD4+ and CD8+ T cells expressing IFN-γ, than vaccination at 6 weeks of age. 
We also showed that greater proportions of TEM could not explain the greater 
frequencies of CD4+ and CD8+ T cells expressing IFN-γ in infants vaccinated at 
birth than at 6 weeks of age. We were therefore interested in exploring other 
potential immunological reasons that may underlie the observed differences in 
frequencies of CD4+ and CD8+ T cells expressing IFN-γ.  
 
Upon BCG-vaccination, APCs, mainly monocytes and dendritic cells, 
phagocytose BCG, kill and process the mycobacteria into small peptides (Inaba 
et al., 2000, Turley et al., 2000). The BCG derived peptides are presented to 
MHC-II or MHC-I restricted T cells. When the APCs process and present BCG 
derived peptides to cognate T cells, the cytokine milieu may influence the BCG-
induced T cell response. Therefore, we reasoned that the differences observed in 
the frequencies of CD4+ and CD8+ T cells expressing IFN-γ between the two 
groups of infants, could be explained by levels of soluble plasma cytokines, a 
surrogate marker for the cytokine milieu.  
 
Cytokine milieu characterised by the presence of high Th2 soluble cytokines; IL-
4, IL-5 and IL-13 may attenuate mycobacteria-induced Th1 immune responses 
(Rook, 2007). For example, IL-4 may attenuate anti-mycobacterial immunity by 
driving arginase production leading to alternative macrophage activation 
(Gordon, 2003). Alternative activation of macrophages leads to decreased IL-12 
production, an important Th1 cells differentiation factor that is critical in the IFN-γ 
production by CD4 and CD8 T cells.  
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During the induction of BCG-induced T cell immunity, presence of high levels of 
the immunoregulatory cytokine, IL-10 has been shown to attenuate the BCG-
induced Th1 (IFN-γ, IL-2) immune response (Pitt et al., 2012). The 
immunoregulatory mechanism of IL-10 involves inhibition of production of the 
Th1 promoting differentiation factor, IL-12. Furthermore, IL-10 has been shown to 
inhibit IFN-γ induced effector mechanisms by driving alternative activation of 
macrophages (Schreiber et al., 2009).  
 
On the other hand, presence of high levels of Th1 cytokines, for example, IL-2 
and IFN-γ, during the induction of BCG-induced T cell immunity may favor 
increased production of IFN-γ by specific CD4+ and CD8+ T cells (Wenner et al., 
1996). Conversely, it has been shown that high IFN-γ levels may attenuate Th2 
differentiation during the priming of the naive T cells (Seder and Paul, 1994).  
 
It is therefore plausible that the cytokine milieu may play a key role in skewing 
the BCG-specific T cell responses. Our aim was to compare soluble levels of 
BCG-specific Th1 (IFN-γ, IL-2), Th2 (IL-4, IL-5 and IL-13) and IL-10 cytokines in 
infants either vaccinated with BCG either at birth or at 6 weeks of age. Our 
hypothesis was that infants vaccinated at 6 weeks of age would show greater 
levels of soluble Th2 and IL-10 cytokine than infants vaccinated at birth. We used 
the bead-based multiplex assay to measure the soluble cytokines levels in 
plasma collected after 7hrs of whole blood stimulation with BCG. 
	   137	  
6.2. Material and methods 
6.2.1. Study participants 
The infants studied in this chapter were selected from the cross sectional cohort 
described in chapter 2.  
 
6.2.2. Whole blood intracellular cytokine (WB-ICC) assay 
Whole blood was stimulated with specific antigens for a total of 7 hours as 
described previously in chapter 2 (section 2.7.1). Plasma was removed and 
stored at -80oC for measurement of soluble cytokine levels. 
 
6.2.3. Multiplex soluble cytokine assay  
Plasma collected after 7 hours of incubation during the short-term whole blood 
assay was used to measure of levels of soluble IFN-γ, IL-2, IL-4, IL-5, IL-10 and 
IL-13 with the MILLIPLEX® MAP assay (Millipore, Billerica, MA), following the 
manufacturers’ instructions. In brief, a filter 96-well plate was blocked with assay 
buffer then aspirated using a vacuum manifold. The provided standards, controls, 
and samples were added to the appropriate wells. Plasma from the unstimulated 
samples as well as from BCG- and PHA–stimulated samples was added 
undiluted into single wells. Then, mixed beads were added to all wells containing 
the plasma samples, and incubated at room temperatures in the dark for one 
hour. Next, the plates were washed twice, detection antibody cocktail added, and 
further incubated for 30 minutes. Thereafter, streptavidin-phycoerythrin solution 
was added. The plates were then washed twice, sheath fluid added, and 
resuspended on a shaker. Fluorescence was detected using a Luminex 100 IS 
machine (xMAP technology, Luminex Corporation). Data were acquired using the 
Bio-Plex Manager™ Software. The standard curve for each cytokine ranged from 
3.2 to 10 000pg/ml. 
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6.2.4. Data analysis 
Values falling outside range of the standard curve were excluded from the 
analysis. For the samples, cytokine values below the lowest level of detection 
were assigned a value of 2.2 pg/mL before background subtraction. 
For each participant, the response detected in the negative control (unstimulated) 
was subtracted from the response detected in the corresponding BCG-stimulated 
sample. Samples were excluded from the final analysis if: (1) response detected 
in the positive control was less than the median plus 3xMAD of the response 
detected in all the negative control samples; (2) response detected in the positive 
control condition was lower than that in the corresponding negative control 
sample; (3) response detected in the positive control was less than the lower limit 
of detection (3.2 pg/mL) for the assay.  
 
The Mann-Whitney U test was used to assess differences in cytokine levels 
between the two groups of infants. A p-value of less than 0.05 was considered 
significant. Spearman-rank correlation was used to assess associations between 
frequencies of CD4+ and CD8+ T cell cytokine producing cells and levels of 
soluble cytokines in plasma. Prism 5.0 (GraphPad Software Inc.) was used for 
statistical analyses.  
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6.3. Results 
6.3.1 Participants excluded in the analysis of the luminex assay  
Table 18 shows the number of infants excluded from the luminex assay results 
as well as reasons for exclusion. In total, we excluded 12 and 11 infants 
vaccinated at birth and 6 weeks of age respectively. 
 
 
Reason for exclusion 
44	  infants	  vaccinated	  
at	  birth	  (all	  samples	  
processed) 
40	  infants	  vaccinated	  
at	  6	  weeks	  (all	  
samples	  processed) 
PHA response  < median + 
3MAD of all negative 
controls samples 
4 5 
PHA response < negative 
control response 
0 2 
PHA response < 3.2 pg/ml 
 
4 2 
 
Table 18: Participants excluded from the final multiplex assay analysis 
 
 
6.3.2. BCG-specific soluble cytokine levels in infants vaccinated at birth or at 6 
weeks of age 
 
We also evaluated levels of IFN-γ, IL-2 (Th1), IL-4, IL-5, IL-13 (Th2) and IL-10 
cytokines in plasma. Our hypothesis was that this would reflect a cytokine milieu 
that would impact the BCG-induced T cell response, e.g., presence of high levels 
of Th2 cytokines (IL-4, IL-5 and IL-13) as well as IL-10 might attenuate this 
immunity (Rook 2007;Schreiber 2009). We reasoned that the differential Th2 and 
IL-10 cytokine soluble cytokine levels would possibly explain why we had 
observed greater frequencies of CD4+ and CD8+ T cells expressing IFN-γ, in birth 
than 6 weeks of age vaccinated infants in our earlier experiments.  The Th2 
cytokines IL-4, IL-5 and IL-13 were all either undetectable or detected at very low 
levels in both groups of infants and were not different (Figures 37A, B and C). 
Relative to Th2 cytokines, IFN-γ and IL-2 were detected at higher levels but were 
also not different in both groups of infants (Figures 37D and E). In part, our 
hypothesis was confirmed by IL-10 results: we observed that infants vaccinated 
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at 6 weeks of age had greater levels of soluble IL-10 than infants vaccinated at 
birth (Figure 37E). However, birth vaccinated infants had higher levels of IL-10 in 
the unstimulated controls, compared with infants vaccinated at 6 weeks of age 
(Figures 38A). Moreover, we observed no difference in the levels of IL-10 in 
BCG-stimulated samples (without background subtraction) in the two groups of 
infants (Figure 38B). We concluded that the greater BCG-specific levels 
observed for in infants vaccinated at 6 weeks compared to those vaccinated at 
birth were influenced by the lower unstimulated IL-10 levels in the former. (IL-10 
was not measured with the WB-ICS, as preliminary experiments showed that T 
cell-specific expression was too low for valid analysis.)  
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Figure 37. BCG-specific soluble cytokine levels in plasma. Plasma was taken from whole 
blood left unstimulated or stimulated with BCG for 7 hours. Soluble cytokine levels were 
measured by luminex assay. The scatter plots show the following cytokines: IL-4 (A), IL-5 (B), IL-
13 (C), IFN-γ (D), IL-2 (E) and IL-10 (F). On the scatter plots, the horizontal lines represent the 
median cytokine levels. The results shown are corrected for unstimulated responses. The Mann–
Whitney U test was used to compare the difference in cytokine levels between the birth (blue 
circles) and 6 weeks of age (red circles) vaccinated infants. P values less than 0.05 was 
considered significant. 
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Figure 38. Unstimulated and BCG stimulated IL-10 soluble cytokine levels. Plasma was 
taken from whole blood left unstimulated or stimulated with BCG for 7 hours. Soluble cytokine 
levels were measured by luminex assay. The scatter plots show soluble levels of IL-10 detected 
in the (A) unstimulated and (B) BCG-stimulated samples (without correction for levels in 
unstimulated samples). Horizontal lines represent the median soluble cytokine levels. The Mann–
Whitney U test was used to compare cytokine levels between the birth (blue circles) and 6 weeks 
of age (red circles) vaccinated infants. P values less than 0.05 was considered significant. 
 
 
 
6.3.3. Correlation of specific IL-10 levels with frequencies of specific IFN-
γ expressing CD4+ and CD8+ T cells 
Our next analysis was aimed at evaluating whether the soluble IL-10 levels were 
associated with decreased frequencies of specific IFN-γ producing CD4+ and 
CD8+ T cells. We therefore performed correlation analysis of soluble IL-10 levels 
with the frequencies of BCG-induced CD4+ and CD8+ T cells expressing IFN-γ. In 
both groups of infants, there was no significant correlation between levels of IL-
10 cytokine and the frequency of IFN-γ expressing CD4+ T cells (Figure 39A). 
However, a significant but weak positive correlation was observed between 
levels of IL-10 cytokine and the frequency of IFN-γ expressing CD8+ T cells, only 
in infants vaccinated at 6 weeks of age (Figure 39B). 
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Figure 39. Correlation analysis of solube IL-10 levels and frequencies of IFN-γ -
expressing T cells. Scatter plots show the correlation analysis between soluble levels of 
BCG-specific IL-10 and frequency of BCG-specific IFN-γ-expressing CD4+ (A) and CD8+ 
(B) T cells. The blue and red circles represent the birth (blue circles) and 6 weeks of age 
(red circles) BCG vaccinated infants respectively. Correlation analysis was performed by 
Spearman test. P values less than 0.05 were considered statistically significant. 
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6.4. Discussion 
In this chapter we compared BCG-induced and non-specific soluble cytokine 
levels in infants vaccinated at birth or at 6 weeks of age. We showed greater 
non-specific IL-10 levels in infants vaccinated at birth, compared with those 
vaccinated at 6 weeks of age. We also showed that in infants vaccinated with 
BCG at 6 weeks of age, BCG-induced IL-10 levels positively correlated with the 
frequencies of BCG-specific IFN-γ-expressing CD8+ T cells. Other soluble 
cytokines were all detected at very low levels and were not different between the 
two groups of infants. 
 
We measured IL-10 cytokine levels based on studies that have shown that this 
cytokine may attenuate Th1 (IFN-γ) T cell responses (Liu et al., 2011). The 
attenuation of IFN-γ by IL-10 was shown in an experimental study using M.tb-
susceptible CBA/J mice where antibody blockade of IL-10R during BCG 
vaccination resulted in an enhanced BCG-specific IFN-γ response and protection 
against subsequent M.tb challenge (Pitt et al., 2012). However, our results do not 
suggest that IL-10 is inhibiting BCG-specific Th1 responses, at least when 
measured at 9 months of age: infants vaccinated with BCG at birth had greater 
levels of non-specific IL-10 production and greater frequencies of BCG-specific 
IFN-γ-expressing CD4+ and CD8+ T cells compared to infants vaccinated with 
BCG at 6 weeks of age. Our finding of elevated pro-inflammatory (IFN-γ) and 
regulatory (IL-10) cytokines is analogous to studies that have reported increased 
soluble levels of these two cytokines in patients with Immune reconstitution 
inflammatory syndrome (IRIS) (Skolimowska et al., 2012, Tadokera et al., 2011). 
The probable explanation for this unexpected paradoxical observation is that 
induction of a pro-inflammatory response may be accompanied by induction of 
regulatory responses that may mediate inhibition of the potentially destructive 
inflammation.  
 
We assessed Th2 (IL-4) soluble levels based on previous studies that have 
reported a reduced mycobacterial-specific Th1 response in the presence of high 
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levels of Th2 (IL-4) cytokines (Hernandez-Pando et al., 1996). The soluble Th2 
cytokine levels we detected in this study were comparable to those reported by 
Soares 2008 et al, where the authors used a similar assay system to measure IL-
4 cytokine in plasma from 10-week old infants vaccinated with BCG-vaccinated 
at birth (Soares et al., 2008). In our study, both groups of infants had too low 
production of IL-4 as well as IL-5 and IL-13.  
 
Our study had several limitations. We assessed the levels of soluble plasma 
cytokine at 9 months of age. However, priming of BCG-specific T cell immune 
responses occurred at the time of vaccination; at birth or at 6 weeks of age. Our 
study setting limited us from accessing participants at these time points to 
measure soluble cytokine levels. Second, we measured cytokine levels in blood 
in unstimulated samples, or following in vitro stimulation with BCG. However, 
upon administration of BCG, the priming of T cell responses is known to occur in 
lymph nodes. We acknowledge that our interpretation of how the cytokine milieu 
may affect the BCG-induced T cell response is speculative, since plasma 
cytokine levels may not necessarily reflect the levels of cytokines in lymph nodes.   
 
In summary, infants vaccinated at 6 weeks of age had lower baseline IL-10 
cytokine levels. We speculate that the greater non-specific IL-10 levels observed 
in infants vaccinated at birth compared to those vaccinated at 6 weeks of age 
may “potentially” result from the differences in social economic status observed 
in the two groups: Infants vaccinated at 6 week of age were from a lower social 
economic category compared to those vaccinated at birth.  
 
 
6.5. Contributions 
Dr. F. Lutwama designed the experiments, conducted the laboratory assays and 
data analysis, and wrote this chapter under supervision of Prof. W.A. Hanekom, 
Dr. B.M.N. Kagina, Dr. C.L. Day and Dr T.J Scriba. 
 
	   146	  
Chapter 7: Comparison of the capacity of BCG-specific T-cells to proliferate 
and produce cytokines in infants following BCG vaccination at birth or at 6 
weeks of age 
 
7.1. Introduction  
Findings from the previous chapters showed that using a short-term ICS assay: 
(1) birth vaccinated infants had greater BCG-specific IFN-γ-expressing CD4+ and 
CD8+ T cells than infants vaccinated at 6 weeks of age, and, (2) in both groups of 
infants, the BCG-specific IFN-γ-expressing CD4+ and CD8+ T cells displayed a 
dominant TCM phenotype. In this chapter, we followed up on these earlier 
observations to establish whether the proliferative capacity of BCG-specific T 
cells would be greater in infants vaccinated at birth than at 6 weeks of age. Our 
hypothesis was that BCG vaccination at birth would induce BCG-specific CD4+ 
and CD8+ T cells with greater proliferative and cytokine-expression capacity than 
vaccination at 6 weeks of age. We used a 6-day whole blood proliferation assay 
to measure the BCG-specific CD4+ and CD8+ T cell proliferative and cytokine 
producing capacity in the two groups of infants. 
 
The ability of T cells to proliferate upon antigenic stimulation is an important 
function of antigen-specific T cell memory. For example, in human viral (small 
pox) models, long-term vaccinees had detectable specific T cell proliferative 
responses to vaccinia after two decades in the absence of exposure to small pox 
(Combadiere et al., 2004). Specific memory T cells are thought to be important in 
mediating long-term protective immunity (Wherry et al., 2003). Investigators in 
our laboratory have previously optimized a sensitive whole blood proliferation 
assay that measures Ki67 expression by specific T cells upon in vitro culture with 
specific antigen, including BCG (Soares et al., 2010). Ki67 is expressed during 
the active phases of cell division; high levels of Ki67 expression is therefore a 
good biomarker of proliferating cells (Gerdes et al., 1984).  
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Advantages of measuring T cell responses with such a long-term proliferation 
assay includes: First, increased sensitivity to measure memory T cell responses 
because long-term culture allows clonal expansion of specific cells; second, the 
assay enables measurement of proliferative capacity of antigen-specific T cells 
as well as production of cytokines, another important function of T cells; Third, 
long-term assays are robust and less sensitive to time between blood draw and 
incubation of whole blood compared with short term assays (Hanekom et al., 
2008).  
 
Therefore, in this study, we aimed to compare the capacity of BCG-specific T 
cells to proliferate and express Th1 (IL-2, IFN-γ and TNF-α) and IL-17 cytokines 
in infants who were vaccinated at birth or at 6 weeks of age. In our previous 
experiments using the short term assay (Chapter two), we reported that infants 
vaccinated with BCG at birth showed greater frequencies of BCG-specific IFN-γ 
expressing CD4+ and CD8+ T cell compared to infants vaccinated at 6 weeks of 
age. We therefore hypothesized that infants vaccinated with BCG at birth would 
show greater BCG-specific proliferative capacity, associated with increased 
production of effector molecules than infants vaccinated at 6 weeks of age.   
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7.2. Material and methods 
7.2.1. Study participants 
The infants studied in this chapter were selected from the cross sectional cohort 
described in chapter 2.  	  
7.2.2. Six-day whole blood proliferation assay 
Whole blood was diluted in with RPMI media and stimulated with specific 
antigens for a total of 6 days as described in chapter 2 (section 2.7.2). 
 
7.2.2. Antibodies 
The following fluorescently conjugated mAbs were used	   in flow cytometry 
experiments: anti-CD3 Pacific Blue (UCHT1), anti-CD8 PerCP-Cy5.5 (SK-1), 
anti-IFN-γ Alexa Fluor 700 (B27), anti-IL-2 FITC (5344.111), anti-Ki67 PE (B56), 
all from BD Biosciences, San Jose, CA, all from Invitrogen, Eugene, OR; anti-
TNF-α PE-Cy7 (Mab11), and anti-IL-17 Alexa Fluor 647 (eBio64CAP17), both 
from eBiosciences, San Diego, CA. All antibodies were titrated to establish the 
optimal concentration for use. Table 19 summarises the flow cytometry panel 
used in this study. 
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Marker Fluorochrome Description 
CD3 Pac Blue T cell marker 
CD8 PerCpCy5.5 Cytolytic T cell marker 
Ki67 PE Proliferation marker 
IFN-γ Alexa Fluor 700 Th1 cytokine 
IL-2 APC Th1 cytokine	  
TNF-α PE-Cy7 Th1 cytokine	  
IL-17 APC Th17 cytokine 
 
Table 19: Flow cytometry antibody-fluorochrome panel to evaluate the capacity of 
CD4+ and CD8+ T cells to proliferate and produce cytokines in cryopreserved fixed cells 
from stimulated whole blood collected from the study participants. 
 
 
7.2.3. Intracellular cytokine staining assay and flow cytometry analysis 
We used a “one step” staining method as described in chapter 3 (section 3.5.4) 
to assess the capacity of BCG-specific T-cells to proliferate and produce 
cytokines in infants following BCG vaccination at birth and at 6 weeks of age. 
 
7.2.4. Data analysis 
For each assay and participant, the response detected in the negative control 
(unstimulated) was subtracted from the response detected in the stimulated 
sample. Samples were excluded from the final analysis if the response detected 
in the positive control condition was lower than the median plus 3 median 
absolute deviations (3MAD) of the negative control samples from all infants. For 
cytokine expression, in addition to the above criterion, samples were excluded if: 
(1) the frequency of BCG-specific Ki67 expressing CD4+ T cells was less than 
0.01%; (2) the number of BCG-specific Ki67 expressing CD4+ T cells was less 
than 20 after correcting for the non-specific cells in the respective unstimulated 
sample. The Mann-Whitney U test was used to compare differences in the 
immunological outcomes between the two groups. A p-value of less than 0.05 
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was considered significant. Prism 5.0 (GraphPad Software Inc.) was used for 
statistical analyses.  
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7.3 Results 
7.3.1. Gating strategy 
We used a modified gating strategy from that described in chapter 3 (section 
3.6.11) to measure BCG-specific proliferative and cytokine production capacity. 
CD4+ T cells were gated as CD3+CD8- because PMA and ionomycin stimulation 
down-regulates CD4 expression on T cells. The flow cytometric representative 
data from an infant vaccinated with BCG at birth are shown in Figure 40. 
 
7.3.2. Participants excluded from analysis based on quality control criteria 
We used the exclusion criteria described in the data analysis to ensure reliability 
of the data reported. Table 20 shows the summary of participants excluded form 
the 6-day proliferation assay analysis. 
 
 
Reason for exclusion Vaccinated at birth 
Excluded (n) 
Vaccinated at 6 weeks 
Excluded (n) 
BCG-specific frequency < 
0.01% 
0 5 
BCG events count < 20 3 13 
 
Table 20: Participants exclusion from the 6-day whole blood proliferation and cytokine expression 
analysis.  
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Figure 40. Gating strategy. Flow cytometry gating strategy of proliferating BCG-specific CD4+ 
(CD8-) and CD8+ T cell and the associated cytokine responses evaluated in the 6-day whole 
blood ICS assay. We first used a time gate to select cells acquired only at the same fluorescence 
intensity over time. Then, doublet cells were excluded by gating on forward scatter-area (FSC-A) 
against forward scatter-height (FSC-H). T cells were selected by gating on CD3 expressing cells, 
which were further divided to CD4+ and CD8+ T cells (A). Representative flow cytometry data of 
Ki67+ CD4 T cells expressing cytokines in a negative control (unstimulated) sample (top row) or 
BCG stimulated sample (bottom row) from a 9 month-old infant vaccinated with BCG at birth (B) 
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7.3.3. No difference in proliferative capacity or cytokine expression of specific 
CD4+ T cells in infants vaccinated with BCG at birth or 6 weeks of age 
 
The ability of cells to proliferate and respond to secondary antigen encounter is 
an important feature of memory and vaccine-induced T cell responses 
(Combadiere et al., 2004).	  Our aim was to compare the capacity of CD4 T cells 
to proliferate and produce cytokines (IL-2, IL-17, IFN-γ and TNF-α) in infants 
vaccinated at birth or at 6 weeks of age. We observed a detectable proliferative 
response of specific CD4+ T cells in majority of infants in both groups. However, 
there was no difference in proliferative capacity of CD4+ T cells between the two 
groups of infants (Figure 41A).  
 
We also assessed the cytokine producing capacity of specific proliferating CD4+ 
T cells, after re-stimulating the cells on day 6 with PMA/ionomycin. The capacity 
of the BCG-specific cells expressing either IL-2, IL-17, IFN-γ or TNF-α was not 
different between the two groups of infants. (Figure. 41B).  
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Figure 41. Proliferative capacity: BCG-specific CD4+ T cell proliferative capacity and cytokine 
production by the proliferating T cells. Scatter plots depict the proportions of proliferating (Ki67+) 
CD4+ T cells (A) and the capacity of the proliferating CD4+ T cells to produce IL-2, IL-17, IFN-γ or 
TNF-α cytokines (B). Horizontal lines represent medians. The blue and red dots represent the 
infants vaccinated at birth or 6 weeks of age respectively. The Mann-Whitney U test was used to 
compare the difference in frequencies between the 2 groups.  
 
 
7.3.4. Greater capacity of specific proliferating CD4+ T cells to co-express IL-2, 
IFN-γ and TNF-α in infants vaccinated at birth, compared with infants vaccinated 
at 6 weeks of age 
 
Our next aim was to compare the capacity of proliferating CD4+ T cells to co-
express IL-2, IL-17, IFN-γ and TNF-α in infants vaccinated at birth or at 6 weeks 
of age. Our results showed that cells from infants vaccinated at birth had greater 
capacity to express IL-2 and IFN-γ and TNF-α together, compared with those 
vaccinated at 6 weeks of age (Figure. 42). However, the proportion of these cells 
able to express only TNF-α was lower in infants vaccinated at birth, compared 
with infants vaccinated at 6 weeks of age (Figure 42).  
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Figure 42. Capacity of proliferating CD4+ T cells to co-express cytokines. The blue and red bars 
represent the birth and 6 weeks BCG vaccinated infants respectively. Whiskers represent the 
maximum and minimum value; the box represents the interquartile range, while the line in the box 
represents the median. The Mann–Whitney U test was used to compare the difference in the two 
groups. 
 
 
7.3.5. No difference in capacity of specific proliferating CD8+ T cells to produce 
IL-2, IFN-γ or TNF-α  in infants vaccinated at birth or at 6 weeks of age 
 
We then assessed the capacity of BCG-specific CD8+ T cell to proliferate and 
produce cytokines in the two groups of infants. As for CD4+ T cells, we observed 
no difference in the capacity of specific CD8+ T cells to proliferate (Figure 43A) 
nor in their production of IL-2, IL-17, IFN-γ or TNF-α (Figure 43B) in the two 
groups of infants. 
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Figure 43. BCG-specific CD8+ T cell proliferative capacity and cytokine production by the 
proliferating T cells. Scatter plots depict the proportions of proliferating (Ki67+) CD8+ T cells (A) 
and the capacity of these proliferating CD8+ T cells to produce IL-2, IL-17, IFN-γ or TNF-α 
cytokines (B). Horizontal lines represent the median frequencies. The blue and red dots represent 
the birth and 6 weeks BCG vaccinated infants respectively. The Mann-Whitney U test was used 
to compare the difference in frequencies of Ki67 expressing CD8+ T cells between the 2 groups.  
 
 
 
7.3.6. No difference in the capacity of specific proliferating CD8+ T cells to co-
express IL-2, IFN-γ and TNF-α  in the two groups of infants 
 
We then evaluated the capacity of BCG-specific proliferating CD8+ T cells to co-
expressing IL-2, IL-17, IFN-γ, and TNF-α. We observed no difference in the 
capacity of proliferating CD8+ T cells to express either IL-2, IL-17, IFN-γ or TNF-α 
alone or in different combinations between infants vaccinated at birth or 6 weeks 
of age (Figure 44).  
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Figure 44. Capacity of proliferating CD8+ T cells to co-express cytokines as measured in 
the 6-day proliferation assay. The blue and red bars represent infants vaccinated with BCG at 
birth or 6 weeks of age respectively. Whiskers represent the maximum and minimum value; the 
box represents the interquartile range, while the line in the box represents the median.  The 
Mann–Whitney U test was used to compare the proportions of Ki67 expressing CD8+ T cells 
between the two groups. 
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7.4. Discussion 
 
In this chapter, we showed that, at 9 months of age, the two groups of infants 
had similar proportions of BCG-specific proliferating CD4+ and CD8+ T cells. 
However, greater capacity of the proliferating CD4+ T cells to co-express IL-2+, 
IFN-γ+, and TNF-α+ was observed in infants vaccinated at birth than at 6 weeks of 
age. While infants vaccinated at 6 weeks of age had greater proportions of single 
TNF-α production compared to those vaccinated at birth.  
 
TCM have the ability to proliferate and differentiate into effector memory T cells 
with cytokine producing potential (Wherry et al., 2003). Our findings of similar T 
cell proliferative potential were in agreement with the phenotypic characteristics 
we had observed by use of the short-term assay in Chapter 5. Phenotypic 
characterization of the memory T cells showed no difference between the two 
groups of infants in the proportions of TCM. However, we observed differences in 
the capacity of the proliferating cells to co-express IL-2+, IFN-γ+, and TNF-α+.  
 
We speculate that greater IL-10 levels observed in infants vaccinated at 6 weeks 
may have attenuated ability to expand into polyfunctional CD4+ T cells.	   IL-10 
inhibits IL-12 production (Liu et al., 2011), a cytokine known to indirectly drive 
proliferation of T cells through positive regulation of IL-2 (Clerici et al., 1993). 
Therefore, it is possible that there were greater levels of IL-12 cytokine at 9 
months in birth-vaccinated infants resulting in increased IL-2 and subsequent 
proliferation of polyfunctional CD4+ T cells with enhanced capacity to produce 
multiple cytokines simultaneously. Our speculation of greater IL-12 levels in birth-
vaccinated compared with 6 week old vaccinated infants is supported by our 
findings of increased IFN-γ production in the former group. 
 
Polyfunctional CD4+ T cells are thought to potentially play an important role in TB 
immunity (Forbes et al., 2008) and are therefore routinely measured in clinical 
trials assessing the immunogenicity of novel TB vaccines (Abel et al., 2010, 
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Sander et al., 2009, Scriba et al., 2012). However, a clinical study from our 
laboratory reported no association between greater proportions of BCG-specific 
polyfunctional T cell and risk of developing TB (Kagina et al., 2010). In our study, 
greater capacity of proliferating BCG-specific CD4+ T cells to co-express IL-2, 
IFN-γ, and TNF-α in infants vaccinated at birth, compared with infants vaccinated 
at 6 weeks, could be again a reflection of more effective vaccine-take in the 
former group. However, in the absence of known immune correlates of risk of TB, 
we can only speculate about clinical relevance of this observation in humans. 
 
In our study, we observed frequencies of BCG-specific T cell proliferation in the 
same range as those reported by Soares, et al., in a study that reported a 
longitudinal assessment of BCG-specific immune responses of infants in the first 
year of life (Soares et al., 2013). However, our results of greater capacity of 
proliferating CD4+ T cells to co-express IL-2, IFN-γ, and TNF-α in infants 
vaccinated at birth compared to those vaccinated at 6 weeks of age differ from 
those in a previous study of delayed BCG vaccination (Kagina et al., 2009). The 
differences between our study finding and that previously reported by Kagina, et 
al. may be explained by the difference in the study design. We used an 
observational study design whereas Kagina, et al. performed a randomized 
controlled trial. 
 
In conclusion, we show greater capacity of proliferating CD4+ T cells to co-
express IL-2, IFN-γ, and TNF-α, when BCG is given at birth versus 6 weeks of 
age. Further follow up studies are needed to give more insight into clinical 
relevance of the results, in terms of risk of developing TB disease.  
 
7.5. Contributions 
Dr. F. Lutwama designed the experiments, conducted the laboratory assays and 
data analysis, and wrote this chapter under supervision of Prof. W.A. Hanekom, 
Dr. B.M.N. Kagina, Dr. C.L. Day and Dr T.J Scriba. 
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Chapter 8: General conclusions 
 
We report evaluation of specific T cell responses in Ugandan infants who 
received BCG either at birth or at 6 weeks of age. We showed that age of 
vaccination impacted BCG-specific immune response measured at 9 months of 
age. Specifically, infants vaccinated at birth had higher frequencies of BCG-
specific CD4+ and CD8+ T cells producing IFN-γ alone, or co-expressing IFN-γ 
and perforin. Further, birth vaccination induced proliferating cells that had greater 
capacity to produce IFN-γ, TNF-α and IL-2 together, compared with delayed 
vaccination at 9 months of age. Finally, we also reported that these infants had 
lower levels of non-specific IL-10, compared with those vaccinated at 6 weeks. 
We propose that this diversity in T cell responses induced when BCG was given 
at birth and at 6 weeks of age might impact protective immunity against TB. 
 
Importantly, contributions from this study differ from previous reports on effects of 
delayed BCG vaccination. The lack of agreement observed between our study 
and those previously reported may be explained by the following: first, the 
differences in the study design (Burl et al., 2010, Hussey et al., 2002, Kagina et 
al., 2009). We studied a “real-life” African situation, where BCG was either given 
at birth or not because of hospital or home delivery of the infant. This is different 
from the randomized controlled trial designs in previous published studies (Burl 
et al., 2010, Hussey et al., 2002, Kagina et al., 2009); Second, different assays 
were used to measure outcomes in previous studies. For example, we used BCG 
as antigen, as did Burl et al. (Burl et al., 2010), while others used PPD (Hussey 
et al., 2002); Third, choice of T cell outcomes differed (Burl et al., 2010, Hussey 
et al., 2002, Kagina et al., 2009). Finally, differences between our results and 
those of delayed BCG vaccination studies in South Africa and the Gambia 
suggest that environmental and genetic background of the populations may 
impact the mycobacterial immune response, as demonstrated by diverse 
patterns of antigen recognition and cytokine production in M.tb-infected persons 
from the Gambia, Uganda and South Africa (Black et al., 2001). Environmental 
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factors may include exposure to helminthes (Elias et al., 2001), other infections 
and diverse nutritional practices (Rodriguez et al., 2005). Genetic variation 
across Africa that is associated with characteristics of BCG-specific immune 
response is well documented in descriptions of single nucleotide polymorphisms 
(Randhawa et al., 2011).	   Currently, ongoing studies in our laboratory are 
investigating whether there is an association between differential gene 
expression profiles and the responsivesness to BCG. 
 
We report that a higher proportion of infants vaccinated at 6 weeks of age were 
from families of lower social economic status than infants vaccinated at birth. 
Lower social economic status may negatively influence health seeking behavior, 
helminth exposure, nutrition possibly leading to altered immune responses	  
(Rodriguez et al., 2005). Furthermore, we observed a significant association 
between the frequency of BCG-specific IFN-γ-expressing CD4+ T cells and 
household income. This is in agreement with previous studies that suggest that 
co-administration of BCG with nutritional supplements (Vitamin A) may impact 
vaccine-specific immune responses (Benn et al., 2005, Humphrey et al., 1996). 
For example, greater in PPD-specific IFN-γ expression was observed at 6 weeks 
post vaccination in infants who received BCG with Vitamin A compared to BCG 
administered with a vitamin placebo (Diness et al., 2007). We therefore propose 
that future studies evaluating delayed BCG-induced immunity should take into 
consideration nutritional parameters as potential covariates.  
 
Our study also highlights a potential interaction that may occur when EPI 
vaccines are co-administered. In this regard, we speculate that the lower Th1 
responses observed in infants vaccinated at 6 weeks of age may be due to co-
administration of BCG with Alum, present in other vaccines such as DPT. In a 
randomized controlled trial, lower vaccine induced Th1 immune responses were 
observed when a novel TB vaccine, MVA85A was co-administered with DPT 
compared to when the MVA85A was given alone (Ota et al., 2011). Alum, the 
adjuvant for DPT, induces predominantly Th2 immune responses (Bungener et 
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al., 2008), which may have attenuated the BCG-induced Th1 responses (Abbas 
et al., 1996). Also, observations made by Sartono et al., indicate that co-
administration of OPV with BCG may attenuate PPD-specific responses (Sartono 
et al., 2010). However, in a subsequent study, no differences were observed 
between infants who received BCG with OPV at birth compared to those who 
received BCG without OPV (Lund et al., 2012). In our study, BCG was co-
administered with OPV in both study groups. Therefore, it is unlikely that the 
differences we observed in our study could be explained by BCG co-
administration with OPV. Nevertheless, any modification in vaccination programs 
when incorporating novel TB vaccines, or revising the timing or vaccines such as 
BCG, into the EPI schedule should take into account the potential interactions 
that may occur when different vaccines are co-administered.  
 
We assessed immune responses at 9 months of age. We do not know if other 
differences in BCG-induced immunity may exist at earlier or later post-
vaccination time points. Our study setting limited us from accessing the 
participants at the peak of the BCG-induced T cell immune response, which 
occurs 6-10 weeks after vaccination (Soares et al., 2013). However, in a clinical 
study of delayed BCG vaccination, Kagina et al. showed the greatest difference 
in BCG-induced T cell immunity was at one year of age and not at the peak time 
point post-vaccination (Kagina et al., 2009).  Another potential limitation in our 
study stems from the fact that the priming of the BCG-specific cells occurs in 
lymphoid tissues, such as lymph nodes that drain the vaccination site, at the time 
of vaccine administration. Again we can only speculate that the soluble cytokine 
levels we measured in plasma may be reflective of the cytokine milieu at the time 
of T cell priming.  
 
In summary, our findings appear to support WHO recommendations that infants 
in high endemic areas for TB, such as Uganda, be vaccinated as soon as 
possible after birth. In this setting, delayed vaccination resulting from home births 
does not appear to hold vaccine induced immunological advantages. We believe 
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these studies provide new insights into how timing of BCG vaccination may affect 
the vaccine induced immune responses. The novel clinical data presented here 
are relevant to the general medical community, particularly paediatricians and 
infectious disease physicians, but also to epidemiologists, immunologists and 
policy makers. 
 
8.1. Contributions 
Dr. F. Lutwama wrote this chapter under supervision of Dr. B.M.N. Kagina, Dr. 
T.J. Scriba and Prof. W.A. Hanekom. 
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Appendix 
M A J O R A R T I C L E
Distinct T-Cell Responses When BCG
Vaccination Is Delayed From Birth to 6 Weeks
of Age in Ugandan Infants
F. Lutwama,1,2,3 B. M. Kagina,1,2 A. Wajja,3 F. Waiswa,3 N. Mansoor,1,2 S. Kirimunda,3 E. J. Hughes,1,2 N. Kiwanuka,3
M. L. Joloba,3 P. Musoke,3 T. J. Scriba,1,2 H. Mayanja-Kizza,3 C. L. Day,1,2,4,5 and W. A. Hanekom1,2
1South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and 2School of Child and Adolescent Health,
University of Cape Town, Cape Town, South Africa; 3Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda;
and 4Department of Global Health, Rollins School of Public Health, and 5Emory Vaccine Center, Emory University, Atlanta, Georgia
Background. In Uganda, the tuberculosis vaccine BCG is administered on the ﬁrst day of life. Infants delivered
at home receive BCG vaccine at their ﬁrst healthcare facility visit at 6 weeks of age. Our aim was to determine the
effect of this delay in BCG vaccination on the induced immune response.
Methods. We assessed CD4+ and CD8+ T-cell responses with a 12-hour whole-blood intracellular cytokine/cy-
totoxic marker assay, and with a 6-day proliferation assay.
Results. We enrolled 92 infants: 50 had received BCG vaccine at birth and 42 at 6 weeks of age. Birth vaccina-
tion was associated with (1) greater induction of CD4+ and CD8+ T cells expressing either interferon γ (IFN-γ)
alone or IFN-γ together with perforin and (2) induction of proliferating cells that had greater capacity to produce
IFN-γ, tumor necrosis factor α (TNF-α), and interleukin 2 together, compared with delayed vaccination.
Conclusions. Distinct patterns of T-cell induction occurred when BCG vaccine was given at birth and at 6
weeks of age. We propose that this diversity might impact protection against tuberculosis. Our results differ from
those of studies of delayed BCG vaccination in South Africa and the Gambia, suggesting that geographical and pop-
ulation heterogeneity may affect the BCG vaccine–induced T-cell response.
Keywords. Uganda; BCG; vaccination; birth; delayed; CD4+ and CD8+ T-cell responses.
BCG vaccine is the only vaccine licensed for prevention
of childhood tuberculosis [1]. BCG protects infants
against severe forms of tuberculosis (meningitis and
miliary tuberculosis) [2] and has a positive inﬂuence on
overall infant morbidity and mortality [3]. Therefore, in
settings where theMycobacterium tuberculosis exposure
risk is high, the World Health Organization (WHO)
recommends BCG vaccination soon after birth [4].
In Uganda, tuberculosis is endemic [5], and BCG
vaccine is routinely administered within 24 hours after
birth among infants born in a healthcare facility.
However, up to 50% of babies are born at home [6, 7].
These infants commonly receive BCG vaccine at the
ﬁrst contact with a healthcare facility, usually at 6
weeks of age, when other WHO Expanded Programme
on Immunization–recommended vaccines are adminis-
tered [8]. We aimed to assess the effect of this delay on
the immune response induced by BCG vaccine.
We proposed to investigate CD4+ and CD8+ T-cell
immunity, which is thought to be critical in the control
of M. tuberculosis. BCG vaccine induces a T-helper
type 1 (Th1) response, characterized by production of
interferon γ (IFN-γ), tumor necrosis factor α (TNF-α),
and interleukin 2 (IL-2) [9–12]. BCG vaccine also
induces cytotoxic T cells [13], as well as interleukin 17
(IL-17; Th17)–producing T cells [14].
Compared with adults, neonates’ innate immune cells
produce less Th1-promoting interleukin 12 (IL-12) [15]
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and display diminished Toll-like receptor 4 (TLR) expression
and signaling [16]. This potentially results in a suboptimal re-
sponse to BCG vaccine. At 6 weeks of age, the infant immune
system would start adapting to the ex utero environment [17],
and enhanced priming of BCG-speciﬁc immune responses
might occur. Multiple studies have investigated the effects of
delaying BCG vaccination. Comparable puriﬁed protein deriva-
tive (PPD)–induced IFN-γ production was shown between
infants vaccinated at birth or later [18–20]. In contrast, a South
African study showed that delaying BCG vaccination from
birth to 10 weeks of age induced a greater frequency of BCG-
speciﬁc polyfunctional CD4+ T cells (ie, cells that express IFN-
γ, TNF-α, and IL-2 together) [21]. Importantly, in all previous
studies, infants were randomized to receive BCG vaccine at
birth or later. In contrast, we addressed the effects in a setting
where delayed vaccination occurred due to home births. We
hypothesized that BCG vaccination at 6 weeks of age would
result in an enhanced speciﬁc T-cell response, compared with
administration at birth. We report a comprehensive immuno-
logical assessment of delayed BCG vaccination.
METHODS
Study Population and Sample Collection
Healthy 9-month-old infants were enrolled at the Child Health
and Development Center in Mulago National Referral Hospital,
Kampala, Uganda. A child health growth card was used to
identify infants who received BCG vaccine at birth or at 6
weeks of age.
Infants were excluded if the mother had documented evi-
dence of a positive HIV test result or had not participated in a
program to prevent mother-to-child HIV transmission and if
the infant lacked a BCG vaccination scar, was born before 37
weeks of gestation, had signiﬁcant perinatal complications, had
any acute or chronic disease symptoms at the time of enroll-
ment or clinically apparent anemia, had a household contact
with tuberculosis, or had an unexplained persistent cough or
conﬁrmed active tuberculosis.
The study was approved by the institutional review board of
the School of Public Health, Makerere University College of
Health Sciences, and the Uganda National Council for Science
and Technology. Good clinical practice procedures were
adhered to.
Blood Collection and Processing
From each study participant, a 4-mL whole-blood specimen
was collected in a sodium-heparin tube and was transported to
the laboratory for processing within 1 hour. One milliliter of
heparinized whole blood was incubated with either BCG
(Danish strain 1331; Statens Serum Institut; 1.2 × 106 colony-
forming units [CFU]/mL) or phytohemagglutinin (PHA; Sigma-
Aldrich; 5 µg/mL) or was left unstimulated, as previously
described [22]. The costimulatory antibodies anti-CD28 and
anti-CD49d (at 1 µg/mL each; BD Biosciences, San Jose, CA)
were added to all assay conditions to enhance the responses
[23]. Blood was incubated at 37°C for 7 hours, after which
plasma was removed and stored at −80°C for later measure-
ment of soluble cytokines. Thereafter, brefeldin A (Sigma-
Aldrich; 10 µg/m) was added, and the blood was incubated for
a further 5 hours. Cells were harvested, ﬁxed in BD FACS
Lysing Solution (BD Biosciences), and cryopreserved for later
measurement of T-cell–associated cytokine expression.
A further 1 mL of whole blood was diluted in 9 mL of
Roswell Park Memorial Institute medium and mixed in a sterile
polypropylene tube. One milliliter of diluted blood was incu-
bated with either BCG (Danish strain 1331; Statens Serum In-
stitut; 1 × 105 CFU/mL) or PHA (Sigma-Aldrich; 1 µg/mL,
added on the third day of incubation) or was left unstimulated.
Incubation continued for 6 days at 37°C in 5% CO2 as previous-
ly described [24]. Four hours before the end of the cell culture,
phorbol 12-myristate 13-acetate (PMA; Sigma-Aldrich; 20 ng/
mL), ionomycin (Sigma-Aldrich; 2 µg/mL), and brefeldin A
(Sigma-Aldrich; 10 µg/mL) were added to induce cytokine ex-
pression. Later, red cells were lysed with BD FACS Lysing Solu-
tion (BD Biosciences), and white blood cells were ﬁxed and
cryopreserved for measurement of the proliferation and cyto-
kine-producing potential of proliferating cells.
Antibodies
The following monoclonal antibodies were used: anti-CD3
Paciﬁc Blue (UCHT1), anti-CD8 PerCP-Cy5.5 (SK-1), anti-CD8
Horizon V500 (RPA-T8), anti-IFN-γ Alexa Fluor 700 (B27),
anti-IL-2 FITC (5344.111), anti-Ki67 PE (B56), anti-CD45RA
FITC (HI100), anti-CD27 APC (L128), and anti-CCR7 PE
(150 503), from BD Biosciences (San Jose, CA); anti-CD4
QDot605 (S3.5) and anti-CD8 QDot565 (3B5), from Invitrogen
(Eugene, OR); anti-TNF-αPE-Cy7 (Mab11) and anti-IL-17
Alexa Fluor 647 (eBio64CAP17), from eBiosciences (San Diego,
CA); anti-CD69 PerCP-Cy5.5 (FN50), from Biolegend (San
Diego, CA); and anti-Perforin PE (B-D48), from Diaclone (Be-
sancon, France).
Intracellular Cytokine Staining (ICS) Assay
Fixed, cryopreserved white cells from the stimulated whole blood
were thawed, washed, and permeabilized before staining, as pre-
viously described [22]. Stained cells were acquired on a LSRII
ﬂow cytometer (BD Biosciences). After acquisition, data were an-
alyzed using FlowJo software (v9.4.11; Tree Star). Compensation
was done with positive and negative anti-mouse immunoglobu-
lin kappa beads (BD Biosciences) labeled with the respective
ﬂuorochrome-conjugated antibodies. Cytometer setting and
tracking beads (BD Biosciences) were used for daily settings.
Flow cytometry data were exported to Pestle v1.7 (Mario
Roederer, Vaccine Research Center, National Institute of
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Allergy and Infectious Diseases, National Institutes of Health)
and Spice (v5.1) for analysis [25].
Multiplex Soluble Cytokine Assay
Plasma collected after 7 hours of incubation during the short-
term whole-blood assay was used to measure levels of IFN-γ,
IL-2, interleukin 4 (IL-4), interleukin 5 (IL-5), interleukin 10
(IL-10), and interleukin 13 (IL-13) with the Milliplex MAP
assay (Millipore, Billerica, MA), in accordance with the manu-
facturer’s instructions. Fluorescence was detected using a
Luminex 100 IS machine (xMAP technology; Luminex). Data
were acquired using the Bio-Plex Manager Software. The stan-
dards for each assay ranged from 3.2 to 10 000 pg/mL.
Data Analysis
The response detected in the negative controls (unstimulated)
was subtracted from the response detected in the BCG-
stimulated samples. For short-term ICS, proliferation, and mul-
tiplex analyses, samples were excluded from the ﬁnal analysis if
the response detected in the positive control (PHA) was lower
than the median plus 3 times the median absolute deviations of
the negative control samples for all infants.
For memory phenotype analysis, in addition to the above crite-
ria, data were excluded if (1) the frequency of BCG-speciﬁc cells
was <0.01%, (2) the ratio of BCG to unstimulated frequencies was
<2, and (3) there were <20 positive events in the BCG-stimulated
sample minus the number of events in the unstimulated sample.
For multiplex analysis, data were excluded if (1) the positive
control response was less than that of the negative control and
(2) the positive control response was <3.2 pg/mL.
The Mann-Whitney U test was used to compare immuno-
logical outcomes between the 2 groups. A P value of <.05 was
considered statistically signiﬁcant. Spearman rank correlation
was used to test for associations between frequencies of the spe-
ciﬁc T cells and the levels of soluble cytokines. Prism v5.0
(GraphPad Software) was used for statistical analyses. The in-
ﬂuence of vaccination group, sex, household income, and
weight on the frequency of cytokine-expressing T cells was de-
termined by linear regression analysis.
RESULTS
Participants
We enrolled 92 infants at 9 months of age between October
2008 and February 2009 in Uganda. Fifty of these infants re-
ceived BCG vaccine at birth and 42 received the vaccine at 6
weeks of age. Six infants who had received BCG vaccine at birth
and 2 infants who had received BCG vaccine at 6 weeks of age
were excluded because of inadequate blood volumes. The body
weight and sex distribution between the 2 groups were not
different at recruitment (Table 1). The birth weight for home-
born infants was not available. Infants who received BCG
vaccine at birth were more likely to be from a household with
higher income than infants vaccinated at 6 weeks of age
(Table 1).
Greater Frequencies of BCG-Speciﬁc CD4+ and CD8+ T Cells
Expressing IFN-γ, With or Without Perforin, in Infants
Vaccinated at Birth, Compared With Infants Vaccinated at 6
Weeks of Age
We compared the frequency of BCG-speciﬁc IL-2–, IL-17–,
IFN-γ–, TNF-α–, and perforin-expressing CD4+ T cells in
infants who received BCG vaccine at birth or at 6 weeks of age,
using a short-term WB-ICS assay (Figure 1A and Supplemen-
tary Figure 1). The great majority of infants vaccinated at either
time point had a detectable speciﬁc IL-2, IL-17, IFN-γ, TNF-α,
and perforin CD4+ T-cell response (Figure 1B and 1C). The
frequencies of BCG-speciﬁc CD4+ T cells expressing IL-2, IL-
17, TNF-α, or perforin were comparable in the 2 vaccination
groups (Figure 1B and 1C). However, infants who received
BCG vaccine at birth had greater frequencies of IFN-γ–express-
ing CD4+ T cells, compared with infants vaccinated at 6 weeks
of age (Figure 1B).
Next, we compared the proﬁle of BCG-speciﬁc CD4+ T cells
expressing IL-2, IL-17, IFN-γ, or TNF-α alone or in different
combinations between the 2 groups of infants. We did not
observe coexpression of IL-17 with any of the Th1 cytokines
(Figure 1D and data not shown), whereas perforin was coex-
pressed with IFN-γ only (Figure 1E and data not shown). Fre-
quencies of BCG-speciﬁc polyfunctional (IL-2+IFN-γ+TNF-
Table 1. Demographic Characteristics of the Study Participants
at 9 Months of Age
Variable
Vaccinated at
Birth (n = 44)
Vaccinated at
6 Weeks of
Age (n = 40) P
Sex
Female 18 (41) 20 (53) .29a
Male 26 (59) 18 (47)
Income
Less than
$125
12 (27) 25 (64) .001a
Greater than
$125
32 (73) 14 (36)
Season of BCG vaccination
Dry 28 (64) 24 (60) .73a
Rainy 16 (36) 16 (40)
Weight at 9 mo
of age, kg
9.0 (8–9.55) 8.5 (8–9.45) .26b
Weight-for-age
z score at 9
mo of age
0.27 (−0.70 to 1.08) 0.04 (−0.42 to 0.89) .53b
Data are no. (%) of infants or median (interquartile range).
a By χ2 analysis.
b By the Mann-Whitney U test.
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Figure 1. Speciﬁc CD4+ T-cell cytokine and perforin responses measured in the short-term whole-blood assay. Representative ﬂow cytometry data of cy-
tokine and perforin expression in a negative control (unstimulated) sample (top row) or BCG-stimulated sample (bottom row) from a 9-month-old infant who
received BCG vaccine at birth (A). Scatterplots depict frequencies of total: interferon γ (IFN-γ)–, tumor necrosis factor α (TNF-α)–, interleukin 2 (IL-2)–, and
interleukin 17 (IL-17)–expressing CD4+ T cells (B) and perforin-expressing CD69+CD4+ T cells (C). In the scatterplots, the horizontal lines represent the
median frequencies. Box and whisker plots show the frequencies of distinct subsets of speciﬁc CD4+ T cells based on combinations of expression of IFN-γ,
TNF-α, IL-2, and IL-17 (D) and the frequencies of CD69+CD4+ T cells expressing IFN-γ and perforin singly or in combination (E ). For box and whiskers plots,
the horizontal line represents the median, the boxes represent the interquartile range, and the whiskers represent the 10th and 90th percentiles. Values
shown are corrected for background responses in the negative control condition. The Mann-Whitney U test was used to assess differences in frequencies
of cytokine- or perforin-expressing CD4+ T cells between infants vaccinated at birth (open dots/bars) and 6 weeks of age (closed dots/bars).
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α+), double positive (IL-2+IFN-γ+, IL-2+TNF-α+, or IFN-
γ+TNF-α+), and single-positive (IL-2+, IL-17+, TNF-α+, or per-
forin+) CD4+ T-cell subsets were not different between the 2
groups (Figure 1D and 1E). However, the group vaccinated at
birth had greater frequencies of BCG-speciﬁc IFN-γ single-
positive and IFN-γ+perforin+ double-positive CD4+ T cells,
compared with those vaccinated at 6 weeks (Figure 1D and 1E).
Next, we analyzed speciﬁc CD8+ T cells. In both groups,
BCG-speciﬁc CD8+ T-cell responses were dominated by IFN-γ
and perforin expression (Figure 2B and 2C). As observed for
CD4+ T cells, frequencies of BCG-speciﬁc IL-2–, IL-17–, TNF-
α–, and perforin-expressing CD8+ T cells in both groups were
not different, whereas infants who received BCG vaccine at
birth had greater frequencies of IFN-γ–expressing CD8+
T cells, compared with infants vaccinated at 6 weeks of age
(Figure 2B). Also, similar to CD4+ T cells, the group vaccinated
at birth had greater frequencies of speciﬁc CD8+ T cells ex-
pressing IFN-γ alone (Figure 2D) or in combination with per-
forin (Figure 2E).
No Difference in Proportions of BCG-Speciﬁc CD4+ and CD8+
T-Cell Memory Phenotypes Between the 2 Groups
Next, we evaluated whether the observed differences in fre-
quencies of BCG-speciﬁc IFN-γ–expressing CD4+ and CD8+
T cells could be associated with differential T-cell memory phe-
notypes, as deﬁned by CCR7 and CD45RA expression
(Figure 3A) [26]. We hypothesized that birth vaccinated infants
would show a greater proportion of BCG-speciﬁc effector
memory (TEM) cells, compared with those vaccinated at 6
weeks of age. Phenotypic markers were measured following
stimulation of whole blood for 12 hours.
The majority of BCG-speciﬁc IFN-γ–expressing CD4+ T
cells showed a central memory (TCM) phenotype, in both
groups of infants (Figure 3B). Proportions of BCG-speciﬁc
IFN-γ–expressing CD4+ T cells showing a naive-like (TNaive),
TCM, TEM, and effector memory RA (TEMRA) phenotype were
not different in the infant groups (Figure 3B). We also mea-
sured memory phenotypes of speciﬁc CD8+ T cells. BCG-spe-
ciﬁc IFN-γ–expressing CD8+ T cells mainly showed TEM and
TEMRA phenotypes in both groups of infants, and no differences
were observed between the 2 vaccination groups (Figure 3C).
Higher IL-10 Levels in Infants Vaccinated at 6 Weeks of Age,
Compared With Those Vaccinated at Birth
We also evaluated levels of Th1 and Th2 cytokines and IL-10 in
plasma. We hypothesized that the cytokine milieu would
impact the BCG-primed T-cell response (eg, the presence of
high levels of Th2 cytokines [IL-4, IL-5, and IL-13], as well as
IL-10, might attenuate Th1 immunity) [27, 28]. Levels of BCG-
induced IL-10 were higher in the infants vaccinated at 6 weeks
of age, compared with the group vaccinated at birth
(Figure 4A–C and 4E). However, infants vaccinated at birth
had higher levels of IL-10 in the unstimulated controls, compared
with infants vaccinated at 6 weeks of age (Figure 4D). We there-
fore calculated a stimulation index and could conﬁrm higher spe-
ciﬁc induction of IL-10 when vaccinated later (Figure 4E); IL-10
was not measured with the WB-ICS, because preliminary experi-
ments showed that T-cell–speciﬁc expression was too low for
valid analysis. Levels of all other cytokines were not different
between the 2 groups of infants (Figure 4A–C and 4E).
Greater Capacity of Speciﬁc Proliferating CD4+ T Cells to
Coexpress IL-2, IFN-γ, and TNF-α in Infants Vaccinated at Birth
Than at 6 Weeks of Age
The ability of T cells to proliferate in response to secondary antigen
encounter is an important feature of memory responses [29]. We
measured this ability of the T cells in a 6-day assay by measur-
ing upregulation of Ki67, a nuclear protein expressed during
the active phases of cell division [30], as a marker for prolifera-
tion (Figure 5A and 5B) [24, 31]. The proliferative capacity of
CD4+ and CD8+ T cells were similar between the 2 groups
(Figure 5C and 5D).
We also assessed the cytokine-producing capacity of speciﬁc
proliferating CD4+ T cells after stimulating the cells on day 6
with PMA/ionomycin. Although the capacity of the speciﬁc
cells (ie, Ki67+ cells) to produce any of the cytokines did not
differ (data not shown), we observed that cells from infants vac-
cinated at birth had a greater capacity to coexpress IL-2, IFN-γ,
and TNF-α, compared with those vaccinated at 6 weeks of age.
However, the proportion of these cells expressing TNF-α only
was lower in the group vaccinated at birth, compared with
those vaccinated at 6 weeks of age (Figure 5E). Cytokine pro-
duction capacity among speciﬁc CD8+ T cells did not differ
between the groups (data not shown).
DISCUSSION
We compared BCG vaccine–induced immunity in Ugandan
infants either vaccinated at birth or at 6 weeks of age. We
showed that age of vaccination impacted speciﬁc immune re-
sponse measured at 9 months of age. Infants vaccinated at birth
had higher frequencies of BCG-speciﬁc CD4+ and CD8+ T cells
producing IFN-γ alone or coexpressing IFN-γ and perforin.
Furthermore, although the T-cell proliferative potential was
similar in the 2 groups, a higher proportion of proliferating
BCG-speciﬁc CD4+ T cells coexpressed IL-2, IFN-γ, and TNF-
α in birth vaccinated infants. These infants also had lower
levels of speciﬁc IL-10, compared with those vaccinated at 6
weeks of age.
We measured speciﬁc Th1 cytokine– and perforin-producing
cells based on the proposed roles for these molecules in control of
mycobacteria. For example, humans with mutations in the IL-12/
IFN-γ pathway show an increased risk of mycobacterial disease
[32, 33]. The role of perforin in mediating immunity against
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Figure 2. Speciﬁc CD8+ T-cell cytokine and perforin responses measured in the short-term whole-blood assay. Representative ﬂow cytometry data of cy-
tokine and perforin expression in a control (unstimulated) sample (top row) or a BCG-stimulated sample (bottom row) from a 9-month-old infant who re-
ceived BCG vaccine at birth (A). Scatterplots depict frequencies of total: interferon γ (IFN-γ)–, tumor necrosis factor α (TNF-α)–, interleukin 2 (IL-2)–, and
interleukin 17 (IL-17)–expressing CD8+ T cells (B) and perforin-expressing CD69+CD8+ T cells (C). On the scatterplots, the horizontal lines represent the
median frequencies. Box and whisker plots show the frequencies of distinct subsets of speciﬁc CD8+ T cells based on combinations of cytokine expression
of IFN-γ TNF-α IL-2, and IL-17 (D) and the frequencies of CD69+CD8+ T cells expressing IFN-γ and perforin singly or in combination (E ). For box and
whisker plots, the horizontal line represents the median, the boxes represent the interquartile range, and the whiskers represent the 10th and 90th percen-
tiles. Values shown are corrected for background responses in the negative control condition. The Mann-Whitney U test was used to assess the differences
in frequencies of cytokine- or perforin-expressing CD8+ T cells between infants vaccinated at birth (open dots/bars) and 6 weeks of age (closed dots/bars).
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M. tuberculosis involves perforation of the cell membrane of an
infected cell to permit entry of cytolytic granzymes that may di-
rectly kill M. tuberculosis or infected cells [34]. Rahman et al
showed that, following vaccination of nonhuman primates with a
recombinant BCG vaccine expressing a pore-forming toxin and
the M. tuberculosis antigens Ag85A, Ag85B, and TB10.4, which
was then boosted with an adenovirus 35 (rAd35) vaccine vector
encoding the same M. tuberculosis antigens, better protection
against M. tuberculosis challenge correlated with greater frequen-
cies of vaccination-induced perforin-expressing T cells [35]. In
our study, greater frequencies of BCG-speciﬁc CD4+ and CD8+ T
cells expressing either IFN-γ and coexpressing IFN-γ and perfor-
in in the group vaccinated at birth, compared with the group vac-
cinated at 6 weeks of age, could be a reﬂection of more effective
Figure 3. Memory phenotype of BCG-speciﬁc CD4+ and CD8+ T cells identiﬁed in the short-term whole blood intracellular cytokine assay. For the gating
strategy to analyze the expression of CD45RA and CCR7 memory markers on BCG-speciﬁc CD4+ T cells, CD3+ cells were separated into CD4+ and CD8+
T cells. Then, cells expressing interferon γ (IFN-γ) or CD69, both considered speciﬁc to BCG stimulation, were selected from the CD4+ T cells. Finally,
CD45RA and CCR7 expression were assessed from these speciﬁc cells (A). A similar analysis strategy was used for CD8+ T cells. Box and whiskers plots
show the frequencies of BCG-speciﬁc IFN-γ+ CD4+ T cells (B) and IFN-γ+ CD8+ T cells (C) expressing the CD45RA and CCR7 memory markers singly or in
combination. The open and closed bars represent the infants vaccinated at birth and 6 weeks of age, respectively. The horizontal line represents the
median, the boxes represent the interquartile range, and the whiskers represent the 10th and 90th percentiles. The Mann-Whitney U test was used to
assess the differences in proportions of memory phenotypes of speciﬁc CD4+ and CD8+ T cells between the 2 groups.
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vaccine-take in the former group. However, we cannot speculate
about clinical relevance of this observation in human infants in
terms of protection against tuberculosis [14]; BCG-induced cor-
relates of protection are not known.
In chronic viral infections, persistence of antigen is associat-
ed with induction of effector memory cells; these cells may be
functionally deﬁned by their ability to produce IFN-γ [36]. The
current study and previous studies from our laboratory have
shown BCG-speciﬁc responses in infants are dominated by
IFN-γ–producing CD4+ and CD8+ T cells [12, 21]. On the basis
of this deﬁnition, it would appear as if vaccination at birth is
more likely to induce an effector phenotype, compared with
delayed vaccination. However, we have shown here and previ-
ously [37] that most BCG-induced IFN-γ–expressing cells have
a TCM surface phenotype—the cells express the surface mole-
cules required by classical TCM to home to lymph nodes [38].
The functional implication of the apparent discrepancy
between functional and phenotypic deﬁnitions of T-cell popu-
lations induced by BCG is the focus of ongoing research; this
may be important, given that BCG is likely to remain a prime
vaccine for quite some time.
We evaluated levels of BCG-induced IL-10 on the basis of
studies showing that this cytokine may attenuate Th1 respons-
es. For example, inM. tuberculosis–susceptible CBA/J mice, an-
tibody blockade of IL-10R during BCG vaccination resulted in
an enhanced BCG-speciﬁc IFN-γ response and better protec-
tion against subsequentM. tuberculosis challenge [39]. We have
shown that infants who received BCG vaccine at 6 weeks of age
had greater levels of BCG-speciﬁc IL-10 production, compared
with infants vaccinated at birth. However, we showed no strong
negative correlation between IL-10 levels and CD4+ T-cell IFN-γ
(Data not shown). The greater BCG-induced IL-10 levels ob-
served in the infants vaccinated at 6 weeks of age may potentially
result in attenuation of mycobacteria-speciﬁc Th1 immune re-
sponses during infection withM. tuberculosis in infants vaccinat-
ed at 6 weeks of age, compared with those vaccinated at birth.
We expanded the speciﬁc memory T cells in a long-term
proliferation assay and measured the capacity of the speciﬁc
Figure 4. BCG-speciﬁc cytokine levels in plasma. The scatterplots show levels of 3 different cytokines measured by multiplex bead array in plasma col-
lected after whole blood was incubated with BCG for 7 hours. The following cytokines are shown: interferon γ (IFN-γ; A), interferon 2 (IL-2; B), and interleu-
kin 10 (IL-10; C). All values are corrected for unstimulated levels (BCG-unstimulated) implies the response detected in the unstimulated sample was
subtracted from that of the stimulated sample. IL-10 levels of the unstimulated samples and the ratio of stimulated divided by unstimulated IL-10 levels are
shown in panels D and E, respectively. The horizontal lines represent the median frequencies. The Mann-Whitney U test was used to assess for differences
between the cytokine levels in the 2 groups.
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Figure 5. Capacity of BCG-speciﬁc CD4+ and CD8+ T cells to proliferate and produce cytokines. Representative ﬂow cytometry data of cytokine expres-
sion by proliferating CD8− (herein referred to as CD4+; A) and CD8+ (B) T cells in a control (unstimulated) sample (top row) or BCG-stimulated sample
(bottom row) from a 9-month-old infant who received BCG vaccine at birth. Scatterplots depict frequencies of proliferating CD4+ (C) and CD8+ (D) T cells.
The capacity of the proliferating CD4+ T cells to express interleukin 2 (IL-2), interleukin 17 (IL-17), interferon γ (IFN-γ), and tumor necrosis factor α (TNF-α)
alone or in combination is shown in (E ). In the scatterplots, the horizontal lines represent the median frequencies. Finally, proportions of distinct subsets
assessed by the cytokine coexpression of the proliferating CD4+ T cells were analyzed (D). The open and closed bars or dots represent the infants vaccinat-
ed at birth and 6 weeks of age, respectively. The Mann-Whitney U test was used to assess for differences between the 2 groups.
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proliferating cells to secrete cytokines. Proliferating CD4+ T
cells from the infants vaccinated at birth showed greater capaci-
ty to coexpress IL-2, IFN-γ, and TNF-α. This was surprising,
given our ﬁndings from the short-term assay, which indicated
that BCG vaccination at birth was more likely to induce cells
able to produce IFN-γ alone. It is possible that greater IL-10
levels observed in the infants vaccinated at 6 weeks of age may
have attenuated the expansion of polyfunctional CD4+ T cells.
Polyfunctional CD4+ T cells are thought to be important in tu-
berculosis immunity [40] and are therefore routinely measured
in clinical trials assessing the immunogenicity of novel tubercu-
losis vaccines [41–43]. However, a clinical study from our labo-
ratory reported no association between greater proportions of
BCG-speciﬁc polyfunctional T cells and the risk of developing
tuberculosis [14].
What are the possible explanations for the differences observed
in the BCG-induced T-cell immunity between the 2 groups of
infants? First, we observed that a higher proportion of infants
vaccinated at 6 weeks of age were from families of lower social
economic status, compared with infants vaccinated at birth
(Table 1). Lower social economic status may negatively impact
health-seeking behavior, nutrition, helminth exposure, and other
factors, possibly leading to altered immune responses [44]. We
showed no difference in the frequencies of BCG-speciﬁc IFN-
γ–expressing CD4+ and CD8+ T-cell responses in infants from
families with a higher income, compared with those from fami-
lies in the lower income categories (Supplementary Figure 2) A
and B. Nevertheless, we observed a signiﬁcant association
between the frequency of IFN-γ–expressing CD4+ T cells and
household income (Supplementary Table 1). Second, we specu-
late that the lower Th1 responses observed in infants vaccinated
at 6 weeks of age may be due to coadministration of BCG
vaccine with alum, which is present in other vaccines [45]. Alum
induces predominantly Th2 immune responses [46], which
might have attenuated the BCG-induced Th1 responses [47].
We assessed the immune responses at 9 months of age. We
do not know whether other differences in BCG-induced immu-
nity may exist at earlier time points after vaccination. Our study
setting limited us from accessing the participants at the peak of
BCG-induced T-cell immune response [37]. However, in a clin-
ical study of delayed BCG vaccination, Kagina et al showed that
the greatest difference in BCG-induced T-cell immunity was at
1 year of age and not at the peak time point after the vaccina-
tion [21]. Differences between our study ﬁndings and those
previously reported may be explained by many factors. First,
we used a cross-sectional design, whereas previous studies were
randomized controlled trials [18, 19, 21]. Second, diverse assays
were used to measure outcomes in previous studies. For
example, we used BCG as antigen, as did Burl et al [18], while
others used PPD [19]. Third, the duration of incubation and
choice of T-cell outcomes differed [18, 19, 21]. Finally, environ-
mental and genetic variation may impact the mycobacterial
immune response, as recently demonstrated by diverse patterns
of antigen recognition and cytokine production in M. tubercu-
losis–infected persons from the Gambia, Uganda, and South
Africa [48]. Environmental factors may include exposure to
helminths [49], other infections, and diverse nutritional prac-
tices [44]. Genetic variation across Africa is well documented in
descriptions of single-nucleotide polymorphisms [50], which
may affect the immune response.
In summary, our ﬁndings appear to support WHO recom-
mendations that infants in areas of high endemicity, such as
Uganda, be vaccinated as soon as possible after birth. In this
setting, delaying vaccination does not appear to hold vaccine-
induced immunological advantages.
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